US20120228134A1 - Electrode systems for electrochemical sensors - Google Patents
Electrode systems for electrochemical sensors Download PDFInfo
- Publication number
- US20120228134A1 US20120228134A1 US13/475,770 US201213475770A US2012228134A1 US 20120228134 A1 US20120228134 A1 US 20120228134A1 US 201213475770 A US201213475770 A US 201213475770A US 2012228134 A1 US2012228134 A1 US 2012228134A1
- Authority
- US
- United States
- Prior art keywords
- oxygen
- electrochemical sensor
- glucose
- electrode
- electrochemical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 92
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 92
- 239000001301 oxygen Substances 0.000 claims abstract description 92
- 239000012491 analyte Substances 0.000 claims abstract description 63
- 102000004190 Enzymes Human genes 0.000 claims abstract description 43
- 108090000790 Enzymes Proteins 0.000 claims abstract description 43
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 98
- 239000008103 glucose Substances 0.000 claims description 98
- 229920000642 polymer Polymers 0.000 claims description 43
- 239000000463 material Substances 0.000 claims description 37
- 239000012528 membrane Substances 0.000 claims description 32
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 30
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 28
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 17
- 230000002452 interceptive effect Effects 0.000 claims description 16
- 229960005489 paracetamol Drugs 0.000 claims description 15
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 14
- 235000010323 ascorbic acid Nutrition 0.000 claims description 14
- 239000011668 ascorbic acid Substances 0.000 claims description 14
- 229920001940 conductive polymer Polymers 0.000 claims description 14
- 239000004020 conductor Substances 0.000 claims description 14
- 229940072107 ascorbate Drugs 0.000 claims description 13
- 229910052751 metal Inorganic materials 0.000 claims description 12
- 239000002184 metal Substances 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 abstract description 31
- 238000006911 enzymatic reaction Methods 0.000 abstract description 13
- 230000004048 modification Effects 0.000 abstract description 6
- 238000012986 modification Methods 0.000 abstract description 6
- 238000002848 electrochemical method Methods 0.000 abstract description 2
- 230000000302 ischemic effect Effects 0.000 abstract description 2
- 229940088598 enzyme Drugs 0.000 description 35
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 26
- 241000894007 species Species 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 208000028867 ischemia Diseases 0.000 description 13
- 230000006870 function Effects 0.000 description 12
- 230000001052 transient effect Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 230000032258 transport Effects 0.000 description 10
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 108010015776 Glucose oxidase Proteins 0.000 description 8
- 239000004366 Glucose oxidase Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229940116332 glucose oxidase Drugs 0.000 description 8
- 235000019420 glucose oxidase Nutrition 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 239000013060 biological fluid Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- -1 PreState Chemical compound 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000003722 extracellular fluid Anatomy 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- HZCBWYNLGPIQRK-LBPRGKRZSA-N 3,3',5'-triiodo-L-thyronine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC=C1OC1=CC(I)=C(O)C(I)=C1 HZCBWYNLGPIQRK-LBPRGKRZSA-N 0.000 description 2
- DIVQKHQLANKJQO-UHFFFAOYSA-N 3-methoxytyramine Chemical compound COC1=CC(CCN)=CC=C1O DIVQKHQLANKJQO-UHFFFAOYSA-N 0.000 description 2
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 2
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
- 102000004452 Arginase Human genes 0.000 description 2
- 108700024123 Arginases Proteins 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000003487 electrochemical reaction Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229960002428 fentanyl Drugs 0.000 description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000012806 monitoring device Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 229960000482 pethidine Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
- 229950010883 phencyclidine Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- PAHGJZDQXIOYTH-UHFFFAOYSA-N pristanic acid Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C(O)=O PAHGJZDQXIOYTH-UHFFFAOYSA-N 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229940034208 thyroxine Drugs 0.000 description 2
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- CIKNYWFPGZCHDL-ZHFUJENKSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[[(2s,3r)-3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N CIKNYWFPGZCHDL-ZHFUJENKSA-N 0.000 description 1
- RLCKHJSFHOZMDR-UHFFFAOYSA-N (3R, 7R, 11R)-1-Phytanoid acid Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-UHFFFAOYSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- UUEZOEBHFHYMGR-RNWHKREASA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;3-(4-chlorophenyl)-n,n-dimethyl-3-pyridin-2-ylpropan-1-amine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC UUEZOEBHFHYMGR-RNWHKREASA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- QNJJECIHYZJXRL-UHFFFAOYSA-N 1-(2-chlorophenyl)-2-methylpropan-2-amine;hydrochloride Chemical compound Cl.CC(C)(N)CC1=CC=CC=C1Cl QNJJECIHYZJXRL-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QNLDTXPVZPRSAM-UHFFFAOYSA-N 17146-95-1 Chemical compound CC(O)C(O)=O.C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C(C)C)CC2 QNLDTXPVZPRSAM-UHFFFAOYSA-N 0.000 description 1
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 description 1
- UYVVLXVBEQAATF-WAIVXGPNSA-N 1b-Hydroxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)C[C@@H](O)[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 UYVVLXVBEQAATF-WAIVXGPNSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- LCZBQMKVFQNSJR-UJPCIWJBSA-N 21-deoxycortisol Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)C[C@@H]2O LCZBQMKVFQNSJR-UJPCIWJBSA-N 0.000 description 1
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
- RLCKHJSFHOZMDR-PWCSWUJKSA-N 3,7R,11R,15-tetramethyl-hexadecanoic acid Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-PWCSWUJKSA-N 0.000 description 1
- WYEPBHZLDUPIOD-UHFFFAOYSA-N 4,6-dioxoheptanoic acid Chemical compound CC(=O)CC(=O)CCC(O)=O WYEPBHZLDUPIOD-UHFFFAOYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- RVWZUOPFHTYIEO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Natural products C1=C(O)C=C2C(C(=O)O)=CNC2=C1 RVWZUOPFHTYIEO-UHFFFAOYSA-N 0.000 description 1
- 239000003310 5-hydroxyindoleacetic acid Substances 0.000 description 1
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 1
- KZFBHCCLJSAHBQ-UHFFFAOYSA-N Benzoylecgonine Natural products CN1C2CCC1C(C(C2)OC(=C)c3ccccc3)C(=O)O KZFBHCCLJSAHBQ-UHFFFAOYSA-N 0.000 description 1
- 108010039206 Biotinidase Proteins 0.000 description 1
- 102100026044 Biotinidase Human genes 0.000 description 1
- JQJPBYFTQAANLE-UHFFFAOYSA-N Butyl nitrite Chemical compound CCCCON=O JQJPBYFTQAANLE-UHFFFAOYSA-N 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- 108010033547 Carbonic Anhydrase I Proteins 0.000 description 1
- 102100025518 Carbonic anhydrase 1 Human genes 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108010089254 Cholesterol oxidase Proteins 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 201000003808 Cystic echinococcosis Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108010071840 Cytosol nonspecific dipeptidase Proteins 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical class OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- LHQIJBMDNUYRAM-AWFVSMACSA-N D-erythro-biopterin Chemical compound N1=C(N)NC(=O)C2=NC([C@H](O)[C@H](O)C)=CN=C21 LHQIJBMDNUYRAM-AWFVSMACSA-N 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 108010028196 Dihydropteridine Reductase Proteins 0.000 description 1
- 102100022317 Dihydropteridine reductase Human genes 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241001319090 Dracunculus medinensis Species 0.000 description 1
- 241000244170 Echinococcus granulosus Species 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102100029115 Fumarylacetoacetase Human genes 0.000 description 1
- 108010015133 Galactose oxidase Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- FOHHNHSLJDZUGQ-VWLOTQADSA-N Halofantrine Chemical compound FC(F)(F)C1=CC=C2C([C@@H](O)CCN(CCCC)CCCC)=CC3=C(Cl)C=C(Cl)C=C3C2=C1 FOHHNHSLJDZUGQ-VWLOTQADSA-N 0.000 description 1
- 239000004866 Hashish Substances 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 108010085682 Hemoglobin A Proteins 0.000 description 1
- 102000007513 Hemoglobin A Human genes 0.000 description 1
- 108010085686 Hemoglobin C Proteins 0.000 description 1
- 108010068323 Hemoglobin E Proteins 0.000 description 1
- 108091005880 Hemoglobin F Proteins 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 102000016871 Hexosaminidase A Human genes 0.000 description 1
- 108010053317 Hexosaminidase A Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108010056651 Hydroxymethylbilane synthase Proteins 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- ZAGRKAFMISFKIO-UHFFFAOYSA-N Isolysergic acid Natural products C1=CC(C2=CC(CN(C2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-UHFFFAOYSA-N 0.000 description 1
- LHQIJBMDNUYRAM-UHFFFAOYSA-N L-erythro-Biopterin Natural products N1=C(N)NC(=O)C2=NC(C(O)C(O)C)=CN=C21 LHQIJBMDNUYRAM-UHFFFAOYSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010073450 Lactate 2-monooxygenase Proteins 0.000 description 1
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 1
- 241000222727 Leishmania donovani Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000883511 Lophophora williamsii Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 102100034391 Porphobilinogen deaminase Human genes 0.000 description 1
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 description 1
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 description 1
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010016797 Sickle Hemoglobin Proteins 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040860 Skin haemorrhages Diseases 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102000002248 Thyroxine-Binding Globulin Human genes 0.000 description 1
- 108010000259 Thyroxine-Binding Globulin Proteins 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 241000223097 Trypanosoma rangeli Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100021436 UDP-glucose 4-epimerase Human genes 0.000 description 1
- 108010075202 UDP-glucose 4-epimerase Proteins 0.000 description 1
- 108010058532 UTP-hexose-1-phosphate uridylyltransferase Proteins 0.000 description 1
- 102000006321 UTP-hexose-1-phosphate uridylyltransferase Human genes 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 241000244005 Wuchereria bancrofti Species 0.000 description 1
- 102100039662 Xaa-Pro dipeptidase Human genes 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- FBDMJGHBCPNRGF-UHFFFAOYSA-M [OH-].[Li+].[O-2].[Mn+2] Chemical group [OH-].[Li+].[O-2].[Mn+2] FBDMJGHBCPNRGF-UHFFFAOYSA-M 0.000 description 1
- 108010063628 acarboxyprothrombin Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960003116 amyl nitrite Drugs 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ANFSNXAXVLRZCG-RSAXXLAASA-N benzphetamine hydrochloride Chemical compound [Cl-].C([C@H](C)[NH+](C)CC=1C=CC=CC=1)C1=CC=CC=C1 ANFSNXAXVLRZCG-RSAXXLAASA-N 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000003869 coulometry Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000000747 designer drug Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- QMQBBUPJKANITL-MYXGOWFTSA-N dextropropoxyphene hydrochloride Chemical compound [H+].[Cl-].C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 QMQBBUPJKANITL-MYXGOWFTSA-N 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229940120144 didrex Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- QCHSEDTUUKDTIG-UHFFFAOYSA-L dipotassium clorazepate Chemical compound [OH-].[K+].[K+].C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 QCHSEDTUUKDTIG-UHFFFAOYSA-L 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- GVGYEFKIHJTNQZ-RFQIPJPRSA-N ecgonine benzoate Chemical compound O([C@@H]1[C@@H]([C@H]2CC[C@@H](C1)N2C)C(O)=O)C(=O)C1=CC=CC=C1 GVGYEFKIHJTNQZ-RFQIPJPRSA-N 0.000 description 1
- 239000007772 electrode material Substances 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 108010022687 fumarylacetoacetase Proteins 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 229940099347 glycocholic acid Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000000380 hallucinogen Substances 0.000 description 1
- 229960003242 halofantrine Drugs 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 108010047389 hemoglobin D Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940087973 lomotil Drugs 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- ZAGRKAFMISFKIO-QMTHXVAHSA-N lysergic acid Chemical compound C1=CC(C2=C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-QMTHXVAHSA-N 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960001962 mefloquine Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960002803 methaqualone Drugs 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- FYHCHSNOXWVJJT-UHFFFAOYSA-N n-debutylhalofantrine Chemical compound FC(F)(F)C1=CC=C2C(C(O)CCNCCCC)=CC3=C(Cl)C=C(Cl)C=C3C2=C1 FYHCHSNOXWVJJT-UHFFFAOYSA-N 0.000 description 1
- CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 238000006395 oxidase reaction Methods 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229940011043 percocet Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- OOBHFESNSZDWIU-UHFFFAOYSA-N phenmetrazine Chemical compound CC1NCCOC1C1=CC=CC=C1 OOBHFESNSZDWIU-UHFFFAOYSA-N 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000036544 posture Effects 0.000 description 1
- 229950009829 prasterone sulfate Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 108010066823 proline dipeptidase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 229940099204 ritalin Drugs 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 108010093322 s-formylglutathione hydrolase Proteins 0.000 description 1
- 102000028528 s-formylglutathione hydrolase Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 206010039766 scrub typhus Diseases 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960004673 sulfadoxine Drugs 0.000 description 1
- 229940066690 talwin Drugs 0.000 description 1
- 229960005367 tetanus antitoxin Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 229940063648 tranxene Drugs 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940071950 tussionex Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940072690 valium Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- FUTVBRXUIKZACV-UHFFFAOYSA-J zinc;3-[18-(2-carboxylatoethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoate Chemical compound [Zn+2].[N-]1C2=C(C)C(CCC([O-])=O)=C1C=C([N-]1)C(CCC([O-])=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 FUTVBRXUIKZACV-UHFFFAOYSA-J 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3271—Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
- G01N27/3274—Corrective measures, e.g. error detection, compensation for temperature or hematocrit, calibration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
- A61B5/14865—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
Definitions
- the present invention relates generally to systems and methods for improving electrochemical sensor performance.
- Electrochemical sensors are useful in chemistry and medicine to determine the presence or concentration of a biological analyte. Such sensors are useful, for example, to monitor glucose in diabetic patients and lactate during critical care events.
- Diabetes mellitus is a disorder in which the pancreas cannot create sufficient insulin (Type I or insulin dependent) and/or in which insulin is not effective (Type 2 or non-insulin dependent).
- Type I or insulin dependent in which the pancreas cannot create sufficient insulin
- Type 2 or non-insulin dependent in which insulin is not effective
- a hypoglycemic reaction low blood sugar is induced by an inadvertent overdose of insulin, or after a normal dose of insulin or glucose-lowering agent accompanied by extraordinary exercise or insufficient food intake.
- SMBG self-monitoring blood glucose
- SMBG self-monitoring blood glucose
- SMBG self-monitoring blood glucose
- transdermal and implantable electrochemical sensors are being developed for continuously detecting and/or quantifying blood glucose values.
- Many implantable glucose sensors suffer from complications within the body and provide only short-term or less-than-accurate working of blood glucose.
- transdermal sensors have problems in accurately working and reporting back glucose values continuously over extended periods of time.
- the sensors of preferred embodiments advantageously generate oxygen to allow the sensor to function at sufficient oxygen levels independent of the oxygen concentration in the surrounding environment.
- systems and methods for modifying electrochemical interferants are provided.
- an electrochemical sensor for determining a presence or a concentration of an analyte in a fluid
- the sensor comprising a membrane system comprising an enzyme, wherein the enzyme reacts with the analyte; an electroactive surface comprising a working electrode, the working electrode comprising a conductive material and configured to measure a product of the reaction of the enzyme with the analyte; and an auxiliary electrode comprising a conductive material and configured to generate oxygen, wherein the auxiliary electrode is situated such that the oxygen generated diffuses to the enzyme or to the electroactive surface.
- the auxiliary electrode comprises a conductive material selected from the group consisting of a conductive metal, a conductive polymer, and a blend of a conductive metal and a conductive polymer.
- the auxiliary electrode comprises a form selected from the group consisting of a mesh, a grid, and a plurality of spaced wires.
- the auxiliary electrode comprises a polymer, wherein the polymer is situated on a surface of the auxiliary electrode.
- the polymer comprises a material that is impermeable to glucose but is permeable to oxygen.
- the polymer comprises a material that is impermeable to glucose but is permeable to oxygen and permeable to interfering species.
- the polymer comprises a material having a molecular weight that blocks glucose and allows transport therethrough of oxygen, urate, ascorbate, and acetaminophen.
- the polymer comprises a material that is permeable to glucose and oxygen.
- the polymer comprises a material that is permeable to glucose, oxygen, and interfering species.
- the polymer comprises a material having a molecular weight that allows transport therethrough of oxygen, glucose, urate, ascorbate, and acetaminophen.
- the auxiliary electrode is configured to be set at a potential of at least about +0.6 V.
- the auxiliary electrode is configured to electrochemically modify an electrochemical interferant to render the electrochemical interferent substantially electrochemically non-reactive at the working electrode.
- the auxiliary electrode is configured to be set at a potential of at least about +0.1 V.
- an electrochemical sensor for determining a presence or a concentration of an analyte in a fluid
- the sensor comprising a membrane system comprising an enzyme, wherein the enzyme reacts with the analyte; an electroactive surface comprising a working electrode, the working electrode comprising a conductive material and configured to measure a product of the reaction of the enzyme with the analyte; and an auxiliary electrode comprising a conductive material and configured to modify an electrochemical interferant such that the electrochemical interferent is rendered substantially electrochemically non-reactive at the working electrode.
- the auxiliary electrode comprises a conductive material selected from the group consisting of a conductive metal, a conductive polymer, and a blend of a conductive metal and a conductive polymer.
- the auxiliary electrode comprises a form selected from the group consisting of a mesh, a grid, and a plurality of spaced wires.
- the auxiliary electrode comprises a polymer, wherein the polymer is situated on a surface of the auxiliary electrode.
- the polymer comprises a material that is permeable to an electrochemical interferant.
- the polymer comprises a material that is impermeable to glucose but is permeable to oxygen.
- the polymer comprises a material that is impermeable to glucose but is permeable to oxygen and interferants.
- the polymer comprises a material having a molecular weight that blocks glucose and allows transport therethrough of oxygen, urate, ascorbate, and acetaminophen.
- the polymer comprises a material that is permeable to glucose and oxygen.
- the polymer comprises a material that is permeable to glucose, oxygen, and interferants.
- the polymer comprises a material having a molecular weight that allows transport therethrough of oxygen, glucose, urate, ascorbate, and acetaminophen.
- the auxiliary electrode is configured to be set at a potential of at least about +0.1V.
- the auxiliary electrode is configured to generate oxygen.
- the auxiliary electrode is configured to be set at a potential of at least about +0.6 V.
- an electrochemical sensor comprising an electroactive surface configured to measure an analyte; and an auxiliary interferant-modifying electrode configured to modify an electrochemical interferant such that the electrochemical interferant is rendered substantially non-reactive at the electroactive surface.
- the auxiliary interferant-modifying electrode comprises a conductive material selected from the group consisting of a conductive metal, a conductive polymer, and a blend of a conductive metal and a conductive polymer.
- the auxiliary interferant-modifying electrode comprises a form selected from the group consisting of a mesh, a grid, and a plurality of spaced wires.
- the auxiliary interferant-modifying electrode comprises a polymer, wherein the polymer is situated on a surface of the auxiliary interferant-modifying electrode.
- FIG. 1 is an exploded perspective view of one exemplary embodiment of a implantable glucose sensor.
- FIG. 2 is a block diagram that illustrates sensor electronics in one exemplary embodiment.
- FIG. 3 is a graph that shows a raw data stream obtained from a glucose sensor without an auxiliary electrode of the preferred embodiments.
- FIG. 4 is a side schematic illustration of a portion of an electrochemical sensor of the preferred embodiments, showing an auxiliary electrode placed proximal to the enzyme domain within a membrane system.
- analyte as used herein is a broad term and is used in its ordinary sense, including, without limitation, to refer to a substance or chemical constituent in a biological fluid (for example, blood, interstitial fluid, cerebral spinal fluid, lymph fluid or urine) that can be analyzed. Analytes can include naturally occurring substances, artificial substances, metabolites, and/or reaction products. In some embodiments, the analyte for measurement by the sensing regions, devices, and methods is glucose.
- analytes are contemplated as well, including but not limited to acarboxyprothrombin; acylcarnitine; adenine phosphoribosyl transferase; adenosine deaminase; albumin; alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, tryptophan); andrenostenedione; antipyrine; arabinitol enantiomers; arginase; benzoylecgonine (cocaine); biotinidase; biopterin; c-reactive protein; carnitine; carnosinase; CD4; ceruloplasmin; chenodeoxycholic acid; chloroquine; cholesterol; cholinesterase; conjugated 1- ⁇ hydroxy-cholic acid; cortisol; creatine kinase; creatine kinase
- Salts, sugar, protein, fat, vitamins and hormones naturally occurring in blood or interstitial fluids can also constitute analytes in certain embodiments.
- the analyte can be naturally present in the biological fluid or endogenous, for example, a metabolic product, a hormone, an antigen, an antibody, and the like.
- the analyte can be introduced into the body or exogenous, for example, a contrast agent for imaging, a radioisotope, a chemical agent, a fluorocarbon-based synthetic blood, or a drug or pharmaceutical composition, including but not limited to insulin; ethanol; cannabis (marijuana, tetrahydrocannabinol, hashish); inhalants (nitrous oxide, amyl nitrite, butyl nitrite, chlorohydrocarbons, hydrocarbons); cocaine (crack cocaine); stimulants (amphetamines, methamphetamines, Ritalin, Cylert, Preludin, Didrex, PreState, Voranil, Sandrex, Plegine); depressants (barbituates, methaqualone, tranquilizers such as Valium, Librium, Miltown, Serax, Equanil, Tranxene); hallucinogens (phencyclidine, lysergic acid, mescaline, peyot
- Analytes such as neurochemicals and other chemicals generated within the body can also be analyzed, such as, for example, ascorbic acid, uric acid, dopamine, noradrenaline, 3-methoxytyramine (3MT), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxytryptamine (5HT), and 5-hydroxyindoleacetic acid (FHIAA).
- operably connection is broad terms and are used in their ordinary sense, including, without limitation, one or more components linked to another component(s) in a manner that allows transmission of signals between the components.
- one or more electrodes can be used to detect the amount of analyte in a sample and convert that information into a signal; the signal can then be transmitted to a circuit.
- the electrode is “operably linked” to the electronic circuitry.
- host as used herein is a broad term and is used in its ordinary sense, including, without limitation, mammals, particularly humans.
- the term “sensor,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, the portion or portions of an analyte-monitoring device that detects an analyte.
- the sensor includes an electrochemical cell that has a working electrode, a reference electrode, and optionally a counter electrode passing through and secured within the sensor body forming an electrochemically reactive surface at one location on the body, an electronic connection at another location on the body, and a membrane system affixed to the body and covering the electrochemically reactive surface.
- a biological sample for example, blood or interstitial fluid
- an enzyme for example, glucose oxidase
- signal output is a broad term and is used in its ordinary sense, including, without limitation, an analog or digital signal directly related to the measured analyte from the analyte-measuring device.
- the term broadly encompasses a single point, or alternatively, a plurality of time spaced data points from a substantially continuous glucose sensor, which comprises individual measurements taken at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes or longer.
- electrochemical cell is a broad term and is used in its ordinary sense, including, without limitation, a device in which chemical energy is converted to electrical energy.
- a cell typically consists of two or more electrodes held apart from each other and in contact with an electrolyte solution. Connection of the electrodes to a source of direct electric current renders one of them negatively charged and the other positively charged. Positive ions in the electrolyte migrate to the negative electrode (cathode) and there combine with one or more electrons, losing part or all of their charge and becoming new ions having lower charge or neutral atoms or molecules; at the same time, negative ions migrate to the positive electrode (anode) and transfer one or more electrons to it, also becoming new ions or neutral particles. The overall effect of the two processes is the transfer of electrons from the negative ions to the positive ions, a chemical reaction.
- potentiostat is a broad term and is used in its ordinary sense, including, without limitation, an electrical system that controls the potential between the working and reference electrodes of a three-electrode cell at a preset value independent of resistance changes between the electrodes. It forces whatever current is necessary to flow between the working and counter electrodes to keep the desired potential, as long as the cell voltage and current do not exceed the compliance limits of the potentiostat.
- electrochemically reactive surface and “electroactive surface” as used herein are broad terms and are used in their ordinary sense, including, without limitation, the surface of an electrode where an electrochemical reaction takes place.
- a working electrode measures hydrogen peroxide produced by the enzyme catalyzed reaction of the analyte being detected reacts creating an electric current (for example, detection of glucose analyte utilizing glucose oxidase produces H 2 O 2 as a by product, H 2 O 2 reacts with the surface of the working electrode producing two protons (2H + ), two electrons (2e ⁇ ) and one molecule of oxygen (O 2 ) which produces the electronic current being detected).
- a reducible species for example, O 2 is reduced at the electrode surface in order to balance the current being generated by the working electrode.
- sensing region is a broad term and is used in its ordinary sense, including, without limitation, the region of a monitoring device responsible for the detection of a particular analyte.
- the sensing region generally comprises a non-conductive body, a working electrode, a reference electrode, and optionally a counter electrode passing through and secured within the body forming electrochemically reactive surfaces on the body and an electronic connective means at another location on the body, and a multi-domain membrane system affixed to the body and covering the electrochemically reactive surface.
- raw data stream and “data stream,” as used herein, are broad terms and are used in their ordinary sense, including, without limitation, an analog or digital signal directly related to the measured an analyte from an analyte sensor.
- the raw data stream is digital data in “counts” converted by an A/D converter from an analog signal (for example, voltage or amps) representative of a analyte concentration.
- the terms broadly encompass a plurality of time spaced data points from a substantially continuous analyte sensor, which comprises individual measurements taken at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes or longer.
- counts is a broad term and is used in its ordinary sense, including, without limitation, a unit of measurement of a digital signal.
- a raw data stream measured in counts is directly related to a voltage (for example, converted by an A/D converter), which is directly related to current from the working electrode.
- counter electrode voltage measured in counts is directly related to a voltage.
- electrical potential and “potential” as used herein, are broad terms and are used in their ordinary sense, including, without limitation, the electrical potential difference between two points in a circuit which is the cause of the flow of a current.
- Ischemia is a broad term and is used in its ordinary sense, including, without limitation, local and temporary deficiency of blood supply due to obstruction of circulation to a part (for example, a sensor). Ischemia can be caused by mechanical obstruction (for example, arterial narrowing or disruption) of the blood supply, for example.
- system noise is a broad term and is used in its ordinary sense, including, without limitation, unwanted electronic or diffusion-related noise which can include Gaussian, motion-related, flicker, kinetic, or other white noise, for example.
- signal artifacts and “transient non-glucose related signal artifacts that have a higher amplitude than system noise,” as used herein, are broad terms and are used in their ordinary sense, including, without limitation, signal noise that is caused by substantially non-glucose reaction rate-limiting phenomena, such as ischemia, pH changes, temperature changes, pressure, and stress, for example.
- Signal artifacts, as described herein, are typically transient and characterized by a higher amplitude than system noise.
- low noise is a broad term and is used in its ordinary sense, including, without limitation, noise that substantially decreases signal amplitude.
- high noise and “high spikes,” as used herein, are broad terms and are used in their ordinary sense, including, without limitation, noise that substantially increases signal amplitude.
- distal to is a broad term and is used in its ordinary sense, including, without limitation, the spatial relationship between various elements in comparison to a particular point of reference.
- some embodiments of a device include a membrane system having a cell disruptive domain and a cell impermeable domain. If the sensor is deemed to be the point of reference and the cell disruptive domain is positioned farther from the sensor, then that domain is distal to the sensor.
- proximal to is a broad term and is used in its ordinary sense, including, without limitation, the spatial relationship between various elements in comparison to a particular point of reference.
- some embodiments of a device include a membrane system having a cell disruptive domain and a cell impermeable domain. If the sensor is deemed to be the point of reference and the cell impermeable domain is positioned nearer to the sensor, then that domain is proximal to the sensor.
- interferants and “interfering species,” as used herein, are broad terms and are used in their ordinary sense, including, but not limited to, effects and/or species that interfere with the measurement of an analyte of interest in a sensor to produce a signal that does not accurately represent the analyte measurement.
- interfering species are compounds with an oxidation potential that overlaps with the analyte to be measured.
- Eq and Eqs (equivalents); mEq (milliequivalents); M (molar); mM (millimolar) ⁇ M (micromolar); N (Normal); mol (moles); mmol (millimoles); ⁇ mol (micromoles); nmol (nanomoles); g (grams); mg (milligrams); ⁇ g (micrograms); Kg (kilograms); L (liters); mL (milliliters); dL (deciliters); ⁇ L (microliters); cm (centimeters); mm (millimeters); ⁇ m (micrometers); nm (nanometers); h and hr (hours); min. (minutes); s and sec. (seconds); ° C. (degrees Centigrade).
- the preferred embodiments relate to the use of an electrochemical sensor that measures a concentration of an analyte of interest or a substance indicative of the concentration or presence of the analyte in fluid.
- the sensor is a continuous device, for example a subcutaneous, transdermal, or intravascular device.
- the device can analyze a plurality of intermittent blood samples.
- the sensor uses any known method, including invasive, minimally invasive, and non-invasive sensing techniques, to provide an output signal indicative of the concentration of the analyte of interest.
- the sensor is of the type that senses a product or reactant of an enzymatic reaction between an analyte and an enzyme in the presence of oxygen as a measure of the analyte in vivo or in vitro.
- Such a sensor typically comprises a membrane surrounding the enzyme through which a bodily fluid passes and in which an analyte within the bodily fluid reacts with an enzyme in the presence of oxygen to generate a product.
- the product is then measured using electrochemical methods and thus the output of an electrode system functions as a measure of the analyte.
- the senor can use an amperometric, coulometric, conductimetric, and/or potentiometric technique for measuring the analyte.
- the electrode system can be used with any of a variety of known in vitro or in vivo analyte sensors or monitors.
- FIG. 1 is an exploded perspective view of one exemplary embodiment of an implantable glucose sensor 10 that utilizes an electrode system 16 .
- a body with a sensing region 14 includes an electrode system ( 16 a to 16 c ), also referred to as the electroactive sensing surface, and sensor electronics, which are described in more detail with reference to FIG. 2 .
- the electrode system 16 is operably connected to the sensor electronics ( FIG. 2 ) and includes electroactive surfaces (including two-, three- or more electrode systems), which are covered by a membrane system 18 .
- the membrane system 18 is disposed over the electroactive surfaces of the electrode system 16 and provides one or more of the following functions: 1) protection of the exposed electrode surface from the biological environment (cell impermeable domain); 2) diffusion resistance (limitation) of the analyte (resistance domain); 3) a catalyst for enabling an enzymatic reaction (enzyme domain); 4) limitation or blocking of interfering species (interference domain); and/or 5) hydrophilicity at the electrochemically reactive surfaces of the sensor interface (electrolyte domain), for example, such as described in co-pending U.S.
- the electrode system 16 includes three electrodes (working electrode 16 a, counter electrode 16 b, and reference electrode 16 c ), wherein the counter electrode is provided to balance the current generated by the species being measured at the working electrode.
- the species measured at the working electrode is H 2 O 2 .
- Glucose oxidase, GOX catalyzes the conversion of oxygen and glucose to hydrogen peroxide and gluconate according to the following reaction:
- the change in H 2 O 2 can be monitored to determine glucose concentration because for each glucose molecule metabolized, there is a proportional change in the product H 2 O 2 .
- Oxidation of H 2 O 2 by the working electrode is balanced by reduction of ambient oxygen, enzyme generated H 2 O 2 , or other reducible species at the counter electrode.
- the H 2 O 2 produced from the glucose oxidase reaction further reacts at the surface of working electrode and produces two protons (2H+), two electrons (2e ⁇ ), and one oxygen molecule (O 2 ).
- the counter electrode utilizes oxygen as an electron acceptor, the most likely reducible species for this system are oxygen or enzyme generated peroxide. There are two main pathways by which oxygen can be consumed at the counter electrode.
- FIG. 2 is a block diagram that illustrates sensor electronics in one exemplary embodiment; one skilled in the art appreciates however that a variety of sensor electronics configurations can be implemented with the preferred embodiments.
- a potentiostat 20 is shown, which is operatively connected to electrode system 16 ( FIG. 1 ) to obtain a current value, and includes a resistor (not shown) that translates the current into voltage.
- the A/D converter 21 digitizes the analog signal into “counts” for processing. Accordingly, the resulting raw data signal in counts is directly related to the current measured by the potentiostat.
- a microprocessor 22 is the central control unit that houses EEPROM 23 and SRAM 24 , and controls the processing of the sensor electronics.
- the alternative embodiments can utilize a computer system other than a microprocessor to process data as described herein.
- an application-specific integrated circuit ASIC can be used for some or all the sensor's central processing.
- EEPROM 23 provides semi-permanent storage of data, storing data such as sensor ID and necessary programming to process data signals (for example, programming for data smoothing such as described elsewhere herein).
- SRAM 24 is used for the system's cache memory, for example for temporarily storing recent sensor data.
- the battery 25 is operatively connected to the microprocessor 22 and provides the necessary power for the sensor.
- the battery is a Lithium Manganese Dioxide battery, however any appropriately sized and powered battery can be used.
- a plurality of batteries can be used to power the system.
- Quartz crystal 26 is operatively connected to the microprocessor 22 and maintains system time for the computer system.
- the RF Transceiver 27 is operably connected to the microprocessor 22 and transmits the sensor data from the sensor to a receiver. Although a RF transceiver is shown here, some other embodiments can include a wired rather than wireless connection to the receiver. In yet other embodiments, the sensor can be transcutaneously connected via an inductive coupling, for example.
- the quartz crystal 28 provides the system time for synchronizing the data transmissions from the RF transceiver.
- the transceiver 27 can be substituted with a transmitter in one embodiment.
- FIGS. 1 and 2 and associated text illustrate and describe an exemplary embodiment of an implantable glucose sensor
- the electrode systems of the preferred embodiments described below can be implemented with any known electrochemical sensor, including U.S. Pat. No. 6,001,067 to Shults et al.; U.S. Pat. No. 6,702,857 to Brauker et al.; U.S. Pat. No. 6,212,416 to Ward et al.; U.S. Pat. No. 6,119,028 to Schulman et al; U.S. Pat. No. 6,400,974 to Lesho; U.S. Pat. No. 6,595,919 to Berner et al.; U.S. Pat. No.
- FIG. 3 is a graph that depicts a raw data stream obtained from a prior art glucose sensor such as described with reference to FIG. 1 .
- the x-axis represents time in minutes.
- the y-axis represents sensor data in counts. In this example, sensor output in counts is transmitted every 30-seconds.
- the raw data stream 30 includes substantially smooth sensor output in some portions, however other portions exhibit erroneous or transient non-glucose related signal artifacts 32 . Particularly, referring to the signal artifacts 32 , it is believed that effects of local ischemia on prior art electrochemical sensors creates erroneous (non-glucose) signal values due to oxygen deficiencies either at the enzyme within the membrane system and/or at the counter electrode on the electrode surface.
- transient ischemia can occur at high glucose levels, wherein oxygen can become limiting to the enzymatic reaction, resulting in a non-glucose dependent downward trend in the data.
- certain movements or postures taken by the patient can cause transient signal artifacts as blood is squeezed out of the capillaries resulting in local ischemia and causing non-glucose dependent signal artifacts.
- oxygen can also become transiently limited due to contracture of tissues around the sensor interface. This is similar to the blanching of skin that can be observed when one puts pressure on it. Under such pressure, transient ischemia can occur in both the epidermis and subcutaneous tissue. Transient ischemia is common and well tolerated by subcutaneous tissue. However, such ischemic periods can cause an oxygen deficit in implanted devices that can last for many minutes or even an hour or longer.
- analyte sensors that use alternative catalysts to detect other analytes, for example, amino acids (amino acid oxidase), alcohol (alcohol oxidase), galactose (galactose oxidase), lactate (lactate oxidase), cholesterol (cholesterol oxidase), or the like.
- amino acids amino acid oxidase
- alcohol alcohol
- galactose galactose oxidase
- lactate lactate oxidase
- cholesterol cholesterol
- interfering species are compounds with an oxidation or reduction potential that overlaps with the analyte to be measured (or the by-product of the enzymatic reaction with the analyte).
- Some conventional glucose sensors utilize a membrane system that blocks at least some interfering species, such as ascorbate and urate.
- at least one layer of the membrane system includes a porous structure that has a relatively impermeable matrix with a plurality of “micro holes” or pores of molecular dimensions, such that transfer through these materials is primarily due to passage of species through the pores (for example, the layer acts as a microporous barrier or sieve blocking interfering species of a particular size).
- at least one layer of the membrane system defines a permeability that allows selective dissolution and diffusion of species as solutes through the layer.
- an electrochemical sensor is provided with an auxiliary electrode configured to generate oxygen in order to overcome the effects of transient ischemia.
- an electrochemical sensor is provided with an auxiliary electrode configured to electrochemically modify (for example, oxidize or reduce) electrochemical interferants to render them substantially non-electroactively reactive at the electroactive sensing surface(s) in order to overcome the effects of interferants on the working electrode.
- oxygen can be generated as a product of electrochemical reactions occurring at a positively charged electrode (for example, set at about +0.6 to about +1.2 V or more).
- a positively charged electrode for example, set at about +0.6 to about +1.2 V or more.
- an oxygen producing reaction is the electrolysis of water, which creates oxygen at the anode (for example, the working electrode).
- glucose is converted to hydrogen peroxide by reacting with glucose oxidase and oxygen, after which the hydrogen peroxide is oxidized at the working electrode and oxygen is generated therefrom.
- auxiliary electrode does produce excess oxygen
- the placement of the auxiliary electrode in proximity to the analyte-measuring working electrode can cause oxidation of hydrogen peroxide at the auxiliary electrode, resulting in reduced signals at the working electrode.
- electrochemical interferants can be reduced at a potential of from about +0.1V to +1.2V or more; for example, acetaminophen is reduced at a potential of about +0.4 V.
- the sensors of preferred embodiments place an auxiliary electrode above the electrode system 16 , or other electroactive sensing surface, thereby reducing or eliminating the problem of inaccurate signals as described above.
- FIG. 4 is a side schematic illustration of a portion of the sensing region of an electrochemical sensor of the preferred embodiments, showing an auxiliary electrode between the enzyme and the outside solution while the working (sensing) electrode is located below the enzyme and further from the outside solution.
- FIG. 4 shows an external solution 12 , which represents the bodily or other fluid to which the sensor is exposed in vivo or in vitro.
- the membrane system 18 includes a plurality of domains (for example, cell impermeable domain, resistance domain, enzyme domain, and/or other domains such as are described in U.S. Published Patent Application 2003/0032874 to Rhodes et al. and copending U.S. patent application Ser. No. 10/885,476, filed Jul. 6, 2004 and entitled, “SYSTEMS AND METHODS FOR MANUFACTURE OF AN ANALYTE-MEASURING DEVICE INCLUDING A MEMBRANE SYSTEM”, the contents of which are incorporated herein by reference in their entireties) is located proximal to the external solution and functions to transport fluids necessary for the enzymatic reaction, while protecting inner components of the sensor from harsh biohazards, for example.
- each domain is not independently shown, the enzyme 38 is shown disposed between an auxiliary electrode 36 and the working electrode 16 a in the illustrated embodiment.
- the auxiliary electrode 36 is located within or adjacent to the membrane system 18 , for example, between the enzyme and other domains, although the auxiliary electrode can be placed anywhere between the electroactive sensing surface and the outside fluid.
- the auxiliary electrode 36 is formed from known working electrode materials (for example, platinum, palladium, graphite, gold, carbon, conductive polymer, or the like) and has a voltage setting that produces oxygen (for example, from about +0.6 V to +1.2 V or more) and/or that electrochemically modifies (for example, reduces) electrochemical interferants to render them substantially non-reactive at the electroactive sensing surface(s) (for example, from about +0.1 V to +1.2 V or more).
- the auxiliary electrode can be a mesh, grid, plurality of spaced wires or conductive polymers, or other configurations designed to allow analytes to penetrate therethrough.
- the oxygen generated from the auxiliary electrode 36 diffuses upward and/or downward to be utilized by the enzyme 38 and/or the counter electrode (depending on the placement of the auxiliary electrode).
- the analyte for example, glucose
- the enzyme 38 reacts with the enzyme 38 and produces a measurable product (for example, hydrogen peroxide). Therefore, the product of the enzymatic reaction diffuses down to the working electrode 16 a for accurate measurement without being eliminated by the auxiliary electrode 36 .
- the auxiliary electrode 36 can be coated with a polymeric material, which is impermeable to glucose but permeable to oxygen. By this coating, glucose will not electroactively react at the auxiliary electrode 36 , which can otherwise cause at least some of the glucose to pre-oxidize as it passes through the auxiliary electrode 36 (when placed above the enzyme), which can prevent accurate glucose concentration measurements at the working electrode in some sensor configurations.
- the polymer coating comprises silicone, however any polymer that is selectively permeable to oxygen, but not glucose, can be used.
- the auxiliary electrode 16 can be coated by any known process, such as dip coating or spray coating, after which is can be blown, blotted, or the like to maintain spaces within the electrode for glucose transport.
- the auxiliary electrode 36 can be coated with a polymeric material that is permeable to glucose and oxygen and can be placed between the enzyme and the outside fluid. Consequently, the polymeric coating will cause glucose from the outside fluid to electroactively react at the auxiliary electrode 36 , thereby limiting the amount of glucose that passes into the enzyme 38 , and thus reducing the amount of oxygen necessary to successfully react with all available glucose in the enzyme.
- the polymeric material can function in place of or in combination with the resistance domain in order to limit the amount of glucose that passes through the membrane system. This embodiment assumes a stoichiometric relationship between glucose oxidation and decreased sensor signal output, which can be compensated for by calibration in some sensor configurations.
- the auxiliary electrode generates oxygen, further reducing the likelihood of oxygen becoming a rate-limiting factor in the enzymatic reaction and/or at the counter electrode, for example.
- the auxiliary electrode 36 is configured to electrochemically modify (for example, oxidize or reduce) electrochemical interferants to render them substantially non-reactive at the electroactive sensing surface(s).
- a polymer coating is chosen to selectively allow interferants (for example, urate, ascorbate, and/or acetaminophen such as described in U.S. Pat. No. 6,579,690 to Bonnecaze, et al.) to pass through the coating and electrochemically react with the auxiliary electrode, which effectively pre-oxidizes the interferants, rendering them substantially non-reactive at the working electrode 16 a.
- silicone materials can be synthesized to allow the transport of oxygen, acetaminophen and other interferants, but not allow the transport of glucose.
- the polymer coating material can be chosen with a molecular weight that blocks glucose and allows the transport of oxygen, urate, ascorbate, and acetaminophen.
- silicone materials can be synthesized to allow the transport of oxygen, glucose, acetaminophen, and other interferants.
- the polymer coating material is chosen with a molecular weight that allows the transport of oxygen, glucose, urate, ascorbate, and acetaminophen.
- the voltage setting necessary to react with interfering species depends on the target electrochemical interferants, for example, from about +0.1 V to about +1.2 V.
- the auxiliary electrode is set at a potential of from about +0.6 to about +1.2 V, both oxygen-generation and electrochemical interferant modification can be achieved.
- the auxiliary electrode is set at a potential below about +0.6 V, the auxiliary electrode will function mainly to electrochemically modify interferants, for example.
- the sensors of preferred embodiments reduce or eliminate oxygen deficiency problems within electrochemical sensors by producing oxygen at an auxiliary electrode located above the enzyme within an enzyme-based electrochemical sensor. Additionally or alternatively, the sensors of preferred embodiments reduce or eliminate interfering species problems by electrochemically reacting with interferants at the auxiliary electrode rendering them substantially non-reactive at the working electrode.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Wood Science & Technology (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- General Physics & Mathematics (AREA)
- Electrochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates generally to systems and methods for improved electrochemical measurement of analytes. The preferred embodiments employ electrode systems including an analyte-measuring electrode for measuring the analyte or the product of an enzyme reaction with the analyte and an auxiliary electrode configured to generate oxygen and/or reduce electrochemical interferants. Oxygen generation by the auxiliary electrode advantageously improves oxygen availability to the enzyme and/or counter electrode; thereby enabling the electrochemical sensors of the preferred embodiments to function even during ischemic conditions. Interferant modification by the auxiliary electrode advantageously renders them substantially non-reactive at the analyte-measuring electrode, thereby reducing or eliminating inaccuracies in the analyte signal due to electrochemical interferants.
Description
- This application is a continuation of U.S. application Ser. No. 12/139,305 filed on Jun. 13, 2008, which is a broadening reissue of U.S. application Ser. No. 10/897312 filed on Jul. 21, 2004, which issued as U.S. Pat. No. 7,074,307, and which claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 60/490,007, filed Jul. 25, 2003, the disclosures of which are hereby expressly incorporated by reference in their entirety and are hereby expressly made a portion of this application.
- The present invention relates generally to systems and methods for improving electrochemical sensor performance.
- Electrochemical sensors are useful in chemistry and medicine to determine the presence or concentration of a biological analyte. Such sensors are useful, for example, to monitor glucose in diabetic patients and lactate during critical care events.
- Diabetes mellitus is a disorder in which the pancreas cannot create sufficient insulin (Type I or insulin dependent) and/or in which insulin is not effective (Type 2 or non-insulin dependent). In the diabetic state, the victim suffers from high blood sugar, which causes an array of physiological derangements (kidney failure, skin ulcers, or bleeding into the vitreous of the eye) associated with the deterioration of small blood vessels. A hypoglycemic reaction (low blood sugar) is induced by an inadvertent overdose of insulin, or after a normal dose of insulin or glucose-lowering agent accompanied by extraordinary exercise or insufficient food intake.
- Conventionally, a diabetic person carries a self-monitoring blood glucose (SMBG) monitor, which typically comprises uncomfortable finger pricking methods. Due to the lack of comfort and convenience, a diabetic will normally only measure his or her glucose level two to four times per day. Unfortunately, these time intervals are spread apart so far that the diabetic will likely find out too late, sometimes incurring dangerous side effects, of a hyperglycemic or hypoglycemic condition. It is not only unlikely that a diabetic will take a timely SMBG value, but additionally the diabetic will not know if their blood glucose value is going up (higher) or down (lower) based on conventional methods.
- Consequently, a variety of transdermal and implantable electrochemical sensors are being developed for continuously detecting and/or quantifying blood glucose values. Many implantable glucose sensors suffer from complications within the body and provide only short-term or less-than-accurate working of blood glucose. Similarly, transdermal sensors have problems in accurately working and reporting back glucose values continuously over extended periods of time. Some efforts have been made to obtain blood glucose data from implantable devices and retrospectively determine blood glucose trends for analysis; however these efforts do not aid the diabetic in determining real-time blood glucose information. Some efforts have also been made to obtain blood glucose data from transdermal devices for prospective data analysis, however similar problems have occurred.
- In contrast to the prior art, the sensors of preferred embodiments advantageously generate oxygen to allow the sensor to function at sufficient oxygen levels independent of the oxygen concentration in the surrounding environment. In another aspect of the preferred embodiments, systems and methods for modifying electrochemical interferants are provided.
- Accordingly, in a first embodiment, an electrochemical sensor for determining a presence or a concentration of an analyte in a fluid is provided, the sensor comprising a membrane system comprising an enzyme, wherein the enzyme reacts with the analyte; an electroactive surface comprising a working electrode, the working electrode comprising a conductive material and configured to measure a product of the reaction of the enzyme with the analyte; and an auxiliary electrode comprising a conductive material and configured to generate oxygen, wherein the auxiliary electrode is situated such that the oxygen generated diffuses to the enzyme or to the electroactive surface.
- In an aspect of the first embodiment, the auxiliary electrode comprises a conductive material selected from the group consisting of a conductive metal, a conductive polymer, and a blend of a conductive metal and a conductive polymer.
- In an aspect of the first embodiment, the auxiliary electrode comprises a form selected from the group consisting of a mesh, a grid, and a plurality of spaced wires.
- In an aspect of the first embodiment, the auxiliary electrode comprises a polymer, wherein the polymer is situated on a surface of the auxiliary electrode.
- In an aspect of the first embodiment, the polymer comprises a material that is impermeable to glucose but is permeable to oxygen.
- In an aspect of the first embodiment, the polymer comprises a material that is impermeable to glucose but is permeable to oxygen and permeable to interfering species.
- In an aspect of the first embodiment, the polymer comprises a material having a molecular weight that blocks glucose and allows transport therethrough of oxygen, urate, ascorbate, and acetaminophen.
- In an aspect of the first embodiment, the polymer comprises a material that is permeable to glucose and oxygen.
- In an aspect of the first embodiment, the polymer comprises a material that is permeable to glucose, oxygen, and interfering species.
- In an aspect of the first embodiment, the polymer comprises a material having a molecular weight that allows transport therethrough of oxygen, glucose, urate, ascorbate, and acetaminophen.
- In an aspect of the first embodiment, the auxiliary electrode is configured to be set at a potential of at least about +0.6 V.
- In an aspect of the first embodiment, the auxiliary electrode is configured to electrochemically modify an electrochemical interferant to render the electrochemical interferent substantially electrochemically non-reactive at the working electrode.
- In an aspect of the first embodiment, the auxiliary electrode is configured to be set at a potential of at least about +0.1 V.
- In a second embodiment, an electrochemical sensor for determining a presence or a concentration of an analyte in a fluid is provided, the sensor comprising a membrane system comprising an enzyme, wherein the enzyme reacts with the analyte; an electroactive surface comprising a working electrode, the working electrode comprising a conductive material and configured to measure a product of the reaction of the enzyme with the analyte; and an auxiliary electrode comprising a conductive material and configured to modify an electrochemical interferant such that the electrochemical interferent is rendered substantially electrochemically non-reactive at the working electrode.
- In an aspect of the second embodiment, the auxiliary electrode comprises a conductive material selected from the group consisting of a conductive metal, a conductive polymer, and a blend of a conductive metal and a conductive polymer.
- In an aspect of the second embodiment, the auxiliary electrode comprises a form selected from the group consisting of a mesh, a grid, and a plurality of spaced wires.
- In an aspect of the second embodiment, the auxiliary electrode comprises a polymer, wherein the polymer is situated on a surface of the auxiliary electrode.
- In an aspect of the second embodiment, the polymer comprises a material that is permeable to an electrochemical interferant.
- In an aspect of the second embodiment, the polymer comprises a material that is impermeable to glucose but is permeable to oxygen.
- In an aspect of the second embodiment, the polymer comprises a material that is impermeable to glucose but is permeable to oxygen and interferants.
- In an aspect of the second embodiment, the polymer comprises a material having a molecular weight that blocks glucose and allows transport therethrough of oxygen, urate, ascorbate, and acetaminophen.
- In an aspect of the second embodiment, the polymer comprises a material that is permeable to glucose and oxygen.
- In an aspect of the second embodiment, the polymer comprises a material that is permeable to glucose, oxygen, and interferants.
- In an aspect of the second embodiment, the polymer comprises a material having a molecular weight that allows transport therethrough of oxygen, glucose, urate, ascorbate, and acetaminophen.
- In an aspect of the second embodiment, the auxiliary electrode is configured to be set at a potential of at least about +0.1V.
- In an aspect of the second embodiment, the auxiliary electrode is configured to generate oxygen.
- In an aspect of the second embodiment, the auxiliary electrode is configured to be set at a potential of at least about +0.6 V.
- In a third embodiment, an electrochemical sensor is provided comprising an electroactive surface configured to measure an analyte; and an auxiliary interferant-modifying electrode configured to modify an electrochemical interferant such that the electrochemical interferant is rendered substantially non-reactive at the electroactive surface.
- In an aspect of the third embodiment, the auxiliary interferant-modifying electrode comprises a conductive material selected from the group consisting of a conductive metal, a conductive polymer, and a blend of a conductive metal and a conductive polymer.
- In an aspect of the third embodiment, the auxiliary interferant-modifying electrode comprises a form selected from the group consisting of a mesh, a grid, and a plurality of spaced wires.
- In an aspect of the third embodiment, the auxiliary interferant-modifying electrode comprises a polymer, wherein the polymer is situated on a surface of the auxiliary interferant-modifying electrode.
-
FIG. 1 is an exploded perspective view of one exemplary embodiment of a implantable glucose sensor. -
FIG. 2 is a block diagram that illustrates sensor electronics in one exemplary embodiment. -
FIG. 3 is a graph that shows a raw data stream obtained from a glucose sensor without an auxiliary electrode of the preferred embodiments. -
FIG. 4 is a side schematic illustration of a portion of an electrochemical sensor of the preferred embodiments, showing an auxiliary electrode placed proximal to the enzyme domain within a membrane system. - The following description and examples illustrate some exemplary embodiments of the disclosed invention in detail. Those of skill in the art will recognize that there are numerous variations and modifications of this invention that are encompassed by its scope. Accordingly, the description of a certain exemplary embodiment should not be deemed to limit the scope of the present invention.
- In order to facilitate an understanding of the preferred embodiments, a number of terms are defined below.
- The term “analyte” as used herein is a broad term and is used in its ordinary sense, including, without limitation, to refer to a substance or chemical constituent in a biological fluid (for example, blood, interstitial fluid, cerebral spinal fluid, lymph fluid or urine) that can be analyzed. Analytes can include naturally occurring substances, artificial substances, metabolites, and/or reaction products. In some embodiments, the analyte for measurement by the sensing regions, devices, and methods is glucose. However, other analytes are contemplated as well, including but not limited to acarboxyprothrombin; acylcarnitine; adenine phosphoribosyl transferase; adenosine deaminase; albumin; alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, tryptophan); andrenostenedione; antipyrine; arabinitol enantiomers; arginase; benzoylecgonine (cocaine); biotinidase; biopterin; c-reactive protein; carnitine; carnosinase; CD4; ceruloplasmin; chenodeoxycholic acid; chloroquine; cholesterol; cholinesterase; conjugated 1-β hydroxy-cholic acid; cortisol; creatine kinase; creatine kinase MM isoenzyme; cyclosporin A; d-penicillamine; de-ethylchloroquine; dehydroepiandrosterone sulfate; DNA (acetylator polymorphism, alcohol dehydrogenase, alpha 1-antitrypsin, cystic fibrosis, Duchenne/Becker muscular dystrophy, glucose-6-phosphate dehydrogenase, hemoglobin A, hemoglobin S, hemoglobin C, hemoglobin D, hemoglobin E, hemoglobin F, D-Punjab, beta-thalassemia, hepatitis B virus, HCMV, HIV-1, HTLV-1, Leber hereditary optic neuropathy, MCAD, RNA, PKU, Plasmodium vivax, sexual differentiation, 21-deoxycortisol); desbutylhalofantrine; dihydropteridine reductase; diptheria/tetanus antitoxin; erythrocyte arginase; erythrocyte protoporphyrin; esterase D; fatty acids/acylglycines; free β-human chorionic gonadotropin; free erythrocyte porphyrin; free thyroxine (FT4); free tri-iodothyronine (FT3); fumarylacetoacetase; galactose/gal-1-phosphate; galactose-1-phosphate uridyltransferase; gentamicin; glucose-6-phosphate dehydrogenase; glutathione; glutathione perioxidase; glycocholic acid; glycosylated hemoglobin; halofantrine; hemoglobin variants; hexosaminidase A; human erythrocyte carbonic anhydrase I; 17-alpha-hydroxyprogesterone; hypoxanthine phosphoribosyl transferase; immunoreactive trypsin; lactate; lead; lipoproteins ((a), B/A-1, β); lysozyme; mefloquine; netilmicin; phenobarbitone; phenytoin; phytanic/pristanic acid; progesterone; prolactin; prolidase; purine nucleoside phosphorylase; quinine; reverse tri-iodothyronine (rT3); selenium; serum pancreatic lipase; sissomicin; somatomedin C; specific antibodies (adenovirus, anti-nuclear antibody, anti-zeta antibody, arbovirus, Aujeszky's disease virus, dengue virus, Dracunculus medinensis, Echinococcus granulosus, Entamoeba histolytica, enterovirus, Giardia duodenalisa, Helicobacter pylori, hepatitis B virus, herpes virus, HIV-1, IgE (atopic disease), influenza virus, Leishmania donovani, leptospira, measles/mumps/rubella, Mycobacterium leprae, Mycoplasma pneumoniae, Myoglobin, Onchocerca volvulus, parainfluenza virus, Plasmodium falciparum, poliovirus, Pseudomonas aeruginosa, respiratory syncytial virus, rickettsia (scrub typhus), Schistosoma mansoni, Toxoplasma gondii, Trepenoma pallidium, Trypanosoma cruzi/rangeli, vesicular stomatis virus, Wuchereria bancrofti, yellow fever virus); specific antigens (hepatitis B virus, HIV-1); succinylacetone; sulfadoxine; theophylline; thyrotropin (TSH); thyroxine (T4); thyroxine-binding globulin; trace elements; transferrin; UDP-galactose-4-epimerase; urea; uroporphyrinogen I synthase; vitamin A; white blood cells; and zinc protoporphyrin. Salts, sugar, protein, fat, vitamins and hormones naturally occurring in blood or interstitial fluids can also constitute analytes in certain embodiments. The analyte can be naturally present in the biological fluid or endogenous, for example, a metabolic product, a hormone, an antigen, an antibody, and the like. Alternatively, the analyte can be introduced into the body or exogenous, for example, a contrast agent for imaging, a radioisotope, a chemical agent, a fluorocarbon-based synthetic blood, or a drug or pharmaceutical composition, including but not limited to insulin; ethanol; cannabis (marijuana, tetrahydrocannabinol, hashish); inhalants (nitrous oxide, amyl nitrite, butyl nitrite, chlorohydrocarbons, hydrocarbons); cocaine (crack cocaine); stimulants (amphetamines, methamphetamines, Ritalin, Cylert, Preludin, Didrex, PreState, Voranil, Sandrex, Plegine); depressants (barbituates, methaqualone, tranquilizers such as Valium, Librium, Miltown, Serax, Equanil, Tranxene); hallucinogens (phencyclidine, lysergic acid, mescaline, peyote, psilocybin); narcotics (heroin, codeine, morphine, opium, meperidine, Percocet, Percodan, Tussionex, Fentanyl, Darvon, Talwin, Lomotil); designer drugs (analogs of fentanyl, meperidine, amphetamines, methamphetamines, and phencyclidine, for example, Ecstasy); anabolic steroids; and nicotine. The metabolic products of drugs and pharmaceutical compositions are also contemplated analytes. Analytes such as neurochemicals and other chemicals generated within the body can also be analyzed, such as, for example, ascorbic acid, uric acid, dopamine, noradrenaline, 3-methoxytyramine (3MT), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxytryptamine (5HT), and 5-hydroxyindoleacetic acid (FHIAA).
- The terms “operable connection,” “operably connected,” and “operably linked” as used herein are broad terms and are used in their ordinary sense, including, without limitation, one or more components linked to another component(s) in a manner that allows transmission of signals between the components. For example, one or more electrodes can be used to detect the amount of analyte in a sample and convert that information into a signal; the signal can then be transmitted to a circuit. In this case, the electrode is “operably linked” to the electronic circuitry.
- The term “host” as used herein is a broad term and is used in its ordinary sense, including, without limitation, mammals, particularly humans.
- The term “sensor,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, the portion or portions of an analyte-monitoring device that detects an analyte. In one embodiment, the sensor includes an electrochemical cell that has a working electrode, a reference electrode, and optionally a counter electrode passing through and secured within the sensor body forming an electrochemically reactive surface at one location on the body, an electronic connection at another location on the body, and a membrane system affixed to the body and covering the electrochemically reactive surface. During general operation of the sensor, a biological sample (for example, blood or interstitial fluid), or a portion thereof, contacts (directly or after passage through one or more membranes or domains) an enzyme (for example, glucose oxidase); the reaction of the biological sample (or portion thereof) results in the formation of reaction products that allow a determination of the analyte level in the biological sample.
- The term “signal output,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, an analog or digital signal directly related to the measured analyte from the analyte-measuring device. The term broadly encompasses a single point, or alternatively, a plurality of time spaced data points from a substantially continuous glucose sensor, which comprises individual measurements taken at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes or longer.
- The term “electrochemical cell,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, a device in which chemical energy is converted to electrical energy. Such a cell typically consists of two or more electrodes held apart from each other and in contact with an electrolyte solution. Connection of the electrodes to a source of direct electric current renders one of them negatively charged and the other positively charged. Positive ions in the electrolyte migrate to the negative electrode (cathode) and there combine with one or more electrons, losing part or all of their charge and becoming new ions having lower charge or neutral atoms or molecules; at the same time, negative ions migrate to the positive electrode (anode) and transfer one or more electrons to it, also becoming new ions or neutral particles. The overall effect of the two processes is the transfer of electrons from the negative ions to the positive ions, a chemical reaction.
- The term “potentiostat,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, an electrical system that controls the potential between the working and reference electrodes of a three-electrode cell at a preset value independent of resistance changes between the electrodes. It forces whatever current is necessary to flow between the working and counter electrodes to keep the desired potential, as long as the cell voltage and current do not exceed the compliance limits of the potentiostat.
- The terms “electrochemically reactive surface” and “electroactive surface” as used herein are broad terms and are used in their ordinary sense, including, without limitation, the surface of an electrode where an electrochemical reaction takes place. In one example, a working electrode measures hydrogen peroxide produced by the enzyme catalyzed reaction of the analyte being detected reacts creating an electric current (for example, detection of glucose analyte utilizing glucose oxidase produces H2O2 as a by product, H2O2 reacts with the surface of the working electrode producing two protons (2H+), two electrons (2e−) and one molecule of oxygen (O2) which produces the electronic current being detected). In the case of the counter electrode, a reducible species, for example, O2 is reduced at the electrode surface in order to balance the current being generated by the working electrode.
- The term “sensing region” as used herein is a broad term and is used in its ordinary sense, including, without limitation, the region of a monitoring device responsible for the detection of a particular analyte. The sensing region generally comprises a non-conductive body, a working electrode, a reference electrode, and optionally a counter electrode passing through and secured within the body forming electrochemically reactive surfaces on the body and an electronic connective means at another location on the body, and a multi-domain membrane system affixed to the body and covering the electrochemically reactive surface.
- The terms “raw data stream” and “data stream,” as used herein, are broad terms and are used in their ordinary sense, including, without limitation, an analog or digital signal directly related to the measured an analyte from an analyte sensor. In one example, the raw data stream is digital data in “counts” converted by an A/D converter from an analog signal (for example, voltage or amps) representative of a analyte concentration. The terms broadly encompass a plurality of time spaced data points from a substantially continuous analyte sensor, which comprises individual measurements taken at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes or longer.
- The term “counts,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, a unit of measurement of a digital signal. In one example, a raw data stream measured in counts is directly related to a voltage (for example, converted by an A/D converter), which is directly related to current from the working electrode. In another example, counter electrode voltage measured in counts is directly related to a voltage.
- The terms “electrical potential” and “potential” as used herein, are broad terms and are used in their ordinary sense, including, without limitation, the electrical potential difference between two points in a circuit which is the cause of the flow of a current.
- The term “ischemia,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, local and temporary deficiency of blood supply due to obstruction of circulation to a part (for example, a sensor). Ischemia can be caused by mechanical obstruction (for example, arterial narrowing or disruption) of the blood supply, for example.
- The term “system noise,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, unwanted electronic or diffusion-related noise which can include Gaussian, motion-related, flicker, kinetic, or other white noise, for example.
- The terms “signal artifacts” and “transient non-glucose related signal artifacts that have a higher amplitude than system noise,” as used herein, are broad terms and are used in their ordinary sense, including, without limitation, signal noise that is caused by substantially non-glucose reaction rate-limiting phenomena, such as ischemia, pH changes, temperature changes, pressure, and stress, for example. Signal artifacts, as described herein, are typically transient and characterized by a higher amplitude than system noise.
- The term “low noise,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, noise that substantially decreases signal amplitude.
- The terms “high noise” and “high spikes,” as used herein, are broad terms and are used in their ordinary sense, including, without limitation, noise that substantially increases signal amplitude.
- The phrase “distal to” as used herein is a broad term and is used in its ordinary sense, including, without limitation, the spatial relationship between various elements in comparison to a particular point of reference. For example, some embodiments of a device include a membrane system having a cell disruptive domain and a cell impermeable domain. If the sensor is deemed to be the point of reference and the cell disruptive domain is positioned farther from the sensor, then that domain is distal to the sensor.
- The phrase “proximal to” as used herein is a broad term and is used in its ordinary sense, including, without limitation, the spatial relationship between various elements in comparison to a particular point of reference. For example, some embodiments of a device include a membrane system having a cell disruptive domain and a cell impermeable domain. If the sensor is deemed to be the point of reference and the cell impermeable domain is positioned nearer to the sensor, then that domain is proximal to the sensor.
- The terms “interferants” and “interfering species,” as used herein, are broad terms and are used in their ordinary sense, including, but not limited to, effects and/or species that interfere with the measurement of an analyte of interest in a sensor to produce a signal that does not accurately represent the analyte measurement. In one example of an electrochemical sensor, interfering species are compounds with an oxidation potential that overlaps with the analyte to be measured.
- As employed herein, the following abbreviations apply: Eq and Eqs (equivalents); mEq (milliequivalents); M (molar); mM (millimolar) μM (micromolar); N (Normal); mol (moles); mmol (millimoles); μmol (micromoles); nmol (nanomoles); g (grams); mg (milligrams); μg (micrograms); Kg (kilograms); L (liters); mL (milliliters); dL (deciliters); μL (microliters); cm (centimeters); mm (millimeters); μm (micrometers); nm (nanometers); h and hr (hours); min. (minutes); s and sec. (seconds); ° C. (degrees Centigrade).
- The preferred embodiments relate to the use of an electrochemical sensor that measures a concentration of an analyte of interest or a substance indicative of the concentration or presence of the analyte in fluid. In some embodiments, the sensor is a continuous device, for example a subcutaneous, transdermal, or intravascular device. In some embodiments, the device can analyze a plurality of intermittent blood samples.
- The sensor uses any known method, including invasive, minimally invasive, and non-invasive sensing techniques, to provide an output signal indicative of the concentration of the analyte of interest. The sensor is of the type that senses a product or reactant of an enzymatic reaction between an analyte and an enzyme in the presence of oxygen as a measure of the analyte in vivo or in vitro. Such a sensor typically comprises a membrane surrounding the enzyme through which a bodily fluid passes and in which an analyte within the bodily fluid reacts with an enzyme in the presence of oxygen to generate a product. The product is then measured using electrochemical methods and thus the output of an electrode system functions as a measure of the analyte. In some embodiments, the sensor can use an amperometric, coulometric, conductimetric, and/or potentiometric technique for measuring the analyte. In some embodiments, the electrode system can be used with any of a variety of known in vitro or in vivo analyte sensors or monitors.
-
FIG. 1 is an exploded perspective view of one exemplary embodiment of animplantable glucose sensor 10 that utilizes an electrode system 16. In this exemplary embodiment, a body with asensing region 14 includes an electrode system (16 a to 16 c), also referred to as the electroactive sensing surface, and sensor electronics, which are described in more detail with reference toFIG. 2 . - In this embodiment, the electrode system 16 is operably connected to the sensor electronics (
FIG. 2 ) and includes electroactive surfaces (including two-, three- or more electrode systems), which are covered by amembrane system 18. Themembrane system 18 is disposed over the electroactive surfaces of the electrode system 16 and provides one or more of the following functions: 1) protection of the exposed electrode surface from the biological environment (cell impermeable domain); 2) diffusion resistance (limitation) of the analyte (resistance domain); 3) a catalyst for enabling an enzymatic reaction (enzyme domain); 4) limitation or blocking of interfering species (interference domain); and/or 5) hydrophilicity at the electrochemically reactive surfaces of the sensor interface (electrolyte domain), for example, such as described in co-pending U.S. patent application Ser. No. 10/838,912, filed May 3, 2004 and entitled “IMPLANTABLE ANALYTE SENSOR,” the contents of which are incorporated herein by reference in their entirety. The membrane system can be attached to the sensor body by mechanical or chemical methods such as described in co-pending U.S. patent application Ser. No. 10/885,476, filed Jul. 6, 2004 and entitled, “SYSTEMS AND METHODS FOR MANUFACTURE OF AN ANALYTE-MEASURING DEVICE INCLUDING A MEMBRANE SYSTEM” and U.S. patent application Ser. No. 10/838,912 filed May 3, 2004 and entitled, “IMPLANTABLE ANALYTE SENSOR”, which are incorporated herein by reference in their entirety. - In the embodiment of
FIG. 1 , the electrode system 16 includes three electrodes (workingelectrode 16 a,counter electrode 16 b, andreference electrode 16 c), wherein the counter electrode is provided to balance the current generated by the species being measured at the working electrode. In the case of a glucose oxidase based glucose sensor, the species measured at the working electrode is H2O2. Glucose oxidase, GOX, catalyzes the conversion of oxygen and glucose to hydrogen peroxide and gluconate according to the following reaction: -
GOX+Glucose+O2→Gluconate+H2O2+reduced GOX - The change in H2O2 can be monitored to determine glucose concentration because for each glucose molecule metabolized, there is a proportional change in the product H2O2. Oxidation of H2O2 by the working electrode is balanced by reduction of ambient oxygen, enzyme generated H2O2, or other reducible species at the counter electrode. The H2O2 produced from the glucose oxidase reaction further reacts at the surface of working electrode and produces two protons (2H+), two electrons (2e−), and one oxygen molecule (O2). In such embodiments, because the counter electrode utilizes oxygen as an electron acceptor, the most likely reducible species for this system are oxygen or enzyme generated peroxide. There are two main pathways by which oxygen can be consumed at the counter electrode. These pathways include a four-electron pathway to produce hydroxide and a two-electron pathway to produce hydrogen peroxide. In addition to the counter electrode, oxygen is further consumed by the reduced glucose oxidase within the enzyme domain. Therefore, due to the oxygen consumption by both the enzyme and the counter electrode, there is a net consumption of oxygen within the electrode system. Theoretically, in the domain of the working electrode there is significantly less net loss of oxygen than in the region of the counter electrode. In some embodiments, there is a close correlation between the ability of the counter electrode to maintain current balance and sensor function.
- In general, in electrochemical sensors wherein an enzymatic reaction depends on oxygen as a co-reactant, depressed function or inaccuracy can be experienced in low oxygen environments, for example in vivo. Subcutaneously implanted devices are especially susceptible to transient ischemia that can compromise device function; for example, because of the enzymatic reaction required for an implantable amperometric glucose sensor, oxygen must be in excess over glucose in order for the sensor to effectively function as a glucose sensor. If glucose becomes in excess, the sensor turns into an oxygen sensitive device. In vivo, glucose concentration can vary from about one hundred times or more that of the oxygen concentration. Consequently, one limitation of prior art enzymatic-based electrochemical analyte sensors can be caused by oxygen deficiencies, which is described in more detail with reference to
FIG. 3 . -
FIG. 2 is a block diagram that illustrates sensor electronics in one exemplary embodiment; one skilled in the art appreciates however that a variety of sensor electronics configurations can be implemented with the preferred embodiments. In this embodiment, apotentiostat 20 is shown, which is operatively connected to electrode system 16 (FIG. 1 ) to obtain a current value, and includes a resistor (not shown) that translates the current into voltage. The A/D converter 21 digitizes the analog signal into “counts” for processing. Accordingly, the resulting raw data signal in counts is directly related to the current measured by the potentiostat. - A
microprocessor 22 is the central control unit that housesEEPROM 23 andSRAM 24, and controls the processing of the sensor electronics. The alternative embodiments can utilize a computer system other than a microprocessor to process data as described herein. In some alternative embodiments, an application-specific integrated circuit (ASIC) can be used for some or all the sensor's central processing.EEPROM 23 provides semi-permanent storage of data, storing data such as sensor ID and necessary programming to process data signals (for example, programming for data smoothing such as described elsewhere herein).SRAM 24 is used for the system's cache memory, for example for temporarily storing recent sensor data. - The
battery 25 is operatively connected to themicroprocessor 22 and provides the necessary power for the sensor. In one embodiment, the battery is a Lithium Manganese Dioxide battery, however any appropriately sized and powered battery can be used. In some embodiments, a plurality of batteries can be used to power the system.Quartz crystal 26 is operatively connected to themicroprocessor 22 and maintains system time for the computer system. - The
RF Transceiver 27 is operably connected to themicroprocessor 22 and transmits the sensor data from the sensor to a receiver. Although a RF transceiver is shown here, some other embodiments can include a wired rather than wireless connection to the receiver. In yet other embodiments, the sensor can be transcutaneously connected via an inductive coupling, for example. Thequartz crystal 28 provides the system time for synchronizing the data transmissions from the RF transceiver. Thetransceiver 27 can be substituted with a transmitter in one embodiment. - Although
FIGS. 1 and 2 and associated text illustrate and describe an exemplary embodiment of an implantable glucose sensor, the electrode systems of the preferred embodiments described below can be implemented with any known electrochemical sensor, including U.S. Pat. No. 6,001,067 to Shults et al.; U.S. Pat. No. 6,702,857 to Brauker et al.; U.S. Pat. No. 6,212,416 to Ward et al.; U.S. Pat. No. 6,119,028 to Schulman et al; U.S. Pat. No. 6,400,974 to Lesho; U.S. Pat. No. 6,595,919 to Berner et al.; U.S. Pat. No. 6,141,573 to Kurnik et al.; U.S. Pat. No. 6,122,536 to Sun et al.; European Patent Application EP 1153571 to Varall et al.; U.S. Pat. No. 6,512,939 to Colvin et al.; U.S. Pat. No. 5,605,152 to Slate et al.; U.S. Pat. No. 4,431,004 to Bessman et al.; U.S. Pat. No. 4,703,756 to Gough et al.; U.S. Pat. No. 6,514,718 to Heller et al; U.S. Pat. No. 5,985,129 to Gough et al.; WO Patent Application Publication No. 2004/021877 to Caduff; U.S. Pat. No. 5,494,562 to Maley et al.; U.S. Pat. No. 6,120,676 to Heller et al.; and U.S. Pat. No. 6,542,765 to Guy et al., co-pending U.S. patent application Ser. No. 10/838,912 filed May 3, 2004 and entitled, “IMPLANTABLE ANALYTE SENSOR”; U.S. patent application Ser. No. 10/789,359 filed Feb. 26, 2004 and entitled, “INTEGRATED DELIVERY DEVICE FOR A CONTINUOUS GLUCOSE SENSOR”; “OPTIMIZED SENSOR GEOMETRY FOR AN IMPLANTABLE GLUCOSE SENSOR”; U.S. application Ser. No. 10/633,367 filed Aug. 1, 2003 entitled, “SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA,” the contents of each of which are incorporated herein by reference in their entirety. -
FIG. 3 is a graph that depicts a raw data stream obtained from a prior art glucose sensor such as described with reference toFIG. 1 . The x-axis represents time in minutes. The y-axis represents sensor data in counts. In this example, sensor output in counts is transmitted every 30-seconds. Theraw data stream 30 includes substantially smooth sensor output in some portions, however other portions exhibit erroneous or transient non-glucoserelated signal artifacts 32. Particularly, referring to thesignal artifacts 32, it is believed that effects of local ischemia on prior art electrochemical sensors creates erroneous (non-glucose) signal values due to oxygen deficiencies either at the enzyme within the membrane system and/or at the counter electrode on the electrode surface. - In one situation, when oxygen is deficient relative to the amount of glucose, then the enzymatic reaction is limited by oxygen rather than glucose. Thus, the output signal is indicative of the oxygen concentration rather than the glucose concentration, producing erroneous signals. Additionally, when an enzymatic reaction is rate-limited by oxygen, glucose is expected to build up in the membrane because it is not completely catabolized during the oxygen deficit. When oxygen is again in excess, there is also excess glucose due to the transient oxygen deficit. The enzyme rate then speeds up for a short period until the excess glucose is catabolized, resulting in spikes of non-glucose related increased sensor output. Accordingly, because excess oxygen (relative to glucose) is necessary for proper sensor function, transient ischemia can result in a loss of signal gain in the sensor data.
- In another situation, oxygen deficiency can be seen at the counter electrode when insufficient oxygen is available for reduction, which thereby affects the counter electrode in that it is unable to balance the current coming from the working electrode. When insufficient oxygen is available for the counter electrode, the counter electrode can be driven in its electrochemical search for electrons all the way to its most negative value, which could be ground or 0.0 V, which causes the reference to shift, reducing the bias voltage, such is as described in more detail below. In other words, a common result of ischemia a drop off in sensor current as a function of glucose concentration (for example, lower sensitivity). This happens because the working electrode no longer oxidizes all of the H2O2 arriving at its surface because of the reduced bias. In some extreme circumstances, an increase in glucose can produce no increase in current or even a decrease in current.
- In some situations, transient ischemia can occur at high glucose levels, wherein oxygen can become limiting to the enzymatic reaction, resulting in a non-glucose dependent downward trend in the data. In some situations, certain movements or postures taken by the patient can cause transient signal artifacts as blood is squeezed out of the capillaries resulting in local ischemia and causing non-glucose dependent signal artifacts. In some situations, oxygen can also become transiently limited due to contracture of tissues around the sensor interface. This is similar to the blanching of skin that can be observed when one puts pressure on it. Under such pressure, transient ischemia can occur in both the epidermis and subcutaneous tissue. Transient ischemia is common and well tolerated by subcutaneous tissue. However, such ischemic periods can cause an oxygen deficit in implanted devices that can last for many minutes or even an hour or longer.
- Although some examples of the effects of transient ischemia on a prior art glucose sensor are described above, similar effects can be seen with analyte sensors that use alternative catalysts to detect other analytes, for example, amino acids (amino acid oxidase), alcohol (alcohol oxidase), galactose (galactose oxidase), lactate (lactate oxidase), cholesterol (cholesterol oxidase), or the like.
- Another problem with conventional electrochemical sensors is that they can electrochemically react not only with the analyte to be measured (or by-product of the enzymatic reaction with the analyte), but additionally can react with other electroactive species that are not intentionally being measured (for example, interfering species), which causes an increase in signal strength due to these “interfering species”. In other words, interfering species are compounds with an oxidation or reduction potential that overlaps with the analyte to be measured (or the by-product of the enzymatic reaction with the analyte). For example, in a conventional amperometric glucose oxidase-based glucose sensor wherein the sensor measures hydrogen peroxide, interfering species such as acetaminophen, ascorbate, and urate are known to produce inaccurate signal strength when they are not properly controlled.
- Some conventional glucose sensors utilize a membrane system that blocks at least some interfering species, such as ascorbate and urate. In some such systems, at least one layer of the membrane system includes a porous structure that has a relatively impermeable matrix with a plurality of “micro holes” or pores of molecular dimensions, such that transfer through these materials is primarily due to passage of species through the pores (for example, the layer acts as a microporous barrier or sieve blocking interfering species of a particular size). In other such systems, at least one layer of the membrane system defines a permeability that allows selective dissolution and diffusion of species as solutes through the layer. Unfortunately, it is difficult to find membranes that are satisfactory or reliable in use, especially in vivo, which effectively block all interferants and/or interfering species in some embodiments.
- In one aspect of the preferred embodiments, an electrochemical sensor is provided with an auxiliary electrode configured to generate oxygen in order to overcome the effects of transient ischemia. In another aspect of the preferred embodiments, an electrochemical sensor is provided with an auxiliary electrode configured to electrochemically modify (for example, oxidize or reduce) electrochemical interferants to render them substantially non-electroactively reactive at the electroactive sensing surface(s) in order to overcome the effects of interferants on the working electrode.
- It is known that oxygen can be generated as a product of electrochemical reactions occurring at a positively charged electrode (for example, set at about +0.6 to about +1.2 V or more). One example of an oxygen producing reaction is the electrolysis of water, which creates oxygen at the anode (for example, the working electrode). In the exemplary electrochemical glucose sensor, glucose is converted to hydrogen peroxide by reacting with glucose oxidase and oxygen, after which the hydrogen peroxide is oxidized at the working electrode and oxygen is generated therefrom. It is noted that one challenge to generating oxygen electrochemically in this way is that while an auxiliary electrode does produce excess oxygen, the placement of the auxiliary electrode in proximity to the analyte-measuring working electrode can cause oxidation of hydrogen peroxide at the auxiliary electrode, resulting in reduced signals at the working electrode. It is also known that many electrochemical interferants can be reduced at a potential of from about +0.1V to +1.2V or more; for example, acetaminophen is reduced at a potential of about +0.4 V.
- Accordingly, the sensors of preferred embodiments place an auxiliary electrode above the electrode system 16, or other electroactive sensing surface, thereby reducing or eliminating the problem of inaccurate signals as described above.
-
FIG. 4 is a side schematic illustration of a portion of the sensing region of an electrochemical sensor of the preferred embodiments, showing an auxiliary electrode between the enzyme and the outside solution while the working (sensing) electrode is located below the enzyme and further from the outside solution. Particularly,FIG. 4 shows anexternal solution 12, which represents the bodily or other fluid to which the sensor is exposed in vivo or in vitro. - The
membrane system 18 includes a plurality of domains (for example, cell impermeable domain, resistance domain, enzyme domain, and/or other domains such as are described in U.S. Published Patent Application 2003/0032874 to Rhodes et al. and copending U.S. patent application Ser. No. 10/885,476, filed Jul. 6, 2004 and entitled, “SYSTEMS AND METHODS FOR MANUFACTURE OF AN ANALYTE-MEASURING DEVICE INCLUDING A MEMBRANE SYSTEM”, the contents of which are incorporated herein by reference in their entireties) is located proximal to the external solution and functions to transport fluids necessary for the enzymatic reaction, while protecting inner components of the sensor from harsh biohazards, for example. Although each domain is not independently shown, theenzyme 38 is shown disposed between anauxiliary electrode 36 and the workingelectrode 16 a in the illustrated embodiment. - Preferably, the
auxiliary electrode 36 is located within or adjacent to themembrane system 18, for example, between the enzyme and other domains, although the auxiliary electrode can be placed anywhere between the electroactive sensing surface and the outside fluid. Theauxiliary electrode 36 is formed from known working electrode materials (for example, platinum, palladium, graphite, gold, carbon, conductive polymer, or the like) and has a voltage setting that produces oxygen (for example, from about +0.6 V to +1.2 V or more) and/or that electrochemically modifies (for example, reduces) electrochemical interferants to render them substantially non-reactive at the electroactive sensing surface(s) (for example, from about +0.1 V to +1.2 V or more). The auxiliary electrode can be a mesh, grid, plurality of spaced wires or conductive polymers, or other configurations designed to allow analytes to penetrate therethrough. - In the aspect of the preferred embodiments wherein the
auxiliary electrode 36 is configured to generate oxygen, the oxygen generated from theauxiliary electrode 36 diffuses upward and/or downward to be utilized by theenzyme 38 and/or the counter electrode (depending on the placement of the auxiliary electrode). Additionally, the analyte (for example, glucose) from the outside solution (diffuses through the auxiliary electrode 36) reacts with theenzyme 38 and produces a measurable product (for example, hydrogen peroxide). Therefore, the product of the enzymatic reaction diffuses down to the workingelectrode 16 a for accurate measurement without being eliminated by theauxiliary electrode 36. - In one alternative embodiment, the
auxiliary electrode 36 can be coated with a polymeric material, which is impermeable to glucose but permeable to oxygen. By this coating, glucose will not electroactively react at theauxiliary electrode 36, which can otherwise cause at least some of the glucose to pre-oxidize as it passes through the auxiliary electrode 36 (when placed above the enzyme), which can prevent accurate glucose concentration measurements at the working electrode in some sensor configurations. In one embodiment, the polymer coating comprises silicone, however any polymer that is selectively permeable to oxygen, but not glucose, can be used. The auxiliary electrode 16 can be coated by any known process, such as dip coating or spray coating, after which is can be blown, blotted, or the like to maintain spaces within the electrode for glucose transport. - In another alternative embodiment, the
auxiliary electrode 36 can be coated with a polymeric material that is permeable to glucose and oxygen and can be placed between the enzyme and the outside fluid. Consequently, the polymeric coating will cause glucose from the outside fluid to electroactively react at theauxiliary electrode 36, thereby limiting the amount of glucose that passes into theenzyme 38, and thus reducing the amount of oxygen necessary to successfully react with all available glucose in the enzyme. The polymeric material can function in place of or in combination with the resistance domain in order to limit the amount of glucose that passes through the membrane system. This embodiment assumes a stoichiometric relationship between glucose oxidation and decreased sensor signal output, which can be compensated for by calibration in some sensor configurations. Additionally, the auxiliary electrode generates oxygen, further reducing the likelihood of oxygen becoming a rate-limiting factor in the enzymatic reaction and/or at the counter electrode, for example. - In another aspect of the preferred embodiments, the
auxiliary electrode 36 is configured to electrochemically modify (for example, oxidize or reduce) electrochemical interferants to render them substantially non-reactive at the electroactive sensing surface(s). In these embodiments, which can be in addition to or alternative to the above-described oxygen-generating embodiments, a polymer coating is chosen to selectively allow interferants (for example, urate, ascorbate, and/or acetaminophen such as described in U.S. Pat. No. 6,579,690 to Bonnecaze, et al.) to pass through the coating and electrochemically react with the auxiliary electrode, which effectively pre-oxidizes the interferants, rendering them substantially non-reactive at the workingelectrode 16 a. In one exemplary embodiment, silicone materials can be synthesized to allow the transport of oxygen, acetaminophen and other interferants, but not allow the transport of glucose. In some embodiments, the polymer coating material can be chosen with a molecular weight that blocks glucose and allows the transport of oxygen, urate, ascorbate, and acetaminophen. In another exemplary embodiment, silicone materials can be synthesized to allow the transport of oxygen, glucose, acetaminophen, and other interferants. In some embodiments, the polymer coating material is chosen with a molecular weight that allows the transport of oxygen, glucose, urate, ascorbate, and acetaminophen. The voltage setting necessary to react with interfering species depends on the target electrochemical interferants, for example, from about +0.1 V to about +1.2 V. In some embodiments, wherein the auxiliary electrode is set at a potential of from about +0.6 to about +1.2 V, both oxygen-generation and electrochemical interferant modification can be achieved. In some embodiments, wherein the auxiliary electrode is set at a potential below about +0.6 V, the auxiliary electrode will function mainly to electrochemically modify interferants, for example. - Therefore, the sensors of preferred embodiments reduce or eliminate oxygen deficiency problems within electrochemical sensors by producing oxygen at an auxiliary electrode located above the enzyme within an enzyme-based electrochemical sensor. Additionally or alternatively, the sensors of preferred embodiments reduce or eliminate interfering species problems by electrochemically reacting with interferants at the auxiliary electrode rendering them substantially non-reactive at the working electrode.
- Methods and devices that are suitable for use in conjunction with aspects of the preferred embodiments are disclosed in co-pending U.S. patent application Ser. No. 10/842,716, filed May 10, 2004 and entitled, “MEMBRANE SYSTEMS INCORPORATING BIOACTIVE AGENTS”; co-pending U.S. patent application Ser No. 10/838,912 filed May 3, 2004 and entitled, “IMPLANTABLE ANALYTE SENSOR”; U.S. patent application Ser. No. 10/789,359 filed Feb. 26, 2004 and entitled, “INTEGRATED DELIVERY DEVICE FOR A CONTINUOUS GLUCOSE SENSOR”; U.S. application Ser. No. 10/685,636 filed Oct. 28, 2003 and entitled, “SILICONE COMPOSITION FOR MEMBRANE SYSTEM”; U.S. application Ser. No. 10/648,849 filed Aug. 22, 2003 and entitled, “SYSTEMS AND METHODS FOR REPLACING SIGNAL ARTIFACTS IN A GLUCOSE SENSOR DATA STREAM”; U.S. application Ser. No. 10/646,333 filed Aug. 22, 2003 entitled, “OPTIMIZED SENSOR GEOMETRY FOR AN IMPLANTABLE GLUCOSE SENSOR”; U.S. application Ser. No. 10/647,065 filed Aug. 22, 2003 entitled, “POROUS MEMBRANES FOR USE WITH IMPLANTABLE DEVICES”; U.S. application Ser. No. 10/633,367 filed Aug. 1, 2003 entitled, “SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA”; U.S. Pat. No. 6,702,857 entitled “MEMBRANE FOR USE WITH IMPLANTABLE DEVICES”; U.S. application Ser. No. 09/916,711 filed Jul. 27, 2001 and entitled “SENSOR HEAD FOR USE WITH IMPLANTABLE DEVICE”; U.S. application Ser. No. 09/447,227 filed Nov. 22, 1999 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS”; U.S. application Ser. No. 10/153,356 filed May 22, 2002 and entitled “TECHNIQUES TO IMPROVE POLYURETHANE MEMBRANES FOR IMPLANTABLE GLUCOSE SENSORS”; U.S. application Ser. No. 09/489,588 filed Jan. 21, 2000 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS”; U.S. application Ser. No. 09/636,369 filed Aug. 11, 2000 and entitled “SYSTEMS AND METHODS FOR REMOTE MONITORING AND MODULATION OF MEDICAL DEVICES”; and U.S. application Ser. No. 09/916,858 filed Jul. 27, 2001 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS,” as well as issued patents including U.S. Pat. No. 6,001,067 issued Dec. 14, 1999 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS”; U.S. Pat. No. 4,994,167 issued Feb. 19, 1991 and entitled “BIOLOGICAL FLUID MEASURING DEVICE”; and U.S. Pat. No. 4,757,022 filed Jul. 12, 1988 and entitled “BIOLOGICAL FLUID MEASURING DEVICE”; U.S. application Ser. No. 60/489,615 filed Jul. 23, 2003 and entitled “ROLLED ELECTRODE ARRAY AND ITS METHOD FOR MANUFACTURE”; U.S. Appl. No. 60/490,010 filed Jul. 25, 2003 and entitled “INCREASING BIAS FOR OXYGEN PRODUCTION IN AN ELECTRODE ASSEMBLY”; U.S. Appl. No. 60/490,009 filed Jul. 25, 2003 and entitled “OXYGEN ENHANCING ENZYME MEMBRANE FOR ELECTROCHEMICAL SENSORS”; U.S. Appl. No. 60/490,007 filed Jul. 25, 2003 and entitled “OXYGEN-GENERATING ELECTRODE FOR USE IN ELECTROCHEMICAL SENSORS”; U.S. Appl. No. __/___,___ filed on even date herewith and entitled “ROLLED ELECTRODE ARRAY AND ITS METHOD FOR MANUFACTURE”; U.S. Appl. No. __/___,___ filed on even date herewith and entitled “INCREASING BIAS FOR OXYGEN PRODUCTION IN AN ELECTRODE ASSEMBLY”; U.S. Appl. No. __/___,___ filed on even date herewith and entitled “OXYGEN ENHANCING ENZYME MEMBRANE FOR ELECTROCHEMICAL SENSORS”; U.S. Appl. No. __/___,___ filed on even date herewith and entitled “ELECTROCHEMICAL SENSORS INCLUDING ELECTRODE SYSTEMS WITH INCREASED OXYGEN GENERATION”. The foregoing patent applications and patents are incorporated herein by reference in their entireties.
- All references cited herein are incorporated herein by reference in their entireties. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.
- The term “comprising” as used herein is synonymous with “including,” “containing,” or “characterized by,” and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps.
- All numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that can vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.
- The above description discloses several methods and materials of the present invention. This invention is susceptible to modifications in the methods and materials, as well as alterations in the fabrication methods and equipment. Such modifications will become apparent to those skilled in the art from a consideration of this disclosure or practice of the invention disclosed herein. Consequently, it is not intended that this invention be limited to the specific embodiments disclosed herein, but that it cover all modifications and alternatives coming within the true scope and spirit of the invention as embodied in the attached claims.
Claims (31)
1. An electrochemical sensor for determining a presence or a concentration of an analyte in a fluid, the sensor comprising:
a membrane system comprising an enzyme, wherein the enzyme reacts with the analyte;
an electroactive surface comprising a working electrode, the working electrode comprising a conductive material and configured to measure a product of the reaction of the enzyme with the analyte; and
an auxiliary electrode comprising a conductive material and configured to generate oxygen, wherein the auxiliary electrode is situated such that the oxygen generated diffuses to the enzyme or to the electroactive surface.
2. The electrochemical sensor of claim 1 , wherein the auxiliary electrode comprises a conductive material selected from the group consisting of a conductive metal, a conductive polymer, and a blend of a conductive metal and a conductive polymer.
3. The electrochemical sensor of claim 1 , wherein the auxiliary electrode comprises a form selected from the group consisting of a mesh, a grid, and a plurality of spaced wires.
4. The electrochemical sensor of claim 1 , wherein the auxiliary electrode comprises a polymer, wherein the polymer is situated on a surface of the auxiliary electrode.
5. The electrochemical sensor of claim 4 , wherein the polymer comprises a material that is impermeable to glucose but is permeable to oxygen.
6. The electrochemical sensor of claim 4 , wherein the polymer comprises a material that is impermeable to glucose but is permeable to oxygen and permeable to interfering species.
7. The electrochemical sensor of claim 6 , wherein the polymer comprises a material having a molecular weight that blocks glucose and allows transport therethrough of oxygen, urate, ascorbate, and acetaminophen.
8. The electrochemical sensor of claim 4 , wherein the polymer comprises a material that is permeable to glucose and oxygen.
9. The electrochemical sensor of claim 4 , wherein the polymer comprises a material that is permeable to glucose, oxygen, and interfering species.
10. The electrochemical sensor of claim 9 , wherein the polymer comprises a material having a molecular weight that allows transport therethrough of oxygen, glucose, urate, ascorbate, and acetaminophen.
11. The electrochemical sensor of claim 1 , wherein the auxiliary electrode is configured to be set at a potential of at least about +0.6 V.
12. The electrochemical sensor of claim 1 , wherein the auxiliary electrode is configured to electrochemically modify an electrochemical interferant to render the electrochemical interferent substantially electrochemically non-reactive at the working electrode.
13. The electrochemical sensor of claim 12 , wherein the auxiliary electrode is configured to be set at a potential of at least about +0.1 V.
14. An electrochemical sensor for determining a presence or a concentration of an analyte in a fluid, the sensor comprising:
a membrane system comprising an enzyme, wherein the enzyme reacts with the analyte;
an electroactive surface comprising a working electrode, the working electrode comprising a conductive material and configured to measure a product of the reaction of the enzyme with the analyte; and
an auxiliary electrode comprising a conductive material and configured to modify an electrochemical interferant such that the electrochemical interferent is rendered substantially electrochemically non-reactive at the working electrode.
15. The electrochemical sensor of claim 14 , wherein the auxiliary electrode comprises a conductive material selected from the group consisting of a conductive metal, a conductive polymer, and a blend of a conductive metal and a conductive polymer.
16. The electrochemical sensor of claim 14 , wherein the auxiliary electrode comprises a form selected from the group consisting of a mesh, a grid, and a plurality of spaced wires.
17. The electrochemical sensor of claim 14 , wherein the auxiliary electrode comprises a polymer, wherein the polymer is situated on a surface of the auxiliary electrode.
18. The electrochemical sensor of claim 17 , wherein the polymer comprises a material that is permeable to an electrochemical interferant.
19. The electrochemical sensor of claim 17 , wherein the polymer comprises a material that is impermeable to glucose but is permeable to oxygen.
20. The electrochemical sensor of claim 17 , wherein the polymer comprises a material that is impermeable to glucose but is permeable to oxygen and interferants.
21. The electrochemical sensor of claim 17 , wherein the polymer comprises a material having a molecular weight that blocks glucose and allows transport therethrough of oxygen, urate, ascorbate, and acetaminophen.
22. The electrochemical sensor of claim 17 , wherein the polymer comprises a material that is permeable to glucose and oxygen.
23. The electrochemical sensor of claim 17 , wherein the polymer comprises a material that is permeable to glucose, oxygen, and interferants.
24. The electrochemical sensor of claim 23 , wherein the polymer comprises a material having a molecular weight that allows transport therethrough of oxygen, glucose, urate, ascorbate, and acetaminophen.
25. The electrochemical sensor of claim 14 , wherein the auxiliary electrode is configured to be set at a potential of at least about +0.1V.
26. The electrochemical sensor of claim 14 , wherein the auxiliary electrode is configured to generate oxygen.
27. The electrochemical sensor of claim 26 , wherein the auxiliary electrode is configured to be set at a potential of at least about +0.6 V.
28. An electrochemical sensor comprising:
an electroactive surface configured to measure an analyte; and
an auxiliary interferant-modifying electrode configured to modify an electrochemical interferant such that the electrochemical interferant is rendered substantially non-reactive at the electroactive surface.
29. The electrochemical sensor of claim 28 , wherein the auxiliary interferant-modifying electrode comprises a conductive material selected from the group consisting of a conductive metal, a conductive polymer, and a blend of a conductive metal and a conductive polymer.
30. The electrochemical sensor of claim 28 , wherein the auxiliary interferant-modifying electrode comprises a form selected from the group consisting of a mesh, a grid, and a plurality of spaced wires.
31. The electrochemical sensor of claim 28 , wherein the auxiliary interferant-modifying electrode comprises a polymer, wherein the polymer is situated on a surface of the auxiliary interferant-modifying electrode.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/475,770 US20120228134A1 (en) | 2003-07-25 | 2012-05-18 | Electrode systems for electrochemical sensors |
| US14/014,216 US20140001042A1 (en) | 2003-07-25 | 2013-08-29 | Electrode systems for electrochemical sensors |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49000703P | 2003-07-25 | 2003-07-25 | |
| US10/897,312 US7074307B2 (en) | 2003-07-25 | 2004-07-21 | Electrode systems for electrochemical sensors |
| US12/139,305 USRE43399E1 (en) | 2003-07-25 | 2008-06-13 | Electrode systems for electrochemical sensors |
| US13/475,770 US20120228134A1 (en) | 2003-07-25 | 2012-05-18 | Electrode systems for electrochemical sensors |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/139,305 Continuation USRE43399E1 (en) | 2003-07-25 | 2008-06-13 | Electrode systems for electrochemical sensors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/014,216 Division US20140001042A1 (en) | 2003-07-25 | 2013-08-29 | Electrode systems for electrochemical sensors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20120228134A1 true US20120228134A1 (en) | 2012-09-13 |
Family
ID=34115342
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/897,312 Ceased US7074307B2 (en) | 2003-07-25 | 2004-07-21 | Electrode systems for electrochemical sensors |
| US12/139,305 Expired - Lifetime USRE43399E1 (en) | 2003-07-25 | 2008-06-13 | Electrode systems for electrochemical sensors |
| US13/475,770 Abandoned US20120228134A1 (en) | 2003-07-25 | 2012-05-18 | Electrode systems for electrochemical sensors |
| US14/014,216 Abandoned US20140001042A1 (en) | 2003-07-25 | 2013-08-29 | Electrode systems for electrochemical sensors |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/897,312 Ceased US7074307B2 (en) | 2003-07-25 | 2004-07-21 | Electrode systems for electrochemical sensors |
| US12/139,305 Expired - Lifetime USRE43399E1 (en) | 2003-07-25 | 2008-06-13 | Electrode systems for electrochemical sensors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/014,216 Abandoned US20140001042A1 (en) | 2003-07-25 | 2013-08-29 | Electrode systems for electrochemical sensors |
Country Status (4)
| Country | Link |
|---|---|
| US (4) | US7074307B2 (en) |
| EP (1) | EP1649260A4 (en) |
| JP (1) | JP2007500336A (en) |
| WO (1) | WO2005012873A2 (en) |
Cited By (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013152090A2 (en) | 2012-04-04 | 2013-10-10 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
| WO2013184566A2 (en) | 2012-06-05 | 2013-12-12 | Dexcom, Inc. | Systems and methods for processing analyte data and generating reports |
| WO2014004460A1 (en) | 2012-06-29 | 2014-01-03 | Dexcom, Inc. | Use of sensor redundancy to detect sensor failures |
| WO2014011488A2 (en) | 2012-07-09 | 2014-01-16 | Dexcom, Inc. | Systems and methods for leveraging smartphone features in continuous glucose monitoring |
| WO2014052080A1 (en) | 2012-09-28 | 2014-04-03 | Dexcom, Inc. | Zwitterion surface modifications for continuous sensors |
| WO2014158327A2 (en) | 2013-03-14 | 2014-10-02 | Dexcom, Inc. | Advanced calibration for analyte sensors |
| WO2014158405A2 (en) | 2013-03-14 | 2014-10-02 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
| WO2015100142A1 (en) * | 2013-12-27 | 2015-07-02 | Abbott Diabetes Care Inc. | Application interface and display control in an analyte monitoring environment |
| WO2015156966A1 (en) | 2014-04-10 | 2015-10-15 | Dexcom, Inc. | Sensors for continuous analyte monitoring, and related methods |
| US9956393B2 (en) | 2015-02-24 | 2018-05-01 | Elira, Inc. | Systems for increasing a delay in the gastric emptying time for a patient using a transcutaneous electro-dermal patch |
| US10118035B2 (en) | 2015-02-24 | 2018-11-06 | Elira, Inc. | Systems and methods for enabling appetite modulation and/or improving dietary compliance using an electro-dermal patch |
| US10335302B2 (en) | 2015-02-24 | 2019-07-02 | Elira, Inc. | Systems and methods for using transcutaneous electrical stimulation to enable dietary interventions |
| US10376145B2 (en) | 2015-02-24 | 2019-08-13 | Elira, Inc. | Systems and methods for enabling a patient to achieve a weight loss objective using an electrical dermal patch |
| US10561349B2 (en) | 2016-03-31 | 2020-02-18 | Dexcom, Inc. | Systems and methods for display device and sensor electronics unit communication |
| EP3654348A1 (en) | 2012-11-07 | 2020-05-20 | Dexcom, Inc. | Systems and methods for managing glycemic variability |
| US10765863B2 (en) | 2015-02-24 | 2020-09-08 | Elira, Inc. | Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy |
| US10860687B2 (en) | 2012-12-31 | 2020-12-08 | Dexcom, Inc. | Remote monitoring of analyte measurements |
| US10856736B2 (en) | 2012-12-31 | 2020-12-08 | Dexcom, Inc. | Remote monitoring of analyte measurements |
| US10864367B2 (en) | 2015-02-24 | 2020-12-15 | Elira, Inc. | Methods for using an electrical dermal patch in a manner that reduces adverse patient reactions |
| US10932672B2 (en) | 2015-12-28 | 2021-03-02 | Dexcom, Inc. | Systems and methods for remote and host monitoring communications |
| US10985804B2 (en) | 2013-03-14 | 2021-04-20 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
| US11112377B2 (en) | 2015-12-30 | 2021-09-07 | Dexcom, Inc. | Enzyme immobilized adhesive layer for analyte sensors |
| EP3925522A1 (en) | 2017-06-23 | 2021-12-22 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
| US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
| US11350862B2 (en) | 2017-10-24 | 2022-06-07 | Dexcom, Inc. | Pre-connected analyte sensors |
| EP4046571A1 (en) | 2015-10-21 | 2022-08-24 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
| US11892426B2 (en) | 2012-06-29 | 2024-02-06 | Dexcom, Inc. | Devices, systems, and methods to compensate for effects of temperature on implantable sensors |
| US11957895B2 (en) | 2015-02-24 | 2024-04-16 | Elira, Inc. | Glucose-based modulation of electrical stimulation to enable weight loss |
| US11998329B2 (en) | 2013-03-15 | 2024-06-04 | Dexcom, Inc. | Membrane for continuous analyte sensors |
| USD1036676S1 (en) | 2018-06-22 | 2024-07-23 | Dexcom, Inc. | Wearable medical monitoring device |
| EP4582022A1 (en) | 2017-01-18 | 2025-07-09 | DexCom, Inc. | Sensors for continuous analyte monitoring |
Families Citing this family (406)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5593852A (en) | 1993-12-02 | 1997-01-14 | Heller; Adam | Subcutaneous glucose electrode |
| SE9700384D0 (en) * | 1997-02-04 | 1997-02-04 | Biacore Ab | Analytical method and apparatus |
| US9155496B2 (en) | 1997-03-04 | 2015-10-13 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
| US6001067A (en) | 1997-03-04 | 1999-12-14 | Shults; Mark C. | Device and method for determining analyte levels |
| US7899511B2 (en) | 2004-07-13 | 2011-03-01 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
| US6862465B2 (en) | 1997-03-04 | 2005-03-01 | Dexcom, Inc. | Device and method for determining analyte levels |
| US20050033132A1 (en) | 1997-03-04 | 2005-02-10 | Shults Mark C. | Analyte measuring device |
| US7657297B2 (en) | 2004-05-03 | 2010-02-02 | Dexcom, Inc. | Implantable analyte sensor |
| US8527026B2 (en) | 1997-03-04 | 2013-09-03 | Dexcom, Inc. | Device and method for determining analyte levels |
| US6036924A (en) | 1997-12-04 | 2000-03-14 | Hewlett-Packard Company | Cassette of lancet cartridges for sampling blood |
| US6134461A (en) | 1998-03-04 | 2000-10-17 | E. Heller & Company | Electrochemical analyte |
| US6391005B1 (en) | 1998-03-30 | 2002-05-21 | Agilent Technologies, Inc. | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
| US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
| US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
| US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
| DE10057832C1 (en) | 2000-11-21 | 2002-02-21 | Hartmann Paul Ag | Blood analysis device has syringe mounted in casing, annular mounting carrying needles mounted behind test strip and being swiveled so that needle can be pushed through strip and aperture in casing to take blood sample |
| US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
| TW522127B (en) * | 2001-02-21 | 2003-03-01 | Daifuku Kk | Cargo storage facility |
| EP1397068A2 (en) | 2001-04-02 | 2004-03-17 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
| US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
| US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
| JP4209767B2 (en) | 2001-06-12 | 2009-01-14 | ペリカン テクノロジーズ インコーポレイテッド | Self-optimized cutting instrument with adaptive means for temporary changes in skin properties |
| EP1395185B1 (en) | 2001-06-12 | 2010-10-27 | Pelikan Technologies Inc. | Electric lancet actuator |
| US7041068B2 (en) | 2001-06-12 | 2006-05-09 | Pelikan Technologies, Inc. | Sampling module device and method |
| US8337419B2 (en) | 2002-04-19 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
| JP4272051B2 (en) | 2001-06-12 | 2009-06-03 | ペリカン テクノロジーズ インコーポレイテッド | Blood sampling apparatus and method |
| US7344507B2 (en) | 2002-04-19 | 2008-03-18 | Pelikan Technologies, Inc. | Method and apparatus for lancet actuation |
| US7981056B2 (en) | 2002-04-19 | 2011-07-19 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
| AU2002344825A1 (en) | 2001-06-12 | 2002-12-23 | Pelikan Technologies, Inc. | Method and apparatus for improving success rate of blood yield from a fingerstick |
| US7749174B2 (en) | 2001-06-12 | 2010-07-06 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device intergrated onto a blood-sampling cartridge |
| US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
| WO2002101359A2 (en) | 2001-06-12 | 2002-12-19 | Pelikan Technologies, Inc. | Integrated blood sampling analysis system with multi-use sampling module |
| US6702857B2 (en) | 2001-07-27 | 2004-03-09 | Dexcom, Inc. | Membrane for use with implantable devices |
| US20030032874A1 (en) | 2001-07-27 | 2003-02-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
| US7344894B2 (en) | 2001-10-16 | 2008-03-18 | Agilent Technologies, Inc. | Thermal regulation of fluidic samples within a diagnostic cartridge |
| US8364229B2 (en) | 2003-07-25 | 2013-01-29 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
| US9282925B2 (en) | 2002-02-12 | 2016-03-15 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
| US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
| US7379765B2 (en) | 2003-07-25 | 2008-05-27 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
| US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
| US7613491B2 (en) | 2002-05-22 | 2009-11-03 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
| US8260393B2 (en) | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
| US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
| US7232451B2 (en) | 2002-04-19 | 2007-06-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
| US7674232B2 (en) | 2002-04-19 | 2010-03-09 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7371247B2 (en) | 2002-04-19 | 2008-05-13 | Pelikan Technologies, Inc | Method and apparatus for penetrating tissue |
| US7901362B2 (en) | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7410468B2 (en) | 2002-04-19 | 2008-08-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7229458B2 (en) | 2002-04-19 | 2007-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
| US7141058B2 (en) | 2002-04-19 | 2006-11-28 | Pelikan Technologies, Inc. | Method and apparatus for a body fluid sampling device using illumination |
| US7481776B2 (en) | 2002-04-19 | 2009-01-27 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
| US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
| US7563232B2 (en) | 2002-04-19 | 2009-07-21 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US8221334B2 (en) | 2002-04-19 | 2012-07-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
| US7524293B2 (en) | 2002-04-19 | 2009-04-28 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7297122B2 (en) | 2002-04-19 | 2007-11-20 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7976476B2 (en) | 2002-04-19 | 2011-07-12 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
| US7331931B2 (en) | 2002-04-19 | 2008-02-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7892183B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
| US7708701B2 (en) | 2002-04-19 | 2010-05-04 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device |
| US7909778B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
| US7547287B2 (en) | 2002-04-19 | 2009-06-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7648468B2 (en) | 2002-04-19 | 2010-01-19 | Pelikon Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7582099B2 (en) | 2002-04-19 | 2009-09-01 | Pelikan Technologies, Inc | Method and apparatus for penetrating tissue |
| US7717863B2 (en) | 2002-04-19 | 2010-05-18 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7291117B2 (en) | 2002-04-19 | 2007-11-06 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US8267870B2 (en) | 2002-04-19 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling with hybrid actuation |
| US7374544B2 (en) | 2002-04-19 | 2008-05-20 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7491178B2 (en) | 2002-04-19 | 2009-02-17 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7813780B2 (en) * | 2005-12-13 | 2010-10-12 | Medtronic Minimed, Inc. | Biosensors and methods for making and using them |
| US7226978B2 (en) | 2002-05-22 | 2007-06-05 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
| US7993108B2 (en) | 2002-10-09 | 2011-08-09 | Abbott Diabetes Care Inc. | Variable volume, shape memory actuated insulin dispensing pump |
| US7727181B2 (en) * | 2002-10-09 | 2010-06-01 | Abbott Diabetes Care Inc. | Fluid delivery device with autocalibration |
| DE60336834D1 (en) | 2002-10-09 | 2011-06-01 | Abbott Diabetes Care Inc | FUEL FEEDING DEVICE, SYSTEM AND METHOD |
| US7381184B2 (en) | 2002-11-05 | 2008-06-03 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
| US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
| US7811231B2 (en) | 2002-12-31 | 2010-10-12 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use |
| US7134999B2 (en) | 2003-04-04 | 2006-11-14 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
| US7587287B2 (en) | 2003-04-04 | 2009-09-08 | Abbott Diabetes Care Inc. | Method and system for transferring analyte test data |
| US7679407B2 (en) | 2003-04-28 | 2010-03-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing peak detection circuitry for data communication systems |
| US7875293B2 (en) | 2003-05-21 | 2011-01-25 | Dexcom, Inc. | Biointerface membranes incorporating bioactive agents |
| US7850621B2 (en) | 2003-06-06 | 2010-12-14 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
| US8460243B2 (en) | 2003-06-10 | 2013-06-11 | Abbott Diabetes Care Inc. | Glucose measuring module and insulin pump combination |
| US8066639B2 (en) | 2003-06-10 | 2011-11-29 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
| WO2006001797A1 (en) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Low pain penetrating |
| US8071028B2 (en) | 2003-06-12 | 2011-12-06 | Abbott Diabetes Care Inc. | Method and apparatus for providing power management in data communication systems |
| EP1635700B1 (en) | 2003-06-13 | 2016-03-09 | Sanofi-Aventis Deutschland GmbH | Apparatus for a point of care device |
| US7722536B2 (en) * | 2003-07-15 | 2010-05-25 | Abbott Diabetes Care Inc. | Glucose measuring device integrated into a holster for a personal area network device |
| WO2007120442A2 (en) * | 2003-07-25 | 2007-10-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US7074307B2 (en) | 2003-07-25 | 2006-07-11 | Dexcom, Inc. | Electrode systems for electrochemical sensors |
| US7424318B2 (en) | 2003-12-05 | 2008-09-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US9763609B2 (en) | 2003-07-25 | 2017-09-19 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
| US7467003B2 (en) * | 2003-12-05 | 2008-12-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US7460898B2 (en) | 2003-12-05 | 2008-12-02 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US8423113B2 (en) | 2003-07-25 | 2013-04-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
| US7366556B2 (en) | 2003-12-05 | 2008-04-29 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US20050176136A1 (en) * | 2003-11-19 | 2005-08-11 | Dexcom, Inc. | Afinity domain for analyte sensor |
| US8160669B2 (en) | 2003-08-01 | 2012-04-17 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US8060173B2 (en) | 2003-08-01 | 2011-11-15 | Dexcom, Inc. | System and methods for processing analyte sensor data |
| US8845536B2 (en) | 2003-08-01 | 2014-09-30 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US20080119703A1 (en) | 2006-10-04 | 2008-05-22 | Mark Brister | Analyte sensor |
| US7774145B2 (en) | 2003-08-01 | 2010-08-10 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
| US7986986B2 (en) | 2003-08-01 | 2011-07-26 | Dexcom, Inc. | System and methods for processing analyte sensor data |
| US9135402B2 (en) | 2007-12-17 | 2015-09-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
| US8886273B2 (en) | 2003-08-01 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
| US20100168657A1 (en) | 2003-08-01 | 2010-07-01 | Dexcom, Inc. | System and methods for processing analyte sensor data |
| US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
| US8275437B2 (en) | 2003-08-01 | 2012-09-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US8761856B2 (en) | 2003-08-01 | 2014-06-24 | Dexcom, Inc. | System and methods for processing analyte sensor data |
| US8369919B2 (en) | 2003-08-01 | 2013-02-05 | Dexcom, Inc. | Systems and methods for processing sensor data |
| US7519408B2 (en) * | 2003-11-19 | 2009-04-14 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
| US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
| US20140121989A1 (en) | 2003-08-22 | 2014-05-01 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
| US8282576B2 (en) | 2003-09-29 | 2012-10-09 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for an improved sample capture device |
| EP1680014A4 (en) | 2003-10-14 | 2009-01-21 | Pelikan Technologies Inc | METHOD AND DEVICE FOR A VARIABLE USER INTERFACE |
| US7299082B2 (en) * | 2003-10-31 | 2007-11-20 | Abbott Diabetes Care, Inc. | Method of calibrating an analyte-measurement device, and associated methods, devices and systems |
| USD902408S1 (en) | 2003-11-05 | 2020-11-17 | Abbott Diabetes Care Inc. | Analyte sensor control unit |
| US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
| US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US8364231B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
| ATE480761T1 (en) | 2003-12-05 | 2010-09-15 | Dexcom Inc | CALIBRATION METHODS FOR A CONTINUOUSLY WORKING ANALYTICAL SENSOR |
| US20100185071A1 (en) * | 2003-12-05 | 2010-07-22 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US8287453B2 (en) | 2003-12-05 | 2012-10-16 | Dexcom, Inc. | Analyte sensor |
| US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| EP2301428B1 (en) | 2003-12-09 | 2016-11-30 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
| US8668656B2 (en) | 2003-12-31 | 2014-03-11 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for improving fluidic flow and sample capture |
| US7822454B1 (en) | 2005-01-03 | 2010-10-26 | Pelikan Technologies, Inc. | Fluid sampling device with improved analyte detecting member configuration |
| US7637868B2 (en) * | 2004-01-12 | 2009-12-29 | Dexcom, Inc. | Composite material for implantable device |
| WO2005089103A2 (en) | 2004-02-17 | 2005-09-29 | Therasense, Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
| WO2009048462A1 (en) | 2007-10-09 | 2009-04-16 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
| US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
| US20050209518A1 (en) * | 2004-03-17 | 2005-09-22 | Therafuse, Inc. | Self-calibrating body analyte monitoring system |
| US8277713B2 (en) | 2004-05-03 | 2012-10-02 | Dexcom, Inc. | Implantable analyte sensor |
| US8792955B2 (en) | 2004-05-03 | 2014-07-29 | Dexcom, Inc. | Transcutaneous analyte sensor |
| WO2006011062A2 (en) | 2004-05-20 | 2006-02-02 | Albatros Technologies Gmbh & Co. Kg | Printable hydrogel for biosensors |
| WO2005120365A1 (en) | 2004-06-03 | 2005-12-22 | Pelikan Technologies, Inc. | Method and apparatus for a fluid sampling device |
| EP1810185A4 (en) | 2004-06-04 | 2010-01-06 | Therasense Inc | Diabetes care host-client architecture and data management system |
| US20060015020A1 (en) * | 2004-07-06 | 2006-01-19 | Dexcom, Inc. | Systems and methods for manufacture of an analyte-measuring device including a membrane system |
| US20070045902A1 (en) | 2004-07-13 | 2007-03-01 | Brauker James H | Analyte sensor |
| US8452368B2 (en) | 2004-07-13 | 2013-05-28 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US8565848B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US20060016700A1 (en) | 2004-07-13 | 2006-01-26 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US7654956B2 (en) | 2004-07-13 | 2010-02-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
| US8886272B2 (en) | 2004-07-13 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
| US9636450B2 (en) | 2007-02-19 | 2017-05-02 | Udo Hoss | Pump system modular components for delivering medication and analyte sensing at seperate insertion sites |
| US8571624B2 (en) | 2004-12-29 | 2013-10-29 | Abbott Diabetes Care Inc. | Method and apparatus for mounting a data transmission device in a communication system |
| US9743862B2 (en) | 2011-03-31 | 2017-08-29 | Abbott Diabetes Care Inc. | Systems and methods for transcutaneously implanting medical devices |
| US8512243B2 (en) | 2005-09-30 | 2013-08-20 | Abbott Diabetes Care Inc. | Integrated introducer and transmitter assembly and methods of use |
| US9572534B2 (en) | 2010-06-29 | 2017-02-21 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
| US9398882B2 (en) | 2005-09-30 | 2016-07-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor and data processing device |
| US9259175B2 (en) | 2006-10-23 | 2016-02-16 | Abbott Diabetes Care, Inc. | Flexible patch for fluid delivery and monitoring body analytes |
| US7697967B2 (en) | 2005-12-28 | 2010-04-13 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
| US7883464B2 (en) | 2005-09-30 | 2011-02-08 | Abbott Diabetes Care Inc. | Integrated transmitter unit and sensor introducer mechanism and methods of use |
| US9788771B2 (en) | 2006-10-23 | 2017-10-17 | Abbott Diabetes Care Inc. | Variable speed sensor insertion devices and methods of use |
| US20090105569A1 (en) | 2006-04-28 | 2009-04-23 | Abbott Diabetes Care, Inc. | Introducer Assembly and Methods of Use |
| US8029441B2 (en) | 2006-02-28 | 2011-10-04 | Abbott Diabetes Care Inc. | Analyte sensor transmitter unit configuration for a data monitoring and management system |
| US10226207B2 (en) | 2004-12-29 | 2019-03-12 | Abbott Diabetes Care Inc. | Sensor inserter having introducer |
| US8333714B2 (en) | 2006-09-10 | 2012-12-18 | Abbott Diabetes Care Inc. | Method and system for providing an integrated analyte sensor insertion device and data processing unit |
| US7731657B2 (en) | 2005-08-30 | 2010-06-08 | Abbott Diabetes Care Inc. | Analyte sensor introducer and methods of use |
| US8652831B2 (en) | 2004-12-30 | 2014-02-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte measurement test time |
| US7545272B2 (en) | 2005-02-08 | 2009-06-09 | Therasense, Inc. | RF tag on test strips, test strip vials and boxes |
| US8133178B2 (en) | 2006-02-22 | 2012-03-13 | Dexcom, Inc. | Analyte sensor |
| US20090076360A1 (en) | 2007-09-13 | 2009-03-19 | Dexcom, Inc. | Transcutaneous analyte sensor |
| JP2008535548A (en) | 2005-03-21 | 2008-09-04 | アボット ダイアビーティーズ ケア インコーポレイテッド | Method and system for providing an integrated pharmaceutical infusion / specimen monitoring system |
| US8744546B2 (en) | 2005-05-05 | 2014-06-03 | Dexcom, Inc. | Cellulosic-based resistance domain for an analyte sensor |
| US8112240B2 (en) | 2005-04-29 | 2012-02-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing leak detection in data monitoring and management systems |
| US7768408B2 (en) | 2005-05-17 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing data management in data monitoring system |
| US7620437B2 (en) | 2005-06-03 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and apparatus for providing rechargeable power in data monitoring and management systems |
| JP2009507224A (en) | 2005-08-31 | 2009-02-19 | ユニヴァーシティー オブ ヴァージニア パテント ファンデーション | Improving the accuracy of continuous glucose sensors |
| US9521968B2 (en) | 2005-09-30 | 2016-12-20 | Abbott Diabetes Care Inc. | Analyte sensor retention mechanism and methods of use |
| US7756561B2 (en) | 2005-09-30 | 2010-07-13 | Abbott Diabetes Care Inc. | Method and apparatus for providing rechargeable power in data monitoring and management systems |
| US8880138B2 (en) | 2005-09-30 | 2014-11-04 | Abbott Diabetes Care Inc. | Device for channeling fluid and methods of use |
| US7583190B2 (en) | 2005-10-31 | 2009-09-01 | Abbott Diabetes Care Inc. | Method and apparatus for providing data communication in data monitoring and management systems |
| US7766829B2 (en) | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
| US8515518B2 (en) | 2005-12-28 | 2013-08-20 | Abbott Diabetes Care Inc. | Analyte monitoring |
| US8160670B2 (en) * | 2005-12-28 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring: stabilizer for subcutaneous glucose sensor with incorporated antiglycolytic agent |
| US8353881B2 (en) * | 2005-12-28 | 2013-01-15 | Abbott Diabetes Care Inc. | Infusion sets for the delivery of a therapeutic substance to a patient |
| CA2636034A1 (en) | 2005-12-28 | 2007-10-25 | Abbott Diabetes Care Inc. | Medical device insertion |
| US11298058B2 (en) | 2005-12-28 | 2022-04-12 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
| US9757061B2 (en) | 2006-01-17 | 2017-09-12 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
| US7736310B2 (en) | 2006-01-30 | 2010-06-15 | Abbott Diabetes Care Inc. | On-body medical device securement |
| US8344966B2 (en) | 2006-01-31 | 2013-01-01 | Abbott Diabetes Care Inc. | Method and system for providing a fault tolerant display unit in an electronic device |
| ES2871822T3 (en) | 2006-02-22 | 2021-11-02 | Dexcom Inc | Analyte sensor |
| US7885698B2 (en) | 2006-02-28 | 2011-02-08 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
| US7826879B2 (en) | 2006-02-28 | 2010-11-02 | Abbott Diabetes Care Inc. | Analyte sensors and methods of use |
| US7981034B2 (en) | 2006-02-28 | 2011-07-19 | Abbott Diabetes Care Inc. | Smart messages and alerts for an infusion delivery and management system |
| EP4218548A1 (en) | 2006-03-09 | 2023-08-02 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
| WO2007102842A2 (en) | 2006-03-09 | 2007-09-13 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
| US8219173B2 (en) | 2008-09-30 | 2012-07-10 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
| US8583205B2 (en) | 2008-03-28 | 2013-11-12 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
| US7630748B2 (en) | 2006-10-25 | 2009-12-08 | Abbott Diabetes Care Inc. | Method and system for providing analyte monitoring |
| US8140312B2 (en) | 2007-05-14 | 2012-03-20 | Abbott Diabetes Care Inc. | Method and system for determining analyte levels |
| US9675290B2 (en) | 2012-10-30 | 2017-06-13 | Abbott Diabetes Care Inc. | Sensitivity calibration of in vivo sensors used to measure analyte concentration |
| US8478557B2 (en) | 2009-07-31 | 2013-07-02 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte monitoring system calibration accuracy |
| US9392969B2 (en) | 2008-08-31 | 2016-07-19 | Abbott Diabetes Care Inc. | Closed loop control and signal attenuation detection |
| US7618369B2 (en) | 2006-10-02 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for dynamically updating calibration parameters for an analyte sensor |
| US7801582B2 (en) | 2006-03-31 | 2010-09-21 | Abbott Diabetes Care Inc. | Analyte monitoring and management system and methods therefor |
| US8473022B2 (en) | 2008-01-31 | 2013-06-25 | Abbott Diabetes Care Inc. | Analyte sensor with time lag compensation |
| US8374668B1 (en) | 2007-10-23 | 2013-02-12 | Abbott Diabetes Care Inc. | Analyte sensor with lag compensation |
| US8346335B2 (en) | 2008-03-28 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
| US9326709B2 (en) | 2010-03-10 | 2016-05-03 | Abbott Diabetes Care Inc. | Systems, devices and methods for managing glucose levels |
| US7653425B2 (en) | 2006-08-09 | 2010-01-26 | Abbott Diabetes Care Inc. | Method and system for providing calibration of an analyte sensor in an analyte monitoring system |
| US8226891B2 (en) | 2006-03-31 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
| US8224415B2 (en) | 2009-01-29 | 2012-07-17 | Abbott Diabetes Care Inc. | Method and device for providing offset model based calibration for analyte sensor |
| US7620438B2 (en) | 2006-03-31 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
| WO2007120381A2 (en) | 2006-04-14 | 2007-10-25 | Dexcom, Inc. | Analyte sensor |
| WO2007143225A2 (en) | 2006-06-07 | 2007-12-13 | Abbott Diabetes Care, Inc. | Analyte monitoring system and method |
| US9119582B2 (en) | 2006-06-30 | 2015-09-01 | Abbott Diabetes Care, Inc. | Integrated analyte sensor and infusion device and methods therefor |
| US8932216B2 (en) | 2006-08-07 | 2015-01-13 | Abbott Diabetes Care Inc. | Method and system for providing data management in integrated analyte monitoring and infusion system |
| US8206296B2 (en) | 2006-08-07 | 2012-06-26 | Abbott Diabetes Care Inc. | Method and system for providing integrated analyte monitoring and infusion system therapy management |
| GB0617276D0 (en) * | 2006-09-04 | 2006-10-11 | Suresensors | Device |
| EP2767826B2 (en) * | 2006-10-04 | 2020-11-11 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US7831287B2 (en) | 2006-10-04 | 2010-11-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US8135548B2 (en) | 2006-10-26 | 2012-03-13 | Abbott Diabetes Care Inc. | Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors |
| US8579853B2 (en) | 2006-10-31 | 2013-11-12 | Abbott Diabetes Care Inc. | Infusion devices and methods |
| US8121857B2 (en) | 2007-02-15 | 2012-02-21 | Abbott Diabetes Care Inc. | Device and method for automatic data acquisition and/or detection |
| US20080199894A1 (en) | 2007-02-15 | 2008-08-21 | Abbott Diabetes Care, Inc. | Device and method for automatic data acquisition and/or detection |
| US8930203B2 (en) | 2007-02-18 | 2015-01-06 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
| US8732188B2 (en) | 2007-02-18 | 2014-05-20 | Abbott Diabetes Care Inc. | Method and system for providing contextual based medication dosage determination |
| US8123686B2 (en) | 2007-03-01 | 2012-02-28 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
| US20100113897A1 (en) * | 2007-03-19 | 2010-05-06 | Bayer Health Care Llc | Continuous analyte monitoring assembly and methods of using the same |
| WO2008118919A1 (en) | 2007-03-26 | 2008-10-02 | Dexcom, Inc. | Analyte sensor |
| US10111608B2 (en) | 2007-04-14 | 2018-10-30 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
| EP2137637A4 (en) | 2007-04-14 | 2012-06-20 | Abbott Diabetes Care Inc | Method and apparatus for providing data processing and control in medical communication system |
| WO2008130898A1 (en) | 2007-04-14 | 2008-10-30 | Abbott Diabetes Care, Inc. | Method and apparatus for providing data processing and control in medical communication system |
| CA2683953C (en) | 2007-04-14 | 2016-08-02 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
| WO2008130895A2 (en) | 2007-04-14 | 2008-10-30 | Abbott Diabetes Care, Inc. | Method and apparatus for providing dynamic multi-stage signal amplification in a medical device |
| WO2008130897A2 (en) | 2007-04-14 | 2008-10-30 | Abbott Diabetes Care, Inc. | Method and apparatus for providing data processing and control in medical communication system |
| US8665091B2 (en) | 2007-05-08 | 2014-03-04 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
| US8461985B2 (en) | 2007-05-08 | 2013-06-11 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
| US7928850B2 (en) | 2007-05-08 | 2011-04-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
| US8456301B2 (en) | 2007-05-08 | 2013-06-04 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
| US7996158B2 (en) | 2007-05-14 | 2011-08-09 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US8444560B2 (en) | 2007-05-14 | 2013-05-21 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US8239166B2 (en) | 2007-05-14 | 2012-08-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US9125548B2 (en) | 2007-05-14 | 2015-09-08 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US8600681B2 (en) | 2007-05-14 | 2013-12-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US8260558B2 (en) | 2007-05-14 | 2012-09-04 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US8560038B2 (en) | 2007-05-14 | 2013-10-15 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US10002233B2 (en) | 2007-05-14 | 2018-06-19 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US8103471B2 (en) | 2007-05-14 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US20200037874A1 (en) | 2007-05-18 | 2020-02-06 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
| WO2008150917A1 (en) | 2007-05-31 | 2008-12-11 | Abbott Diabetes Care, Inc. | Insertion devices and methods |
| WO2008154312A1 (en) | 2007-06-08 | 2008-12-18 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
| WO2008157820A1 (en) | 2007-06-21 | 2008-12-24 | Abbott Diabetes Care, Inc. | Health management devices and methods |
| AU2008265542B2 (en) | 2007-06-21 | 2014-07-24 | Abbott Diabetes Care Inc. | Health monitor |
| US8641618B2 (en) | 2007-06-27 | 2014-02-04 | Abbott Diabetes Care Inc. | Method and structure for securing a monitoring device element |
| US8085151B2 (en) | 2007-06-28 | 2011-12-27 | Abbott Diabetes Care Inc. | Signal converting cradle for medical condition monitoring and management system |
| US8160900B2 (en) | 2007-06-29 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
| US8834366B2 (en) | 2007-07-31 | 2014-09-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor calibration |
| US7768386B2 (en) | 2007-07-31 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US20090043183A1 (en) * | 2007-08-08 | 2009-02-12 | Lifescan, Inc. | Integrated stent and blood analyte monitoring system |
| US7747302B2 (en) * | 2007-08-08 | 2010-06-29 | Lifescan, Inc. | Method for integrating facilitated blood flow and blood analyte monitoring |
| US20120046533A1 (en) | 2007-08-29 | 2012-02-23 | Medtronic Minimed, Inc. | Combined sensor and infusion sets |
| US9968742B2 (en) | 2007-08-29 | 2018-05-15 | Medtronic Minimed, Inc. | Combined sensor and infusion set using separated sites |
| US8216138B1 (en) | 2007-10-23 | 2012-07-10 | Abbott Diabetes Care Inc. | Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration |
| US8409093B2 (en) | 2007-10-23 | 2013-04-02 | Abbott Diabetes Care Inc. | Assessing measures of glycemic variability |
| US8377031B2 (en) | 2007-10-23 | 2013-02-19 | Abbott Diabetes Care Inc. | Closed loop control system with safety parameters and methods |
| EP4250312A3 (en) | 2007-10-25 | 2023-11-01 | DexCom, Inc. | Systems and methods for processing sensor data |
| US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
| US8290559B2 (en) | 2007-12-17 | 2012-10-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
| US20090164239A1 (en) | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Dynamic Display Of Glucose Information |
| EP2252196A4 (en) | 2008-02-21 | 2013-05-15 | Dexcom Inc | Systems and methods for processing, transmitting and displaying sensor data |
| KR100964225B1 (en) * | 2008-03-19 | 2010-06-17 | 삼성모바일디스플레이주식회사 | Organic light emitting display device |
| US8396528B2 (en) | 2008-03-25 | 2013-03-12 | Dexcom, Inc. | Analyte sensor |
| US8682408B2 (en) | 2008-03-28 | 2014-03-25 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
| US11730407B2 (en) | 2008-03-28 | 2023-08-22 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
| WO2009121026A1 (en) * | 2008-03-28 | 2009-10-01 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
| US8583204B2 (en) | 2008-03-28 | 2013-11-12 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
| EP2982383B1 (en) | 2008-04-10 | 2019-05-15 | Abbott Diabetes Care, Inc. | Method for sterilizing an analyte sensor |
| EP2265324B1 (en) | 2008-04-11 | 2015-01-28 | Sanofi-Aventis Deutschland GmbH | Integrated analyte measurement system |
| US7826382B2 (en) | 2008-05-30 | 2010-11-02 | Abbott Diabetes Care Inc. | Close proximity communication device and methods |
| US8924159B2 (en) | 2008-05-30 | 2014-12-30 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
| US8591410B2 (en) | 2008-05-30 | 2013-11-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
| US8876755B2 (en) | 2008-07-14 | 2014-11-04 | Abbott Diabetes Care Inc. | Closed loop control system interface and methods |
| WO2010027771A1 (en) | 2008-08-27 | 2010-03-11 | Edwards Lifesciences Corporation | Analyte sensor |
| US9943644B2 (en) | 2008-08-31 | 2018-04-17 | Abbott Diabetes Care Inc. | Closed loop control with reference measurement and methods thereof |
| US8622988B2 (en) | 2008-08-31 | 2014-01-07 | Abbott Diabetes Care Inc. | Variable rate closed loop control and methods |
| US8734422B2 (en) | 2008-08-31 | 2014-05-27 | Abbott Diabetes Care Inc. | Closed loop control with improved alarm functions |
| US20100057040A1 (en) | 2008-08-31 | 2010-03-04 | Abbott Diabetes Care, Inc. | Robust Closed Loop Control And Methods |
| EP4227675B1 (en) | 2008-09-19 | 2024-12-11 | DexCom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
| US8986208B2 (en) | 2008-09-30 | 2015-03-24 | Abbott Diabetes Care Inc. | Analyte sensor sensitivity attenuation mitigation |
| KR101278605B1 (en) | 2008-11-04 | 2013-06-25 | 파나소닉 주식회사 | Measuring device, insulin injection device, measuring method, control method and program of insulin injection device |
| US9326707B2 (en) | 2008-11-10 | 2016-05-03 | Abbott Diabetes Care Inc. | Alarm characterization for analyte monitoring devices and systems |
| US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
| US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
| US8560082B2 (en) | 2009-01-30 | 2013-10-15 | Abbott Diabetes Care Inc. | Computerized determination of insulin pump therapy parameters using real time and retrospective data processing |
| US9402544B2 (en) | 2009-02-03 | 2016-08-02 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
| US9446194B2 (en) | 2009-03-27 | 2016-09-20 | Dexcom, Inc. | Methods and systems for promoting glucose management |
| US8497777B2 (en) | 2009-04-15 | 2013-07-30 | Abbott Diabetes Care Inc. | Analyte monitoring system having an alert |
| WO2010129375A1 (en) | 2009-04-28 | 2010-11-11 | Abbott Diabetes Care Inc. | Closed loop blood glucose control algorithm analysis |
| WO2010127050A1 (en) | 2009-04-28 | 2010-11-04 | Abbott Diabetes Care Inc. | Error detection in critical repeating data in a wireless sensor system |
| US8368556B2 (en) | 2009-04-29 | 2013-02-05 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
| EP2425209A4 (en) | 2009-04-29 | 2013-01-09 | Abbott Diabetes Care Inc | METHOD AND SYSTEM FOR PROVIDING REAL-TIME ANALYTE SENSOR CALIBRATION WITH RETROSPECTIVE FILLING |
| WO2010135646A1 (en) | 2009-05-22 | 2010-11-25 | Abbott Diabetes Care Inc. | Usability features for integrated insulin delivery system |
| WO2010138856A1 (en) | 2009-05-29 | 2010-12-02 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
| US8613892B2 (en) | 2009-06-30 | 2013-12-24 | Abbott Diabetes Care Inc. | Analyte meter with a moveable head and methods of using the same |
| EP2448486B1 (en) | 2009-07-02 | 2021-08-25 | Dexcom, Inc. | Analyte sensors and methods of manufacturing same |
| US8798934B2 (en) | 2009-07-23 | 2014-08-05 | Abbott Diabetes Care Inc. | Real time management of data relating to physiological control of glucose levels |
| DK3689237T3 (en) | 2009-07-23 | 2021-08-16 | Abbott Diabetes Care Inc | Method of preparation and system for continuous analyte measurement |
| US9314195B2 (en) | 2009-08-31 | 2016-04-19 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
| LT4147999T (en) | 2009-08-31 | 2024-10-10 | Abbott Diabetes Care, Inc. | MEDICAL DEVICE DISPLAYS |
| EP3001194B1 (en) | 2009-08-31 | 2019-04-17 | Abbott Diabetes Care, Inc. | Medical devices and methods |
| US8993331B2 (en) | 2009-08-31 | 2015-03-31 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods for managing power and noise |
| US9320461B2 (en) | 2009-09-29 | 2016-04-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
| WO2011041531A1 (en) | 2009-09-30 | 2011-04-07 | Abbott Diabetes Care Inc. | Interconnect for on-body analyte monitoring device |
| US20110082356A1 (en) * | 2009-10-01 | 2011-04-07 | Medtronic Minimed, Inc. | Analyte sensor apparatuses having interference rejection membranes and methods for making and using them |
| WO2011053881A1 (en) | 2009-10-30 | 2011-05-05 | Abbott Diabetes Care Inc. | Method and apparatus for detecting false hypoglycemic conditions |
| US20110288388A1 (en) | 2009-11-20 | 2011-11-24 | Medtronic Minimed, Inc. | Multi-conductor lead configurations useful with medical device systems and methods for making and using them |
| US8660628B2 (en) | 2009-12-21 | 2014-02-25 | Medtronic Minimed, Inc. | Analyte sensors comprising blended membrane compositions and methods for making and using them |
| USD924406S1 (en) | 2010-02-01 | 2021-07-06 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
| US10448872B2 (en) | 2010-03-16 | 2019-10-22 | Medtronic Minimed, Inc. | Analyte sensor apparatuses having improved electrode configurations and methods for making and using them |
| LT3622883T (en) | 2010-03-24 | 2021-08-25 | Abbott Diabetes Care, Inc. | Medical device inserters and processes of inserting and using medical devices |
| US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
| US8235897B2 (en) | 2010-04-27 | 2012-08-07 | A.D. Integrity Applications Ltd. | Device for non-invasively measuring glucose |
| US9215995B2 (en) | 2010-06-23 | 2015-12-22 | Medtronic Minimed, Inc. | Sensor systems having multiple probes and electrode arrays |
| US8635046B2 (en) | 2010-06-23 | 2014-01-21 | Abbott Diabetes Care Inc. | Method and system for evaluating analyte sensor response characteristics |
| US10092229B2 (en) | 2010-06-29 | 2018-10-09 | Abbott Diabetes Care Inc. | Calibration of analyte measurement system |
| US11064921B2 (en) | 2010-06-29 | 2021-07-20 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
| EP2608715B1 (en) * | 2010-08-24 | 2016-06-22 | Microchips, Inc. | Implantable biosensor device and methods of use thereof |
| US11213226B2 (en) | 2010-10-07 | 2022-01-04 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods |
| US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
| CN107019515B (en) | 2011-02-28 | 2021-02-26 | 雅培糖尿病护理公司 | Method of displaying sensor readings and analyte monitoring device and method of operating the same |
| EP2693945B1 (en) | 2011-04-08 | 2019-03-13 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
| EP2697650B1 (en) | 2011-04-15 | 2020-09-30 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
| US9008744B2 (en) | 2011-05-06 | 2015-04-14 | Medtronic Minimed, Inc. | Method and apparatus for continuous analyte monitoring |
| US9974472B2 (en) | 2011-06-16 | 2018-05-22 | Abbott Diabetes Care Inc. | Temperature-compensated analyte monitoring devices, systems, and methods thereof |
| EP3505065B1 (en) | 2011-09-23 | 2021-03-03 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
| US9069536B2 (en) | 2011-10-31 | 2015-06-30 | Abbott Diabetes Care Inc. | Electronic devices having integrated reset systems and methods thereof |
| US9622691B2 (en) | 2011-10-31 | 2017-04-18 | Abbott Diabetes Care Inc. | Model based variable risk false glucose threshold alarm prevention mechanism |
| WO2013070794A2 (en) | 2011-11-07 | 2013-05-16 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods |
| US9317656B2 (en) | 2011-11-23 | 2016-04-19 | Abbott Diabetes Care Inc. | Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof |
| US8710993B2 (en) | 2011-11-23 | 2014-04-29 | Abbott Diabetes Care Inc. | Mitigating single point failure of devices in an analyte monitoring system and methods thereof |
| WO2013078426A2 (en) | 2011-11-25 | 2013-05-30 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods of use |
| EP2713879B1 (en) | 2011-12-11 | 2017-07-26 | Abbott Diabetes Care, Inc. | Analyte sensor devices, connections, and methods |
| WO2013138369A1 (en) | 2012-03-16 | 2013-09-19 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
| US9493807B2 (en) | 2012-05-25 | 2016-11-15 | Medtronic Minimed, Inc. | Foldover sensors and methods for making and using them |
| US20140012115A1 (en) | 2012-07-03 | 2014-01-09 | Medtronic Minimed, Inc. | Plasma deposited adhesion promoter layers for use with analyte sensors |
| US10132793B2 (en) | 2012-08-30 | 2018-11-20 | Abbott Diabetes Care Inc. | Dropout detection in continuous analyte monitoring data during data excursions |
| US9968306B2 (en) | 2012-09-17 | 2018-05-15 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
| WO2014052136A1 (en) | 2012-09-26 | 2014-04-03 | Abbott Diabetes Care Inc. | Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data |
| US10194840B2 (en) | 2012-12-06 | 2019-02-05 | Medtronic Minimed, Inc. | Microarray electrodes useful with analyte sensors and methods for making and using them |
| US10426383B2 (en) | 2013-01-22 | 2019-10-01 | Medtronic Minimed, Inc. | Muting glucose sensor oxygen response and reducing electrode edge growth with pulsed current plating |
| US9474475B1 (en) | 2013-03-15 | 2016-10-25 | Abbott Diabetes Care Inc. | Multi-rate analyte sensor data collection with sample rate configurable signal processing |
| US10433773B1 (en) | 2013-03-15 | 2019-10-08 | Abbott Diabetes Care Inc. | Noise rejection methods and apparatus for sparsely sampled analyte sensor data |
| US10076285B2 (en) | 2013-03-15 | 2018-09-18 | Abbott Diabetes Care Inc. | Sensor fault detection using analyte sensor data pattern comparison |
| US20150122647A1 (en) | 2013-11-07 | 2015-05-07 | Medtronic Minimed, Inc. | Enzyme matrices for use with ethylene oxide sterilization |
| WO2015102745A1 (en) | 2013-12-31 | 2015-07-09 | Abbott Diabetes Care Inc. | Self-powered analyte sensor and devices using the same |
| US20170185748A1 (en) | 2014-03-30 | 2017-06-29 | Abbott Diabetes Care Inc. | Method and Apparatus for Determining Meal Start and Peak Events in Analyte Monitoring Systems |
| WO2015155171A1 (en) | 2014-04-08 | 2015-10-15 | Novartis Ag | Ophthalmic lenses with oxygen-generating elements therein |
| WO2016183493A1 (en) | 2015-05-14 | 2016-11-17 | Abbott Diabetes Care Inc. | Compact medical device inserters and related systems and methods |
| US10213139B2 (en) | 2015-05-14 | 2019-02-26 | Abbott Diabetes Care Inc. | Systems, devices, and methods for assembling an applicator and sensor control device |
| WO2016196516A1 (en) | 2015-06-03 | 2016-12-08 | William Kenneth Ward | Measurement of glucose in an insulin delivery catheter by minimizing the adverse effects of insulin preservatives |
| DE202016009220U1 (en) | 2015-07-10 | 2024-07-09 | Abbott Diabetes Care, Inc. | Device and system for dynamic glucose profile response to physiological parameters |
| US10324058B2 (en) | 2016-04-28 | 2019-06-18 | Medtronic Minimed, Inc. | In-situ chemistry stack for continuous glucose sensors |
| US11179078B2 (en) | 2016-06-06 | 2021-11-23 | Medtronic Minimed, Inc. | Polycarbonate urea/urethane polymers for use with analyte sensors |
| CN110418605A (en) | 2017-01-19 | 2019-11-05 | 德克斯康公司 | Flexible Analyte Sensors |
| US11071478B2 (en) | 2017-01-23 | 2021-07-27 | Abbott Diabetes Care Inc. | Systems, devices and methods for analyte sensor insertion |
| US12109032B1 (en) | 2017-03-11 | 2024-10-08 | Biolinq Incorporated | Methods for achieving an isolated electrical interface between an anterior surface of a microneedle structure and a posterior surface of a support structure |
| US11134868B2 (en) | 2017-03-17 | 2021-10-05 | Medtronic Minimed, Inc. | Metal pillar device structures and methods for making and using them in electrochemical and/or electrocatalytic applications |
| WO2018175489A1 (en) | 2017-03-21 | 2018-09-27 | Abbott Diabetes Care Inc. | Methods, devices and system for providing diabetic condition diagnosis and therapy |
| US11045142B1 (en) | 2017-04-29 | 2021-06-29 | Biolinq, Inc. | Heterogeneous integration of silicon-fabricated solid microneedle sensors and CMOS circuitry |
| US10856784B2 (en) | 2017-06-30 | 2020-12-08 | Medtronic Minimed, Inc. | Sensor initialization methods for faster body sensor response |
| US12042284B2 (en) | 2018-01-23 | 2024-07-23 | Medtronic Minimed, Inc. | Implantable polymer surfaces exhibiting reduced in vivo inflammatory responses |
| US11186859B2 (en) | 2018-02-07 | 2021-11-30 | Medtronic Minimed, Inc. | Multilayer electrochemical analyte sensors and methods for making and using them |
| US11583213B2 (en) | 2018-02-08 | 2023-02-21 | Medtronic Minimed, Inc. | Glucose sensor electrode design |
| US11220735B2 (en) | 2018-02-08 | 2022-01-11 | Medtronic Minimed, Inc. | Methods for controlling physical vapor deposition metal film adhesion to substrates and surfaces |
| EP3794135A1 (en) | 2018-05-16 | 2021-03-24 | Medtronic MiniMed, Inc. | Thermally stable glucose limiting membrane for glucose sensors |
| CN112423664B (en) | 2018-06-07 | 2025-01-21 | 雅培糖尿病护理公司 | Focused sterilization and sterilized sub-assemblies for analyte monitoring systems |
| TWI672499B (en) * | 2018-07-26 | 2019-09-21 | 劉茂誠 | Non-invasive nitrate detection apparatus and method for fruits/vegetables |
| USD1002852S1 (en) | 2019-06-06 | 2023-10-24 | Abbott Diabetes Care Inc. | Analyte sensor device |
| US11718865B2 (en) | 2019-07-26 | 2023-08-08 | Medtronic Minimed, Inc. | Methods to improve oxygen delivery to implantable sensors |
| US11523757B2 (en) | 2019-08-01 | 2022-12-13 | Medtronic Minimed, Inc. | Micro-pillar working electrodes design to reduce backflow of hydrogen peroxide in glucose sensor |
| KR102506277B1 (en) | 2019-08-02 | 2023-03-07 | 바이오나임 코포레이션 | Micro biosensor and measuring method thereof |
| CN111060573B (en) * | 2019-12-19 | 2022-07-08 | 衡阳师范学院 | CoFe Prussian blue analogue modified electrode and application thereof in simultaneous determination of dopamine and 5-hydroxytryptamine contents |
| SE2251496A1 (en) | 2020-07-29 | 2022-12-20 | Biolinq Incorporated | Continuous analyte monitoring system with microneedle array |
| US12082924B2 (en) | 2020-07-31 | 2024-09-10 | Medtronic Minimed, Inc. | Sensor identification and integrity check design |
| CA3188510A1 (en) | 2020-08-31 | 2022-03-03 | Vivek S. RAO | Systems, devices, and methods for analyte sensor insertion |
| US20220133190A1 (en) | 2020-10-29 | 2022-05-05 | Medtronic Minimed, Inc. | Glucose biosensors comprising direct electron transfer enzymes and methods of making and using them |
| USD999913S1 (en) | 2020-12-21 | 2023-09-26 | Abbott Diabetes Care Inc | Analyte sensor inserter |
| US11998330B2 (en) | 2021-01-29 | 2024-06-04 | Medtronic Minimed, Inc. | Interference rejection membranes useful with analyte sensors |
| WO2022212867A1 (en) | 2021-04-02 | 2022-10-06 | Dexcom, Inc. | Personalized modeling of blood glucose concentration impacted by individualized sensor characteristics and individualized physiological characteristics |
| US20220338768A1 (en) | 2021-04-09 | 2022-10-27 | Medtronic Minimed, Inc. | Hexamethyldisiloxane membranes for analyte sensors |
| CA3184224A1 (en) | 2021-05-08 | 2022-11-17 | Joshua Ray Windmiller | Fault detection for microneedle array based continuous analyte monitoring device |
| CN113804744B (en) * | 2021-08-12 | 2024-03-26 | 云南警官学院 | Quick morphine detection method based on carboxylated multiwall carbon nanotube modified electrode |
| US12433515B2 (en) | 2021-08-13 | 2025-10-07 | Medtronic Minimed, Inc. | Dry electrochemical impedance spectroscopy metrology for conductive chemical layers |
| EP4401634A1 (en) | 2021-09-15 | 2024-07-24 | Dexcom, Inc. | Bioactive releasing membrane for analyte sensor |
| US12201421B2 (en) | 2021-10-08 | 2025-01-21 | Medtronic Minimed, Inc. | Immunosuppressant releasing coatings |
| EP4174188A1 (en) | 2021-10-14 | 2023-05-03 | Medtronic Minimed, Inc. | Sensors for 3-hydroxybutyrate detection |
| US20230172497A1 (en) | 2021-12-02 | 2023-06-08 | Medtronic Minimed, Inc. | Ketone limiting membrane and dual layer membrane approach for ketone sensing |
| US20230408437A1 (en) * | 2022-05-18 | 2023-12-21 | Apex Biotechnology Corp. | Electrochemical system and implantable biochemical test chip |
| US20240023849A1 (en) | 2022-07-20 | 2024-01-25 | Medtronic Minimed, Inc. | Acrylate hydrogel membrane for dual function of diffusion limiting membrane as well as attenuation to the foreign body response |
| EP4382611A1 (en) | 2022-08-31 | 2024-06-12 | Medtronic MiniMed, Inc. | Sensors for 3-hydroxybutyrate detection |
| US12336816B2 (en) | 2023-02-02 | 2025-06-24 | Biolinq Incorporated | Method for improved sensor sensitivity of a microneedle-based continuous analyte monitoring system |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4431507A (en) * | 1981-01-14 | 1984-02-14 | Matsushita Electric Industrial Co., Ltd. | Enzyme electrode |
| US4909908A (en) * | 1986-04-24 | 1990-03-20 | Pepi Ross | Electrochemical cncentration detector method |
| US6066448A (en) * | 1995-03-10 | 2000-05-23 | Meso Sclae Technologies, Llc. | Multi-array, multi-specific electrochemiluminescence testing |
| US6081736A (en) * | 1997-10-20 | 2000-06-27 | Alfred E. Mann Foundation | Implantable enzyme-based monitoring systems adapted for long term use |
Family Cites Families (425)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19852258A1 (en) | 1998-11-11 | 2000-05-18 | Agfa Gevaert Ag | Radiation-sensitive recording material for the production of waterless offset printing plates |
| US1564641A (en) | 1922-04-10 | 1925-12-08 | Chicago Miniature Lamp Works | Detector for wireless systems |
| US2402306A (en) | 1943-10-07 | 1946-06-18 | Turkel Henry | Retaining guard guide for needles |
| US3210578A (en) | 1962-01-12 | 1965-10-05 | Westinghouse Electric Corp | Multispeed motor connector |
| US3381371A (en) | 1965-09-27 | 1968-05-07 | Sanders Associates Inc | Method of constructing lightweight antenna |
| USRE31916E (en) | 1970-11-10 | 1985-06-18 | Becton Dickinson & Company | Electrochemical detection cell |
| US3933593A (en) | 1971-02-22 | 1976-01-20 | Beckman Instruments, Inc. | Rate sensing batch analysis method |
| CH559912A5 (en) | 1971-09-09 | 1975-03-14 | Hoffmann La Roche | |
| US3775182A (en) | 1972-02-25 | 1973-11-27 | Du Pont | Tubular electrochemical cell with coiled electrodes and compressed central spindle |
| GB1442303A (en) | 1972-09-08 | 1976-07-14 | Radiometer As | Cell for electro-chemical analysis |
| US3826244A (en) | 1973-07-20 | 1974-07-30 | Us Health Education & Welfare | Thumbtack microelectrode and method of making same |
| US4067322A (en) | 1974-07-19 | 1978-01-10 | Johnson Joseph H | Disposable, pre-gel body electrodes |
| US3982530A (en) | 1975-04-22 | 1976-09-28 | Egon Storch | Penial appliance |
| US4052754A (en) | 1975-08-14 | 1977-10-11 | Homsy Charles A | Implantable structure |
| CH591237A5 (en) | 1975-11-06 | 1977-09-15 | Bbc Brown Boveri & Cie | |
| JPS5921500B2 (en) | 1978-01-28 | 1984-05-21 | 東洋紡績株式会社 | Enzyme membrane for oxygen electrode |
| NL7801867A (en) | 1978-02-20 | 1979-08-22 | Philips Nv | DEVICE FOR THE TRANSCUTANEOUS MEASUREMENT OF THE PARTIAL OXYGEN PRESSURE IN BLOOD. |
| US4255500A (en) | 1979-03-29 | 1981-03-10 | General Electric Company | Vibration resistant electrochemical cell having deformed casing and method of making same |
| JPS5627643A (en) | 1979-08-14 | 1981-03-18 | Toshiba Corp | Electrochemical measuring device |
| US4861830A (en) | 1980-02-29 | 1989-08-29 | Th. Goldschmidt Ag | Polymer systems suitable for blood-contacting surfaces of a biomedical device, and methods for forming |
| SE419903B (en) * | 1980-03-05 | 1981-08-31 | Enfors Sven Olof | enzyme electrode |
| US4442841A (en) | 1981-04-30 | 1984-04-17 | Mitsubishi Rayon Company Limited | Electrode for living bodies |
| US4378016A (en) | 1981-07-15 | 1983-03-29 | Biotek, Inc. | Artificial endocrine gland containing hormone-producing cells |
| US4402694A (en) | 1981-07-16 | 1983-09-06 | Biotek, Inc. | Body cavity access device containing a hormone source |
| EP0078636B2 (en) | 1981-10-23 | 1997-04-02 | MediSense, Inc. | Sensor for components of a liquid mixture |
| US4431004A (en) | 1981-10-27 | 1984-02-14 | Bessman Samuel P | Implantable glucose sensor |
| US4418148A (en) | 1981-11-05 | 1983-11-29 | Miles Laboratories, Inc. | Multilayer enzyme electrode membrane |
| NL193256C (en) | 1981-11-10 | 1999-04-02 | Cordis Europ | Sensor system. |
| US4494950A (en) | 1982-01-19 | 1985-01-22 | The Johns Hopkins University | Plural module medication delivery system |
| JPS58137840U (en) | 1982-03-12 | 1983-09-16 | 三菱自動車工業株式会社 | Injection timing control device |
| EP0098592A3 (en) | 1982-07-06 | 1985-08-21 | Fujisawa Pharmaceutical Co., Ltd. | Portable artificial pancreas |
| DE3228551A1 (en) | 1982-07-30 | 1984-02-02 | Siemens AG, 1000 Berlin und 8000 München | METHOD FOR DETERMINING SUGAR CONCENTRATION |
| US4571292A (en) | 1982-08-12 | 1986-02-18 | Case Western Reserve University | Apparatus for electrochemical measurements |
| CA1219040A (en) | 1983-05-05 | 1987-03-10 | Elliot V. Plotkin | Measurement of enzyme-catalysed reactions |
| US5682884A (en) | 1983-05-05 | 1997-11-04 | Medisense, Inc. | Strip electrode with screen printing |
| CA1226036A (en) | 1983-05-05 | 1987-08-25 | Irving J. Higgins | Analytical equipment and sensor electrodes therefor |
| US4484987A (en) | 1983-05-19 | 1984-11-27 | The Regents Of The University Of California | Method and membrane applicable to implantable sensor |
| US4650547A (en) | 1983-05-19 | 1987-03-17 | The Regents Of The University Of California | Method and membrane applicable to implantable sensor |
| US4655880A (en) | 1983-08-01 | 1987-04-07 | Case Western Reserve University | Apparatus and method for sensing species, substances and substrates using oxidase |
| US4578215A (en) | 1983-08-12 | 1986-03-25 | Micro-Circuits Company | Electrical conductivity-enhancing and protecting material |
| US4883057A (en) | 1984-05-09 | 1989-11-28 | Research Foundation, The City University Of New York | Cathodic electrochemical current arrangement with telemetric application |
| JPS6130697A (en) | 1984-07-20 | 1986-02-12 | Kawasaki Steel Corp | Manufacture of zn-fe alloy electroplated steel sheet having fine appearance, color tone and superior adhesion to its plating |
| CA1258496A (en) | 1984-07-30 | 1989-08-15 | Teruyoshi Uchida | Insulated noble metal wire and porous membrane as po.sub.2 bioelectrode |
| US5030333A (en) | 1984-09-13 | 1991-07-09 | Children's Hospital Medical Center | Polarographic method for measuring both analyte and oxygen with the same detecting electrode of an electroenzymatic sensor |
| US5171689A (en) | 1984-11-08 | 1992-12-15 | Matsushita Electric Industrial Co., Ltd. | Solid state bio-sensor |
| US4781798A (en) | 1985-04-19 | 1988-11-01 | The Regents Of The University Of California | Transparent multi-oxygen sensor array and method of using same |
| GB8514176D0 (en) | 1985-06-05 | 1985-07-10 | Ici Plc | Membrane |
| US4671288A (en) | 1985-06-13 | 1987-06-09 | The Regents Of The University Of California | Electrochemical cell sensor for continuous short-term use in tissues and blood |
| JPH0629873B2 (en) * | 1985-09-06 | 1994-04-20 | 株式会社島津製作所 | Enzyme functional electrode |
| US4680268A (en) | 1985-09-18 | 1987-07-14 | Children's Hospital Medical Center | Implantable gas-containing biosensor and method for measuring an analyte such as glucose |
| US4890620A (en) | 1985-09-20 | 1990-01-02 | The Regents Of The University Of California | Two-dimensional diffusion glucose substrate sensing electrode |
| JPS6283849A (en) | 1985-10-04 | 1987-04-17 | Reiji Yoshinaka | Method of purifying collagen |
| JPS6283849U (en) | 1985-11-12 | 1987-05-28 | ||
| JPS6283649U (en) | 1985-11-14 | 1987-05-28 | ||
| US4776944A (en) | 1986-03-20 | 1988-10-11 | Jiri Janata | Chemical selective sensors utilizing admittance modulated membranes |
| US4685463A (en) | 1986-04-03 | 1987-08-11 | Williams R Bruce | Device for continuous in vivo measurement of blood glucose concentrations |
| US4994167A (en) | 1986-04-15 | 1991-02-19 | Markwell Medical Institute, Inc. | Biological fluid measuring device |
| US4757022A (en) | 1986-04-15 | 1988-07-12 | Markwell Medical Institute, Inc. | Biological fluid measuring device |
| US4795542A (en) * | 1986-04-24 | 1989-01-03 | St. Jude Medical, Inc. | Electrochemical concentration detector device |
| US4703756A (en) | 1986-05-06 | 1987-11-03 | The Regents Of The University Of California | Complete glucose monitoring system with an implantable, telemetered sensor module |
| GB8612861D0 (en) | 1986-05-27 | 1986-07-02 | Cambridge Life Sciences | Immobilised enzyme biosensors |
| US4726381A (en) | 1986-06-04 | 1988-02-23 | Solutech, Inc. | Dialysis system and method |
| US4763658A (en) | 1986-06-04 | 1988-08-16 | Solutech, Inc. | Dialysis system 2nd method |
| US4750496A (en) | 1987-01-28 | 1988-06-14 | Xienta, Inc. | Method and apparatus for measuring blood glucose concentration |
| JPH07122621B2 (en) * | 1986-09-09 | 1995-12-25 | 鐘淵化学工業株式会社 | Enzyme electrode |
| DE3700119A1 (en) | 1987-01-03 | 1988-07-14 | Inst Diabetestechnologie Gemei | IMPLANTABLE ELECTROCHEMICAL SENSOR |
| DE3875149T2 (en) | 1987-03-27 | 1993-02-11 | Fujitsu Ltd | MINIATURIZED BIO-SENSOR WITH MINIATURIZED OXYGEN ELECTRODE AND ITS PRODUCTION PROCESS. |
| US5352348A (en) | 1987-04-09 | 1994-10-04 | Nova Biomedical Corporation | Method of using enzyme electrode |
| US5286364A (en) | 1987-06-08 | 1994-02-15 | Rutgers University | Surface-modified electochemical biosensor |
| US4786657A (en) | 1987-07-02 | 1988-11-22 | Minnesota Mining And Manufacturing Company | Polyurethanes and polyurethane/polyureas crosslinked using 2-glyceryl acrylate or 2-glyceryl methacrylate |
| JPH07122624B2 (en) | 1987-07-06 | 1995-12-25 | ダイキン工業株式会社 | Biosensor |
| DE3725728A1 (en) | 1987-08-04 | 1989-02-16 | Freudenberg Carl Fa | MEDICAL DEVICE AND METHOD FOR THE PRODUCTION THEREOF |
| US4974929A (en) | 1987-09-22 | 1990-12-04 | Baxter International, Inc. | Fiber optical probe connector for physiologic measurement devices |
| NL8702370A (en) | 1987-10-05 | 1989-05-01 | Groningen Science Park | METHOD AND SYSTEM FOR GLUCOSE DETERMINATION AND USEABLE MEASURING CELL ASSEMBLY. |
| US5242835A (en) | 1987-11-03 | 1993-09-07 | Radiometer A/S | Method and apparatus for determining the concentration of oxygen |
| GB8725936D0 (en) | 1987-11-05 | 1987-12-09 | Genetics Int Inc | Sensing system |
| US4813424A (en) | 1987-12-23 | 1989-03-21 | University Of New Mexico | Long-life membrane electrode for non-ionic species |
| US4890621A (en) | 1988-01-19 | 1990-01-02 | Northstar Research Institute, Ltd. | Continuous glucose monitoring and a system utilized therefor |
| US5362307A (en) | 1989-01-24 | 1994-11-08 | The Regents Of The University Of California | Method for the iontophoretic non-invasive-determination of the in vivo concentration level of an inorganic or organic substance |
| US4822336A (en) | 1988-03-04 | 1989-04-18 | Ditraglia John | Blood glucose level sensing |
| US4955861A (en) | 1988-04-21 | 1990-09-11 | Therex Corp. | Dual access infusion and monitoring system |
| US5034112A (en) | 1988-05-19 | 1991-07-23 | Nissan Motor Company, Ltd. | Device for measuring concentration of nitrogen oxide in combustion gas |
| EP0353328A1 (en) | 1988-08-03 | 1990-02-07 | Dräger Nederland B.V. | A polarographic-amperometric three-electrode sensor |
| US5438984A (en) | 1988-09-08 | 1995-08-08 | Sudor Partners | Apparatus and method for the collection of analytes on a dermal patch |
| NL8802481A (en) | 1988-10-10 | 1990-05-01 | Texas Instruments Holland | TRANSPONDER AND METHOD FOR MAKING THE SAME |
| US5212050A (en) | 1988-11-14 | 1993-05-18 | Mier Randall M | Method of forming a permselective layer |
| US5200051A (en) | 1988-11-14 | 1993-04-06 | I-Stat Corporation | Wholly microfabricated biosensors and process for the manufacture and use thereof |
| US5063081A (en) | 1988-11-14 | 1991-11-05 | I-Stat Corporation | Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor |
| WO1990007575A1 (en) | 1988-12-30 | 1990-07-12 | Anderson David M | Stabilized microporous materials and hydrogel materials |
| JPH02298855A (en) | 1989-03-20 | 1990-12-11 | Assoc Univ Inc | Electrochemical biosensor using immobilized enzyme and redox polymer |
| US5089112A (en) | 1989-03-20 | 1992-02-18 | Associated Universities, Inc. | Electrochemical biosensor based on immobilized enzymes and redox polymers |
| US4953552A (en) | 1989-04-21 | 1990-09-04 | Demarzo Arthur P | Blood glucose monitoring system |
| EP0396788A1 (en) * | 1989-05-08 | 1990-11-14 | Dräger Nederland B.V. | Process and sensor for measuring the glucose content of glucosecontaining fluids |
| US4927407A (en) | 1989-06-19 | 1990-05-22 | Regents Of The University Of Minnesota | Cardiac assist pump with steady rate supply of fluid lubricant |
| US5431160A (en) | 1989-07-19 | 1995-07-11 | University Of New Mexico | Miniature implantable refillable glucose sensor and material therefor |
| US5264104A (en) | 1989-08-02 | 1993-11-23 | Gregg Brian A | Enzyme electrodes |
| US5190041A (en) | 1989-08-11 | 1993-03-02 | Palti Yoram Prof | System for monitoring and controlling blood glucose |
| US5050612A (en) | 1989-09-12 | 1991-09-24 | Matsumura Kenneth N | Device for computer-assisted monitoring of the body |
| FR2652736A1 (en) | 1989-10-06 | 1991-04-12 | Neftel Frederic | IMPLANTABLE DEVICE FOR EVALUATING THE RATE OF GLUCOSE. |
| US5140985A (en) | 1989-12-11 | 1992-08-25 | Schroeder Jon M | Noninvasive blood glucose measuring device |
| JP3105243B2 (en) | 1989-12-14 | 2000-10-30 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | How to increase the useful life of an implantable sensor |
| US5985129A (en) | 1989-12-14 | 1999-11-16 | The Regents Of The University Of California | Method for increasing the service life of an implantable sensor |
| FR2656423A1 (en) | 1989-12-22 | 1991-06-28 | Rhone Poulenc Chimie | Electrochemical biosensor |
| US5183549A (en) | 1990-01-26 | 1993-02-02 | Commtech International Management Corporation | Multi-analyte sensing electrolytic cell |
| JPH07101215B2 (en) | 1990-04-11 | 1995-11-01 | 国立身体障害者リハビリテーションセンター総長 | Analytical method using biofunctional substance-immobilized electrode |
| US5165407A (en) | 1990-04-19 | 1992-11-24 | The University Of Kansas | Implantable glucose sensor |
| US5250439A (en) | 1990-07-19 | 1993-10-05 | Miles Inc. | Use of conductive sensors in diagnostic assays |
| US5202261A (en) | 1990-07-19 | 1993-04-13 | Miles Inc. | Conductive sensors and their use in diagnostic assays |
| JPH0820412B2 (en) | 1990-07-20 | 1996-03-04 | 松下電器産業株式会社 | Quantitative analysis method and device using disposable sensor |
| US5746898A (en) | 1990-08-10 | 1998-05-05 | Siemens Aktiengesellschaft | Electrochemical-enzymatic sensor |
| JP2779456B2 (en) | 1990-08-28 | 1998-07-23 | ミードックス・メディカルス・インコーポレイテッド | Self-holding woven artificial blood vessel and method for producing the same |
| KR960012335B1 (en) | 1990-09-17 | 1996-09-18 | 후지쓰 가부시끼가이샤 | Oxygen electrode |
| ATE138256T1 (en) | 1990-10-31 | 1996-06-15 | Baxter Int | IMPLANT MATERIAL THAT ALLOWS VASCULARIZATION |
| US5354449A (en) | 1991-01-10 | 1994-10-11 | Band David M | pH electrode |
| AU1356792A (en) | 1991-01-25 | 1992-08-27 | Markwell Medical Institute, Inc. | Implantable biological fluid measuring device |
| US5593852A (en) | 1993-12-02 | 1997-01-14 | Heller; Adam | Subcutaneous glucose electrode |
| US5632272A (en) | 1991-03-07 | 1997-05-27 | Masimo Corporation | Signal processing apparatus |
| US5271736A (en) | 1991-05-13 | 1993-12-21 | Applied Medical Research | Collagen disruptive morphology for implants |
| JP3118015B2 (en) | 1991-05-17 | 2000-12-18 | アークレイ株式会社 | Biosensor and separation and quantification method using the same |
| JP2816262B2 (en) | 1991-07-09 | 1998-10-27 | 工業技術院長 | Carbon microsensor electrode and method of manufacturing the same |
| US5198771A (en) | 1991-09-03 | 1993-03-30 | Transducer Research, Inc. | Potentiostatic apparatus and methods |
| US5312361A (en) | 1991-09-13 | 1994-05-17 | Zadini Filiberto P | Automatic cannulation device |
| ES2089556T3 (en) | 1991-09-13 | 1996-10-01 | Rodney Arthur Stafford | ELECTRONIC SYSTEM FOR THE IDENTIFICATION OF ANIMALS. |
| DE4130742A1 (en) | 1991-09-16 | 1993-03-18 | Inst Diabetestechnologie Gemei | METHOD AND ARRANGEMENT FOR DETERMINING THE CONCENTRATION OF INGREDIENTS IN BODY LIQUIDS |
| GB9120144D0 (en) | 1991-09-20 | 1991-11-06 | Imperial College | A dialysis electrode device |
| US5322063A (en) | 1991-10-04 | 1994-06-21 | Eli Lilly And Company | Hydrophilic polyurethane membranes for electrochemical glucose sensors |
| US5155149A (en) | 1991-10-10 | 1992-10-13 | Boc Health Care, Inc. | Silicone polyurethane copolymers containing oxygen sensitive phosphorescent dye compounds |
| US5249576A (en) | 1991-10-24 | 1993-10-05 | Boc Health Care, Inc. | Universal pulse oximeter probe |
| EP0539625A1 (en) * | 1991-10-28 | 1993-05-05 | Dräger Medical Electronics B.V. | Electrochemical sensor for measuring the glucose content of glucose containing fluids |
| US5310469A (en) | 1991-12-31 | 1994-05-10 | Abbott Laboratories | Biosensor with a membrane containing biologically active material |
| US5582497A (en) | 1992-01-29 | 1996-12-10 | Wing Labo Co., Ltd. | Automatic warehouse system |
| WO1993014693A1 (en) | 1992-02-01 | 1993-08-05 | The Victoria University Of Manchester | Electrode |
| NL9200207A (en) | 1992-02-05 | 1993-09-01 | Nedap Nv | IMPLANTABLE BIOMEDICAL SENSOR DEVICE, IN PARTICULAR FOR MEASUREMENT OF THE GLUCOSE CONCENTRATION. |
| US5284140A (en) | 1992-02-11 | 1994-02-08 | Eli Lilly And Company | Acrylic copolymer membranes for biosensors |
| ATE169941T1 (en) | 1992-04-24 | 1998-09-15 | Polymer Technology Group Inc | COPOLYMERS, AND NON-POROUS SEMI-PERMEABLE MEMBRANES MADE THEREOF AND THEIR USE FOR FILTERING MOLECULES IN A GIVEN MOLECULAR WEIGHT RANGE |
| GB9211402D0 (en) | 1992-05-29 | 1992-07-15 | Univ Manchester | Sensor devices |
| US5330634A (en) | 1992-08-28 | 1994-07-19 | Via Medical Corporation | Calibration solutions useful for analyses of biological fluids and methods employing same |
| JP2541081B2 (en) | 1992-08-28 | 1996-10-09 | 日本電気株式会社 | Biosensor and method of manufacturing and using biosensor |
| US5298144A (en) | 1992-09-15 | 1994-03-29 | The Yellow Springs Instrument Company, Inc. | Chemically wired fructose dehydrogenase electrodes |
| GB9221099D0 (en) | 1992-10-07 | 1992-11-18 | Ecossensors Ltd | Improvements in and relating to gas permeable membranes for amperometric gas electrodes |
| US5750029A (en) | 1992-10-16 | 1998-05-12 | Suprex Corporation | Method and apparatus for determination of analyte concentration |
| US5387327A (en) | 1992-10-19 | 1995-02-07 | Duquesne University Of The Holy Ghost | Implantable non-enzymatic electrochemical glucose sensor |
| US5307263A (en) | 1992-11-17 | 1994-04-26 | Raya Systems, Inc. | Modular microprocessor-based health monitoring system |
| US6256522B1 (en) | 1992-11-23 | 2001-07-03 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Sensors for continuous monitoring of biochemicals and related method |
| ZA938555B (en) | 1992-11-23 | 1994-08-02 | Lilly Co Eli | Technique to improve the performance of electrochemical sensors |
| US5299571A (en) | 1993-01-22 | 1994-04-05 | Eli Lilly And Company | Apparatus and method for implantation of sensors |
| US5411866A (en) | 1993-03-30 | 1995-05-02 | National Research Council Of Canada | Method and system for determining bioactive substances |
| WO1994022367A1 (en) | 1993-03-30 | 1994-10-13 | Pfizer Inc. | Radiotelemetry impedance plethysmography device |
| US5425717A (en) | 1993-05-07 | 1995-06-20 | The Kendall Company | Epidural catheter system utilizing splittable needle |
| US5352351A (en) | 1993-06-08 | 1994-10-04 | Boehringer Mannheim Corporation | Biosensing meter with fail/safe procedures to prevent erroneous indications |
| DE4427363A1 (en) | 1993-08-03 | 1995-03-09 | A & D Co Ltd | A disposable chemical sensor |
| DE4329898A1 (en) | 1993-09-04 | 1995-04-06 | Marcus Dr Besson | Wireless medical diagnostic and monitoring device |
| FR2710413B1 (en) | 1993-09-21 | 1995-11-03 | Asulab Sa | Measuring device for removable sensors. |
| EP0670738A1 (en) | 1993-09-24 | 1995-09-13 | Baxter International Inc. | Methods for enhancing vascularization of implant devices |
| US5582184A (en) | 1993-10-13 | 1996-12-10 | Integ Incorporated | Interstitial fluid collection and constituent measurement |
| KR970010981B1 (en) | 1993-11-04 | 1997-07-05 | 엘지전자 주식회사 | Alcohol concentration measuring bio-sensor, manufacturing method and related apparatus |
| US5791344A (en) | 1993-11-19 | 1998-08-11 | Alfred E. Mann Foundation For Scientific Research | Patient monitoring system |
| US5497772A (en) | 1993-11-19 | 1996-03-12 | Alfred E. Mann Foundation For Scientific Research | Glucose monitoring system |
| US5508509A (en) | 1993-11-30 | 1996-04-16 | Minnesota Mining And Manufacturing Company | Sensing elements and methods for uniformly making individual sensing elements |
| DE4401400A1 (en) | 1994-01-19 | 1995-07-20 | Ernst Prof Dr Pfeiffer | Method and arrangement for continuously monitoring the concentration of a metabolite |
| US5391250A (en) | 1994-03-15 | 1995-02-21 | Minimed Inc. | Method of fabricating thin film sensors |
| US5390671A (en) | 1994-03-15 | 1995-02-21 | Minimed Inc. | Transcutaneous sensor insertion set |
| AUPM506894A0 (en) | 1994-04-14 | 1994-05-05 | Memtec Limited | Novel electrochemical cells |
| US5569186A (en) | 1994-04-25 | 1996-10-29 | Minimed Inc. | Closed loop infusion pump system with removable glucose sensor |
| DE4415896A1 (en) | 1994-05-05 | 1995-11-09 | Boehringer Mannheim Gmbh | Analysis system for monitoring the concentration of an analyte in the blood of a patient |
| US5482473A (en) | 1994-05-09 | 1996-01-09 | Minimed Inc. | Flex circuit connector |
| DE59509994D1 (en) | 1994-06-03 | 2002-02-21 | Metrohm Ag Herisau | Device for voltammetry, indicator electrode arrangement for such a device, in particular as part of a tape cassette, and row analysis method for voltammetry |
| DE4422068A1 (en) | 1994-06-23 | 1996-01-04 | Siemens Ag | Electro-catalytic glucose sensor in catheter form |
| US5494562A (en) | 1994-06-27 | 1996-02-27 | Ciba Corning Diagnostics Corp. | Electrochemical sensors |
| US5474552A (en) | 1994-06-27 | 1995-12-12 | Cb-Carmel Biotechnology Ltd. | Implantable drug delivery pump |
| US5605152A (en) | 1994-07-18 | 1997-02-25 | Minimed Inc. | Optical glucose sensor |
| US5624537A (en) | 1994-09-20 | 1997-04-29 | The University Of British Columbia - University-Industry Liaison Office | Biosensor and interface membrane |
| US5486776A (en) | 1994-09-29 | 1996-01-23 | Xilinx, Inc. | Antifuse-based programmable logic circuit |
| IE72524B1 (en) | 1994-11-04 | 1997-04-23 | Elan Med Tech | Analyte-controlled liquid delivery device and analyte monitor |
| JP2807650B2 (en) | 1994-12-24 | 1998-10-08 | ベーリンガー・マンハイム・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Equipment for tissue characterization |
| US5676820A (en) | 1995-02-03 | 1997-10-14 | New Mexico State University Technology Transfer Corp. | Remote electrochemical sensor |
| US5568806A (en) | 1995-02-16 | 1996-10-29 | Minimed Inc. | Transcutaneous sensor insertion set |
| US5786439A (en) | 1996-10-24 | 1998-07-28 | Minimed Inc. | Hydrophilic, swellable coatings for biosensors |
| US5882494A (en) | 1995-03-27 | 1999-03-16 | Minimed, Inc. | Polyurethane/polyurea compositions containing silicone for biosensor membranes |
| US5607565A (en) | 1995-03-27 | 1997-03-04 | Coulter Corporation | Apparatus for measuring analytes in a fluid sample |
| FR2733104B1 (en) | 1995-04-12 | 1997-06-06 | Droz Francois | SMALL-DIMENSIONAL ANSWERING MACHINE AND METHOD FOR MANUFACTURING SUCH ANSWERING MACHINES |
| US5620579A (en) | 1995-05-05 | 1997-04-15 | Bayer Corporation | Apparatus for reduction of bias in amperometric sensors |
| US5840148A (en) | 1995-06-30 | 1998-11-24 | Bio Medic Data Systems, Inc. | Method of assembly of implantable transponder |
| US5995860A (en) | 1995-07-06 | 1999-11-30 | Thomas Jefferson University | Implantable sensor and system for measurement and control of blood constituent levels |
| US5611900A (en) | 1995-07-20 | 1997-03-18 | Michigan State University | Microbiosensor used in-situ |
| AUPN487495A0 (en) | 1995-08-18 | 1995-09-14 | Cardiac Crc Nominees Pty Limited | A multipolar transmural probe |
| US5989409A (en) | 1995-09-11 | 1999-11-23 | Cygnus, Inc. | Method for glucose sensing |
| US5735273A (en) | 1995-09-12 | 1998-04-07 | Cygnus, Inc. | Chemical signal-impermeable mask |
| US5628890A (en) | 1995-09-27 | 1997-05-13 | Medisense, Inc. | Electrochemical sensor |
| US6689265B2 (en) | 1995-10-11 | 2004-02-10 | Therasense, Inc. | Electrochemical analyte sensors using thermostable soybean peroxidase |
| US5665222A (en) | 1995-10-11 | 1997-09-09 | E. Heller & Company | Soybean peroxidase electrochemical sensor |
| US5972199A (en) | 1995-10-11 | 1999-10-26 | E. Heller & Company | Electrochemical analyte sensors using thermostable peroxidase |
| US5711861A (en) | 1995-11-22 | 1998-01-27 | Ward; W. Kenneth | Device for monitoring changes in analyte concentration |
| EP0862648B1 (en) | 1995-11-22 | 2004-10-06 | Medtronic MiniMed, Inc. | Detection of biological molecules using chemical amplification and optical sensors |
| US5795453A (en) | 1996-01-23 | 1998-08-18 | Gilmartin; Markas A. T. | Electrodes and metallo isoindole ringed compounds |
| US5833603A (en) | 1996-03-13 | 1998-11-10 | Lipomatrix, Inc. | Implantable biosensing transponder |
| US6407195B2 (en) | 1996-04-25 | 2002-06-18 | 3M Innovative Properties Company | Tackified polydiorganosiloxane oligourea segmented copolymers and a process for making same |
| US5776324A (en) | 1996-05-17 | 1998-07-07 | Encelle, Inc. | Electrochemical biosensors |
| EP0923335B1 (en) | 1996-07-08 | 2006-08-23 | Animas Corporation | Implantable sensor and system for in vivo measurement and control of fluid constituent levels |
| JP2943700B2 (en) | 1996-07-10 | 1999-08-30 | 日本電気株式会社 | Biosensor |
| US5707502A (en) | 1996-07-12 | 1998-01-13 | Chiron Diagnostics Corporation | Sensors for measuring analyte concentrations and methods of making same |
| US5703359A (en) | 1996-07-29 | 1997-12-30 | Leybold Inficon, Inc. | Composite membrane and support assembly |
| US5963132A (en) | 1996-10-11 | 1999-10-05 | Avid Indentification Systems, Inc. | Encapsulated implantable transponder |
| DE19642453C2 (en) | 1996-10-15 | 1998-07-23 | Bosch Gmbh Robert | Arrangement for gas sensor electrodes |
| US6001068A (en) | 1996-10-22 | 1999-12-14 | Terumo Kabushiki Kaisha | Guide wire having tubular connector with helical slits |
| ES2186003T3 (en) | 1996-10-30 | 2003-05-01 | Amira Medical | SYNCHRONIZED ANALYZE ANALYSIS SYSTEM. |
| ATE316147T1 (en) | 1996-11-14 | 2006-02-15 | Radiometer Medical Aps | ENZYME SENSOR |
| AU5461298A (en) | 1996-12-04 | 1998-06-29 | Enact Health Management Systems | System for downloading and reporting medical information |
| US6027459A (en) | 1996-12-06 | 2000-02-22 | Abbott Laboratories | Method and apparatus for obtaining blood for diagnostic tests |
| US5964993A (en) | 1996-12-19 | 1999-10-12 | Implanted Biosystems Inc. | Glucose sensor |
| DE19653436C1 (en) * | 1996-12-20 | 1998-08-13 | Inst Chemo Biosensorik | Electrochemical sensor |
| US5914026A (en) | 1997-01-06 | 1999-06-22 | Implanted Biosystems Inc. | Implantable sensor employing an auxiliary electrode |
| US6607509B2 (en) | 1997-12-31 | 2003-08-19 | Medtronic Minimed, Inc. | Insertion device for an insertion set and method of using the same |
| US5851197A (en) | 1997-02-05 | 1998-12-22 | Minimed Inc. | Injector for a subcutaneous infusion set |
| US6093172A (en) | 1997-02-05 | 2000-07-25 | Minimed Inc. | Injector for a subcutaneous insertion set |
| AU6157898A (en) | 1997-02-06 | 1998-08-26 | E. Heller & Company | Small volume (in vitro) analyte sensor |
| US6891317B2 (en) | 2001-05-22 | 2005-05-10 | Sri International | Rolled electroactive polymers |
| US6001067A (en) | 1997-03-04 | 1999-12-14 | Shults; Mark C. | Device and method for determining analyte levels |
| US6558321B1 (en) | 1997-03-04 | 2003-05-06 | Dexcom, Inc. | Systems and methods for remote monitoring and modulation of medical devices |
| US7657297B2 (en) | 2004-05-03 | 2010-02-02 | Dexcom, Inc. | Implantable analyte sensor |
| US6862465B2 (en) | 1997-03-04 | 2005-03-01 | Dexcom, Inc. | Device and method for determining analyte levels |
| US6741877B1 (en) | 1997-03-04 | 2004-05-25 | Dexcom, Inc. | Device and method for determining analyte levels |
| US7899511B2 (en) | 2004-07-13 | 2011-03-01 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
| US7192450B2 (en) | 2003-05-21 | 2007-03-20 | Dexcom, Inc. | Porous membranes for use with implantable devices |
| US20050033132A1 (en) | 1997-03-04 | 2005-02-10 | Shults Mark C. | Analyte measuring device |
| FR2760962B1 (en) | 1997-03-20 | 1999-05-14 | Sillonville Francis Klefstad | REMOTE MEDICAL ASSISTANCE AND SURVEILLANCE SYSTEM |
| US6270455B1 (en) | 1997-03-28 | 2001-08-07 | Health Hero Network, Inc. | Networked system for interactive communications and remote monitoring of drug delivery |
| US6059946A (en) | 1997-04-14 | 2000-05-09 | Matsushita Electric Industrial Co., Ltd. | Biosensor |
| US5944661A (en) | 1997-04-16 | 1999-08-31 | Giner, Inc. | Potential and diffusion controlled solid electrolyte sensor for continuous measurement of very low levels of transdermal alcohol |
| US6558351B1 (en) | 1999-06-03 | 2003-05-06 | Medtronic Minimed, Inc. | Closed loop system for controlling insulin infusion |
| US5954643A (en) | 1997-06-09 | 1999-09-21 | Minimid Inc. | Insertion set for a transcutaneous sensor |
| US7267665B2 (en) | 1999-06-03 | 2007-09-11 | Medtronic Minimed, Inc. | Closed loop system for controlling insulin infusion |
| JP2002505008A (en) | 1997-06-16 | 2002-02-12 | エラン コーポレーション ピーエルシー | Methods for calibrating and testing sensors for in vivo measurement of analytes and devices for use in such methods |
| US6309526B1 (en) | 1997-07-10 | 2001-10-30 | Matsushita Electric Industrial Co., Ltd. | Biosensor |
| US5999848A (en) | 1997-09-12 | 1999-12-07 | Alfred E. Mann Foundation | Daisy chainable sensors and stimulators for implantation in living tissue |
| US6259937B1 (en) | 1997-09-12 | 2001-07-10 | Alfred E. Mann Foundation | Implantable substrate sensor |
| US6117290A (en) | 1997-09-26 | 2000-09-12 | Pepex Biomedical, Llc | System and method for measuring a bioanalyte such as lactate |
| US6268161B1 (en) | 1997-09-30 | 2001-07-31 | M-Biotech, Inc. | Biosensor |
| US7115884B1 (en) | 1997-10-06 | 2006-10-03 | Trustees Of Tufts College | Self-encoding fiber optic sensor |
| US6409674B1 (en) | 1998-09-24 | 2002-06-25 | Data Sciences International, Inc. | Implantable sensor with wireless communication |
| US6119028A (en) | 1997-10-20 | 2000-09-12 | Alfred E. Mann Foundation | Implantable enzyme-based monitoring systems having improved longevity due to improved exterior surfaces |
| US6088608A (en) | 1997-10-20 | 2000-07-11 | Alfred E. Mann Foundation | Electrochemical sensor and integrity tests therefor |
| US6893552B1 (en) | 1997-12-29 | 2005-05-17 | Arrowhead Center, Inc. | Microsensors for glucose and insulin monitoring |
| WO1999033504A1 (en) | 1997-12-31 | 1999-07-08 | Minimed Inc. | Insertion device for an insertion set and method of using the same |
| US6030827A (en) | 1998-01-23 | 2000-02-29 | I-Stat Corporation | Microfabricated aperture-based sensor |
| US6134461A (en) | 1998-03-04 | 2000-10-17 | E. Heller & Company | Electrochemical analyte |
| US6013113A (en) | 1998-03-06 | 2000-01-11 | Wilson Greatbatch Ltd. | Slotted insulator for unsealed electrode edges in electrochemical cells |
| US5928130A (en) | 1998-03-16 | 1999-07-27 | Schmidt; Bruno | Apparatus and method for implanting radioactive seeds in tissue |
| GB9805896D0 (en) | 1998-03-20 | 1998-05-13 | Eglise David | Remote analysis system |
| JP3104672B2 (en) | 1998-03-31 | 2000-10-30 | 日本電気株式会社 | Current detection type sensor element and method of manufacturing the same |
| US6534711B1 (en) | 1998-04-14 | 2003-03-18 | The Goodyear Tire & Rubber Company | Encapsulation package and method of packaging an electronic circuit module |
| US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
| US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
| DE69910003T2 (en) | 1998-05-13 | 2004-04-22 | Cygnus, Inc., Redwood City | MONITORING PHYSIOLOGICAL ANALYSIS |
| WO1999058050A1 (en) | 1998-05-13 | 1999-11-18 | Cygnus, Inc. | Signal processing for measurement of physiological analytes |
| US6294281B1 (en) | 1998-06-17 | 2001-09-25 | Therasense, Inc. | Biological fuel cell and method |
| US6290839B1 (en) * | 1998-06-23 | 2001-09-18 | Clinical Micro Sensors, Inc. | Systems for electrophoretic transport and detection of analytes |
| EP0967788A2 (en) | 1998-06-26 | 1999-12-29 | Hewlett-Packard Company | Dynamic generation of multi-resolution and tile-based images from flat compressed images |
| US6495023B1 (en) | 1998-07-09 | 2002-12-17 | Michigan State University | Electrochemical methods for generation of a biological proton motive force and pyridine nucleotide cofactor regeneration |
| US6248067B1 (en) | 1999-02-05 | 2001-06-19 | Minimed Inc. | Analyte sensor and holter-type monitor system and method of using the same |
| US6558320B1 (en) | 2000-01-20 | 2003-05-06 | Medtronic Minimed, Inc. | Handheld personal data assistant (PDA) with a medical device and method of using the same |
| ATE241933T1 (en) | 1998-09-30 | 2003-06-15 | Cygnus Therapeutic Systems | METHOD AND DEVICE FOR PREDICTING PHYSIOLOGICAL MEASUREMENT VALUES |
| CA2345043C (en) | 1998-10-08 | 2009-08-11 | Minimed, Inc. | Telemetered characteristic monitor system |
| US6338790B1 (en) | 1998-10-08 | 2002-01-15 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
| US6366794B1 (en) | 1998-11-20 | 2002-04-02 | The University Of Connecticut | Generic integrated implantable potentiostat telemetry unit for electrochemical sensors |
| US6066083A (en) | 1998-11-27 | 2000-05-23 | Syntheon Llc | Implantable brachytherapy device having at least partial deactivation capability |
| AU762948B2 (en) | 1998-12-02 | 2003-07-10 | Ut-Battelle, Llc | In vivo biosensor apparatus and method of use |
| US6447448B1 (en) | 1998-12-31 | 2002-09-10 | Ball Semiconductor, Inc. | Miniature implanted orthopedic sensors |
| WO2000049942A2 (en) | 1999-02-25 | 2000-08-31 | Minimed, Inc. | Test plug and cable for a glucose monitor |
| US6424847B1 (en) | 1999-02-25 | 2002-07-23 | Medtronic Minimed, Inc. | Glucose monitor calibration methods |
| US6360888B1 (en) | 1999-02-25 | 2002-03-26 | Minimed Inc. | Glucose sensor package system |
| WO2000059373A1 (en) | 1999-04-07 | 2000-10-12 | Spectrx, Inc. | Assay device for measuring characteristics of a fluid on a continual basis |
| US6285897B1 (en) | 1999-04-07 | 2001-09-04 | Endonetics, Inc. | Remote physiological monitoring system |
| US6189536B1 (en) | 1999-04-15 | 2001-02-20 | Medtronic Inc. | Method for protecting implantable devices |
| CA2369336A1 (en) | 1999-04-22 | 2000-11-02 | Cygnus, Inc. | Hydrogel in an iontophoretic device to measure glucose |
| US6300002B1 (en) | 1999-05-13 | 2001-10-09 | Moltech Power Systems, Inc. | Notched electrode and method of making same |
| US6546268B1 (en) | 1999-06-02 | 2003-04-08 | Ball Semiconductor, Inc. | Glucose sensor |
| US6972080B1 (en) | 1999-06-10 | 2005-12-06 | Matsushita Electric Industrial Co., Ltd. | Electrochemical device for moving particles covered with protein |
| EP1192269A2 (en) | 1999-06-18 | 2002-04-03 | Therasense, Inc. | MASS TRANSPORT LIMITED i IN VIVO /i ANALYTE SENSOR |
| GB2351153B (en) | 1999-06-18 | 2003-03-26 | Abbott Lab | Electrochemical sensor for analysis of liquid samples |
| US6368274B1 (en) | 1999-07-01 | 2002-04-09 | Medtronic Minimed, Inc. | Reusable analyte sensor site and method of using the same |
| US7247138B2 (en) | 1999-07-01 | 2007-07-24 | Medtronic Minimed, Inc. | Reusable analyte sensor site and method of using the same |
| US6413393B1 (en) | 1999-07-07 | 2002-07-02 | Minimed, Inc. | Sensor including UV-absorbing polymer and method of manufacture |
| US6343225B1 (en) | 1999-09-14 | 2002-01-29 | Implanted Biosystems, Inc. | Implantable glucose sensor |
| US6616819B1 (en) | 1999-11-04 | 2003-09-09 | Therasense, Inc. | Small volume in vitro analyte sensor and methods |
| DE19956822B4 (en) | 1999-11-25 | 2004-01-29 | Siemens Ag | Method for determining the NOx concentration |
| US6612984B1 (en) | 1999-12-03 | 2003-09-02 | Kerr, Ii Robert A. | System and method for collecting and transmitting medical data |
| US7003336B2 (en) | 2000-02-10 | 2006-02-21 | Medtronic Minimed, Inc. | Analyte sensor method of making the same |
| US6484045B1 (en) | 2000-02-10 | 2002-11-19 | Medtronic Minimed, Inc. | Analyte sensor and method of making the same |
| ATE373443T1 (en) | 2000-02-10 | 2007-10-15 | Medtronic Minimed Inc | ANALYTE SENSOR |
| US6895263B2 (en) | 2000-02-23 | 2005-05-17 | Medtronic Minimed, Inc. | Real time self-adjusting calibration algorithm |
| ES2420279T3 (en) | 2000-03-02 | 2013-08-23 | Microchips, Inc. | Microfabricated devices and methods for storage and selective exposure of chemicals |
| US6551496B1 (en) | 2000-03-03 | 2003-04-22 | Ysi Incorporated | Microstructured bilateral sensor |
| US6498941B1 (en) | 2000-03-09 | 2002-12-24 | Advanced Cardiovascular Systems, Inc. | Catheter based probe and method of using same for detecting chemical analytes |
| US6405066B1 (en) | 2000-03-17 | 2002-06-11 | The Regents Of The University Of California | Implantable analyte sensor |
| IT1314759B1 (en) | 2000-05-08 | 2003-01-03 | Menarini Farma Ind | INSTRUMENTATION FOR MEASUREMENT AND CONTROL OF THE CONTENT OF GLUCOSIOLACTATE OR OTHER METABOLITES IN BIOLOGICAL FLUIDS |
| WO2001088524A1 (en) | 2000-05-12 | 2001-11-22 | Therasense, Inc. | Electrodes with multilayer membranes and methods of using and making the electrodes |
| US7769420B2 (en) | 2000-05-15 | 2010-08-03 | Silver James H | Sensors for detecting substances indicative of stroke, ischemia, or myocardial infarction |
| US7181261B2 (en) | 2000-05-15 | 2007-02-20 | Silver James H | Implantable, retrievable, thrombus minimizing sensors |
| US6442413B1 (en) | 2000-05-15 | 2002-08-27 | James H. Silver | Implantable sensor |
| US6459917B1 (en) | 2000-05-22 | 2002-10-01 | Ashok Gowda | Apparatus for access to interstitial fluid, blood, or blood plasma components |
| US6773565B2 (en) | 2000-06-22 | 2004-08-10 | Kabushiki Kaisha Riken | NOx sensor |
| US6400974B1 (en) | 2000-06-29 | 2002-06-04 | Sensors For Medicine And Science, Inc. | Implanted sensor processing system and method for processing implanted sensor output |
| US6553241B2 (en) | 2000-08-31 | 2003-04-22 | Mallinckrodt Inc. | Oximeter sensor with digital memory encoding sensor expiration data |
| FR2815199B1 (en) | 2000-10-10 | 2003-01-17 | Canon Kk | CIRCULAR TURBOCODING METHODS OF LARGE MINIMUM DISTANCE, AND SYSTEMS FOR IMPLEMENTING THE SAME |
| JP2002189015A (en) | 2000-12-20 | 2002-07-05 | Sankyo Co Ltd | Reaction-current measuring method by enzyme electrode |
| US6642015B2 (en) | 2000-12-29 | 2003-11-04 | Minimed Inc. | Hydrophilic polymeric material for coating biosensors |
| US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
| US6793802B2 (en) | 2001-01-04 | 2004-09-21 | Tyson Bioresearch, Inc. | Biosensors having improved sample application and measuring properties and uses thereof |
| US7078582B2 (en) | 2001-01-17 | 2006-07-18 | 3M Innovative Properties Company | Stretch removable adhesive articles and methods |
| US6547839B2 (en) | 2001-01-23 | 2003-04-15 | Skc Co., Ltd. | Method of making an electrochemical cell by the application of polysiloxane onto at least one of the cell components |
| US6510329B2 (en) | 2001-01-24 | 2003-01-21 | Datex-Ohmeda, Inc. | Detection of sensor off conditions in a pulse oximeter |
| US6721587B2 (en) | 2001-02-15 | 2004-04-13 | Regents Of The University Of California | Membrane and electrode structure for implantable sensor |
| US6576102B1 (en) | 2001-03-23 | 2003-06-10 | Virotek, L.L.C. | Electrochemical sensor and method thereof |
| US6454710B1 (en) | 2001-04-11 | 2002-09-24 | Motorola, Inc. | Devices and methods for monitoring an analyte |
| US6613379B2 (en) | 2001-05-08 | 2003-09-02 | Isense Corp. | Implantable analyte sensor |
| US20020177763A1 (en) | 2001-05-22 | 2002-11-28 | Burns David W. | Integrated lancets and methods |
| US6872297B2 (en) * | 2001-05-31 | 2005-03-29 | Instrumentation Laboratory Company | Analytical instruments, biosensors and methods thereof |
| US6501976B1 (en) | 2001-06-12 | 2002-12-31 | Lifescan, Inc. | Percutaneous biological fluid sampling and analyte measurement devices and methods |
| US7011630B2 (en) | 2001-06-22 | 2006-03-14 | Animas Technologies, Llc | Methods for computing rolling analyte measurement values, microprocessors comprising programming to control performance of the methods, and analyte monitoring devices employing the methods |
| US6802827B2 (en) | 2001-06-26 | 2004-10-12 | Stig O. Andersson | Hypodermic implant device |
| GB0115793D0 (en) | 2001-06-28 | 2001-08-22 | Univ Cranfield | A novel mediator for electrochemical detection |
| ATE285756T1 (en) | 2001-06-28 | 2005-01-15 | Microchips Inc | METHOD FOR HERMETIC SEALING MICROCHIP RESERVOIR DEVICES |
| US7150737B2 (en) | 2001-07-13 | 2006-12-19 | Sci/Med Life Systems, Inc. | Methods and apparatuses for navigating the subarachnoid space |
| US20030032874A1 (en) | 2001-07-27 | 2003-02-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
| US6702857B2 (en) | 2001-07-27 | 2004-03-09 | Dexcom, Inc. | Membrane for use with implantable devices |
| US7481759B2 (en) | 2001-08-03 | 2009-01-27 | Cardiac Pacemakers, Inc. | Systems and methods for treatment of coronary artery disease |
| WO2003025559A1 (en) | 2001-09-11 | 2003-03-27 | Arkray, Inc. | Measuring instrument, installation body, and density measurer |
| US6802957B2 (en) | 2001-09-28 | 2004-10-12 | Marine Biological Laboratory | Self-referencing enzyme-based microsensor and method of use |
| US6809507B2 (en) | 2001-10-23 | 2004-10-26 | Medtronic Minimed, Inc. | Implantable sensor electrodes and electronic circuitry |
| US20050101841A9 (en) | 2001-12-04 | 2005-05-12 | Kimberly-Clark Worldwide, Inc. | Healthcare networks with biosensors |
| EP1455641B1 (en) | 2001-12-17 | 2008-09-03 | Danfoss A/S | Method and device for monitoring analyte concentration by optical detection |
| US6952604B2 (en) | 2001-12-21 | 2005-10-04 | Becton, Dickinson And Company | Minimally-invasive system and method for monitoring analyte levels |
| US20050027182A1 (en) | 2001-12-27 | 2005-02-03 | Uzair Siddiqui | System for monitoring physiological characteristics |
| US7018336B2 (en) | 2001-12-27 | 2006-03-28 | Medtronic Minimed, Inc. | Implantable sensor flush sleeve |
| US7399277B2 (en) | 2001-12-27 | 2008-07-15 | Medtronic Minimed, Inc. | System for monitoring physiological characteristics |
| US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
| US8364229B2 (en) | 2003-07-25 | 2013-01-29 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
| US7379765B2 (en) | 2003-07-25 | 2008-05-27 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
| ATE507766T1 (en) | 2002-03-22 | 2011-05-15 | Animas Technologies Llc | PERFORMANCE IMPROVEMENT OF AN ANALYTE MONITORING DEVICE |
| US20030225437A1 (en) | 2002-04-04 | 2003-12-04 | Ferguson Patrick J. | Device for retaining material |
| AU2003233468A1 (en) | 2002-04-05 | 2003-10-27 | Eyelab Group, Llc | Monitoring blood substances using self-sampled tears |
| US20070227907A1 (en) | 2006-04-04 | 2007-10-04 | Rajiv Shah | Methods and materials for controlling the electrochemistry of analyte sensors |
| US7153265B2 (en) | 2002-04-22 | 2006-12-26 | Medtronic Minimed, Inc. | Anti-inflammatory biosensor for reduced biofouling and enhanced sensor performance |
| US7813780B2 (en) | 2005-12-13 | 2010-10-12 | Medtronic Minimed, Inc. | Biosensors and methods for making and using them |
| US6743635B2 (en) | 2002-04-25 | 2004-06-01 | Home Diagnostics, Inc. | System and methods for blood glucose sensing |
| US7008979B2 (en) | 2002-04-30 | 2006-03-07 | Hydromer, Inc. | Coating composition for multiple hydrophilic applications |
| US7166235B2 (en) | 2002-05-09 | 2007-01-23 | The Procter & Gamble Company | Compositions comprising anionic functionalized polyorganosiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents to surfaces treated therewith |
| EP1501565B1 (en) | 2002-05-09 | 2006-11-02 | Hemoteq GmbH | Compounds and method for coating surfaces in a haemocompatible manner |
| US6801041B2 (en) | 2002-05-14 | 2004-10-05 | Abbott Laboratories | Sensor having electrode for determining the rate of flow of a fluid |
| US20060258761A1 (en) | 2002-05-22 | 2006-11-16 | Robert Boock | Silicone based membranes for use in implantable glucose sensors |
| US20030225324A1 (en) | 2002-06-03 | 2003-12-04 | Anderson Edward J. | Noninvasive detection of a physiologic Parameter within a body tissue of a patient |
| US8996090B2 (en) | 2002-06-03 | 2015-03-31 | Exostat Medical, Inc. | Noninvasive detection of a physiologic parameter within a body tissue of a patient |
| AU2003279777A1 (en) | 2002-06-28 | 2004-01-19 | November Aktiengesellschaft Gesellschaft Fur Molekulare Medizin | Electrochemical detection method and device |
| US20040063167A1 (en) | 2002-07-12 | 2004-04-01 | Peter Kaastrup | Minimising calibration problems of in vivo glucose sensors |
| ATE446045T1 (en) | 2002-09-04 | 2009-11-15 | Solianis Holding Ag | METHOD AND DEVICE FOR MEASURING GLUCOSE |
| US20040180391A1 (en) | 2002-10-11 | 2004-09-16 | Miklos Gratzl | Sliver type autonomous biosensors |
| US20050272989A1 (en) | 2004-06-04 | 2005-12-08 | Medtronic Minimed, Inc. | Analyte sensors and methods for making and using them |
| US20040074785A1 (en) | 2002-10-18 | 2004-04-22 | Holker James D. | Analyte sensors and methods for making them |
| US6737158B1 (en) | 2002-10-30 | 2004-05-18 | Gore Enterprise Holdings, Inc. | Porous polymeric membrane toughened composites |
| US7381184B2 (en) | 2002-11-05 | 2008-06-03 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
| US7120483B2 (en) | 2003-01-13 | 2006-10-10 | Isense Corporation | Methods for analyte sensing and measurement |
| US6965791B1 (en) | 2003-03-26 | 2005-11-15 | Sorenson Medical, Inc. | Implantable biosensor system, apparatus and method |
| US7070580B2 (en) | 2003-04-01 | 2006-07-04 | Unomedical A/S | Infusion device and an adhesive sheet material and a release liner |
| US7134999B2 (en) | 2003-04-04 | 2006-11-14 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
| US7279174B2 (en) | 2003-05-08 | 2007-10-09 | Advanced Cardiovascular Systems, Inc. | Stent coatings comprising hydrophilic additives |
| US7875293B2 (en) | 2003-05-21 | 2011-01-25 | Dexcom, Inc. | Biointerface membranes incorporating bioactive agents |
| US7687586B2 (en) | 2003-05-21 | 2010-03-30 | Isense Corporation | Biosensor membrane material |
| US20040254433A1 (en) | 2003-06-12 | 2004-12-16 | Bandis Steven D. | Sensor introducer system, apparatus and method |
| WO2005010518A1 (en) | 2003-07-23 | 2005-02-03 | Dexcom, Inc. | Rolled electrode array and its method for manufacture |
| WO2005012871A2 (en) | 2003-07-25 | 2005-02-10 | Dexcom, Inc. | Increasing bias for oxygen production in an electrode system |
| US7424318B2 (en) | 2003-12-05 | 2008-09-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| WO2007120442A2 (en) | 2003-07-25 | 2007-10-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US20050176136A1 (en) | 2003-11-19 | 2005-08-11 | Dexcom, Inc. | Afinity domain for analyte sensor |
| US7460898B2 (en) | 2003-12-05 | 2008-12-02 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US7074307B2 (en) | 2003-07-25 | 2006-07-11 | Dexcom, Inc. | Electrode systems for electrochemical sensors |
| WO2005019795A2 (en) | 2003-07-25 | 2005-03-03 | Dexcom, Inc. | Electrochemical sensors including electrode systems with increased oxygen generation |
| US7651596B2 (en) | 2005-04-08 | 2010-01-26 | Dexcom, Inc. | Cellulosic-based interference domain for an analyte sensor |
| US7467003B2 (en) | 2003-12-05 | 2008-12-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US7366556B2 (en) | 2003-12-05 | 2008-04-29 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US8845536B2 (en) | 2003-08-01 | 2014-09-30 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US8060173B2 (en) | 2003-08-01 | 2011-11-15 | Dexcom, Inc. | System and methods for processing analyte sensor data |
| US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
| US8275437B2 (en) | 2003-08-01 | 2012-09-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US7774145B2 (en) | 2003-08-01 | 2010-08-10 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US7723099B2 (en) | 2003-09-10 | 2010-05-25 | Abbott Point Of Care Inc. | Immunoassay device with immuno-reference electrode |
| CA2541616A1 (en) | 2003-09-30 | 2005-04-14 | Andre Mang | Sensor with increased biocompatibility |
| US20050090607A1 (en) | 2003-10-28 | 2005-04-28 | Dexcom, Inc. | Silicone composition for biocompatible membrane |
| ATE480761T1 (en) | 2003-12-05 | 2010-09-15 | Dexcom Inc | CALIBRATION METHODS FOR A CONTINUOUSLY WORKING ANALYTICAL SENSOR |
| DE602004028164D1 (en) | 2003-12-08 | 2010-08-26 | Dexcom Inc | SYSTEMS AND METHOD FOR IMPROVING ELECTROCHEMICAL ANALYTIC SENSORS |
| EP2301428B1 (en) | 2003-12-09 | 2016-11-30 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
| US7637868B2 (en) | 2004-01-12 | 2009-12-29 | Dexcom, Inc. | Composite material for implantable device |
| US20050182451A1 (en) | 2004-01-12 | 2005-08-18 | Adam Griffin | Implantable device with improved radio frequency capabilities |
| US8165651B2 (en) | 2004-02-09 | 2012-04-24 | Abbott Diabetes Care Inc. | Analyte sensor, and associated system and method employing a catalytic agent |
| WO2005084191A2 (en) | 2004-02-13 | 2005-09-15 | The University Of North Carolina At Chapel Hill | Functional materials and novel methods for the fabrication of microfluidic devices |
| US20050197554A1 (en) | 2004-02-26 | 2005-09-08 | Michael Polcha | Composite thin-film glucose sensor |
| US8277713B2 (en) | 2004-05-03 | 2012-10-02 | Dexcom, Inc. | Implantable analyte sensor |
| US20050245799A1 (en) | 2004-05-03 | 2005-11-03 | Dexcom, Inc. | Implantable analyte sensor |
| US7125382B2 (en) | 2004-05-20 | 2006-10-24 | Digital Angel Corporation | Embedded bio-sensor system |
| JP4799557B2 (en) | 2004-06-09 | 2011-10-26 | ベクトン・ディキンソン・アンド・カンパニー | Multi-sample sensor |
| US20060015020A1 (en) | 2004-07-06 | 2006-01-19 | Dexcom, Inc. | Systems and methods for manufacture of an analyte-measuring device including a membrane system |
| US20060016700A1 (en) | 2004-07-13 | 2006-01-26 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
| US20070045902A1 (en) | 2004-07-13 | 2007-03-01 | Brauker James H | Analyte sensor |
| US8886272B2 (en) | 2004-07-13 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
| US8452368B2 (en) | 2004-07-13 | 2013-05-28 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US20080242961A1 (en) | 2004-07-13 | 2008-10-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US7654956B2 (en) | 2004-07-13 | 2010-02-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US8962165B2 (en) | 2006-05-02 | 2015-02-24 | The Penn State Research Foundation | Materials and configurations for scalable microbial fuel cells |
| EP1784249A2 (en) | 2004-08-16 | 2007-05-16 | Novo Nordisk A/S | Multiphase biocompatible semi-permeable membrane for biosensors |
| WO2006127023A2 (en) | 2004-08-24 | 2006-11-30 | University Of South Florida | Epoxy enhanced polymer membrane to increase durability of biosensors |
| CN100367906C (en) | 2004-12-08 | 2008-02-13 | 圣美迪诺医疗科技(湖州)有限公司 | Subcutaneous Implantable Biosensors |
| EA011594B1 (en) | 2004-12-30 | 2009-04-28 | Синвеншен Аг | Combination comprising an agent providing a signal, an implant material and a drug |
| US8133178B2 (en) | 2006-02-22 | 2012-03-13 | Dexcom, Inc. | Analyte sensor |
| US20090076360A1 (en) | 2007-09-13 | 2009-03-19 | Dexcom, Inc. | Transcutaneous analyte sensor |
| CA2602259A1 (en) | 2005-03-29 | 2006-10-05 | Arkal Medical, Inc. | Devices, systems, methods and tools for continuous glucose monitoring |
| US7959791B2 (en) | 2005-05-17 | 2011-06-14 | Radiometer Medical Aps | Enzyme sensor with a cover membrane layer covered by a hydrophilic polymer |
| US20060275859A1 (en) | 2005-05-17 | 2006-12-07 | Kjaer Thomas | Enzyme sensor including a water-containing spacer layer |
| US20060263839A1 (en) | 2005-05-17 | 2006-11-23 | Isense Corporation | Combined drug delivery and analyte sensor apparatus |
| US7725148B2 (en) | 2005-09-23 | 2010-05-25 | Medtronic Minimed, Inc. | Sensor with layered electrodes |
| EP2004796B1 (en) | 2006-01-18 | 2015-04-08 | DexCom, Inc. | Membranes for an analyte sensor |
| US8114023B2 (en) | 2006-07-28 | 2012-02-14 | Legacy Emanuel Hospital & Health Center | Analyte sensing and response system |
| US7871456B2 (en) | 2006-08-10 | 2011-01-18 | The Regents Of The University Of California | Membranes with controlled permeability to polar and apolar molecules in solution and methods of making same |
| EP2079358B1 (en) | 2006-09-27 | 2011-08-10 | University of Connecticut | Implantable biosensor and methods of use thereof |
| US7831287B2 (en) | 2006-10-04 | 2010-11-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
-
2004
- 2004-07-21 US US10/897,312 patent/US7074307B2/en not_active Ceased
- 2004-07-21 EP EP04757321A patent/EP1649260A4/en not_active Withdrawn
- 2004-07-21 WO PCT/US2004/024178 patent/WO2005012873A2/en active Application Filing
- 2004-07-21 JP JP2006521312A patent/JP2007500336A/en active Pending
-
2008
- 2008-06-13 US US12/139,305 patent/USRE43399E1/en not_active Expired - Lifetime
-
2012
- 2012-05-18 US US13/475,770 patent/US20120228134A1/en not_active Abandoned
-
2013
- 2013-08-29 US US14/014,216 patent/US20140001042A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4431507A (en) * | 1981-01-14 | 1984-02-14 | Matsushita Electric Industrial Co., Ltd. | Enzyme electrode |
| US4909908A (en) * | 1986-04-24 | 1990-03-20 | Pepi Ross | Electrochemical cncentration detector method |
| US6066448A (en) * | 1995-03-10 | 2000-05-23 | Meso Sclae Technologies, Llc. | Multi-array, multi-specific electrochemiluminescence testing |
| US6081736A (en) * | 1997-10-20 | 2000-06-27 | Alfred E. Mann Foundation | Implantable enzyme-based monitoring systems adapted for long term use |
Cited By (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4275598A2 (en) | 2012-04-04 | 2023-11-15 | DexCom, Inc. | Applicator and method for applying a transcutaneous analyte sensor |
| WO2013152090A2 (en) | 2012-04-04 | 2013-10-10 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
| EP3975192A1 (en) | 2012-06-05 | 2022-03-30 | Dexcom, Inc. | Systems and methods for processing analyte data and generating reports |
| WO2013184566A2 (en) | 2012-06-05 | 2013-12-12 | Dexcom, Inc. | Systems and methods for processing analyte data and generating reports |
| US12080414B2 (en) | 2012-06-05 | 2024-09-03 | Dexcom, Inc. | Dynamic report building |
| US11145410B2 (en) | 2012-06-05 | 2021-10-12 | Dexcom, Inc. | Dynamic report building |
| US11737692B2 (en) | 2012-06-29 | 2023-08-29 | Dexcom, Inc. | Implantable sensor devices, systems, and methods |
| WO2014004460A1 (en) | 2012-06-29 | 2014-01-03 | Dexcom, Inc. | Use of sensor redundancy to detect sensor failures |
| US11892426B2 (en) | 2012-06-29 | 2024-02-06 | Dexcom, Inc. | Devices, systems, and methods to compensate for effects of temperature on implantable sensors |
| EP4018929A1 (en) | 2012-06-29 | 2022-06-29 | Dexcom, Inc. | Method and system for processing data from a continuous glucose sensor |
| EP3915465A2 (en) | 2012-06-29 | 2021-12-01 | Dexcom, Inc. | Use of sensor redundancy to detect sensor failures |
| EP4075441A1 (en) | 2012-07-09 | 2022-10-19 | Dexcom, Inc. | Systems and methods for leveraging smartphone features in continuous glucose monitoring |
| WO2014011488A2 (en) | 2012-07-09 | 2014-01-16 | Dexcom, Inc. | Systems and methods for leveraging smartphone features in continuous glucose monitoring |
| EP4080517A1 (en) | 2012-07-09 | 2022-10-26 | Dexcom, Inc. | Systems and methods for leveraging smartphone features in continuous glucose monitoring |
| EP3767633A1 (en) | 2012-07-09 | 2021-01-20 | Dexcom, Inc. | Systems and methods for leveraging smartphone features in continuous glucose monitoring |
| US12303266B2 (en) | 2012-09-28 | 2025-05-20 | Dexcom, Inc. | Zwitterion surface modifications for continuous sensors |
| US11179079B2 (en) | 2012-09-28 | 2021-11-23 | Dexcom, Inc. | Zwitterion surface modifications for continuous sensors |
| WO2014052080A1 (en) | 2012-09-28 | 2014-04-03 | Dexcom, Inc. | Zwitterion surface modifications for continuous sensors |
| US11864891B2 (en) | 2012-09-28 | 2024-01-09 | Dexcom, Inc. | Zwitterion surface modifications for continuous sensors |
| EP4344632A2 (en) | 2012-09-28 | 2024-04-03 | DexCom, Inc. | Zwitterion surface modifications for continuous sensors |
| EP3782550A1 (en) | 2012-09-28 | 2021-02-24 | Dexcom, Inc. | Zwitterion surface modifications for continuous sensors |
| EP4231309A2 (en) | 2012-11-07 | 2023-08-23 | DexCom, Inc. | Systems and methods for managing glycemic variability |
| EP3654348A1 (en) | 2012-11-07 | 2020-05-20 | Dexcom, Inc. | Systems and methods for managing glycemic variability |
| US11160452B2 (en) | 2012-12-31 | 2021-11-02 | Dexcom, Inc. | Remote monitoring of analyte measurements |
| US10993617B2 (en) | 2012-12-31 | 2021-05-04 | Dexcom, Inc. | Remote monitoring of analyte measurements |
| US11213204B2 (en) | 2012-12-31 | 2022-01-04 | Dexcom, Inc. | Remote monitoring of analyte measurements |
| US10856736B2 (en) | 2012-12-31 | 2020-12-08 | Dexcom, Inc. | Remote monitoring of analyte measurements |
| US10860687B2 (en) | 2012-12-31 | 2020-12-08 | Dexcom, Inc. | Remote monitoring of analyte measurements |
| US12396687B2 (en) | 2012-12-31 | 2025-08-26 | Dexcom, Inc. | Remote monitoring of analyte measurements |
| US11744463B2 (en) | 2012-12-31 | 2023-09-05 | Dexcom, Inc. | Remote monitoring of analyte measurements |
| US11382508B2 (en) | 2012-12-31 | 2022-07-12 | Dexcom, Inc. | Remote monitoring of analyte measurements |
| US10869599B2 (en) | 2012-12-31 | 2020-12-22 | Dexcom, Inc. | Remote monitoring of analyte measurements |
| US11109757B2 (en) | 2012-12-31 | 2021-09-07 | Dexcom, Inc. | Remote monitoring of analyte measurements |
| US11850020B2 (en) | 2012-12-31 | 2023-12-26 | Dexcom, Inc. | Remote monitoring of analyte measurements |
| US12081287B2 (en) | 2013-03-14 | 2024-09-03 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
| EP4235684A1 (en) | 2013-03-14 | 2023-08-30 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
| US10985804B2 (en) | 2013-03-14 | 2021-04-20 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
| WO2014158327A2 (en) | 2013-03-14 | 2014-10-02 | Dexcom, Inc. | Advanced calibration for analyte sensors |
| WO2014158405A2 (en) | 2013-03-14 | 2014-10-02 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
| US12081288B2 (en) | 2013-03-14 | 2024-09-03 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
| EP4542574A2 (en) | 2013-03-14 | 2025-04-23 | DexCom, Inc. | Systems and methods for processing and transmitting sensor data |
| EP3401818A1 (en) | 2013-03-14 | 2018-11-14 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
| EP3806103A1 (en) | 2013-03-14 | 2021-04-14 | Dexcom, Inc. | Advanced calibration for analyte sensors |
| US12125588B2 (en) | 2013-03-14 | 2024-10-22 | Dexcom Inc. | Systems and methods for processing and transmitting sensor data |
| US12052067B2 (en) | 2013-03-14 | 2024-07-30 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
| US11677443B1 (en) | 2013-03-14 | 2023-06-13 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
| EP4220654A1 (en) | 2013-03-14 | 2023-08-02 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
| US11998329B2 (en) | 2013-03-15 | 2024-06-04 | Dexcom, Inc. | Membrane for continuous analyte sensors |
| US12411930B2 (en) | 2013-12-27 | 2025-09-09 | Abbott Diabetes Care Inc. | Application interface and display control in an analyte monitoring environment |
| WO2015100142A1 (en) * | 2013-12-27 | 2015-07-02 | Abbott Diabetes Care Inc. | Application interface and display control in an analyte monitoring environment |
| US10360368B2 (en) | 2013-12-27 | 2019-07-23 | Abbott Diabetes Care Inc. | Application interface and display control in an analyte monitoring environment |
| WO2015156966A1 (en) | 2014-04-10 | 2015-10-15 | Dexcom, Inc. | Sensors for continuous analyte monitoring, and related methods |
| EP4257044A2 (en) | 2014-04-10 | 2023-10-11 | DexCom, Inc. | Sensor for continuous analyte monitoring |
| US10864367B2 (en) | 2015-02-24 | 2020-12-15 | Elira, Inc. | Methods for using an electrical dermal patch in a manner that reduces adverse patient reactions |
| US11197613B2 (en) | 2015-02-24 | 2021-12-14 | Elira, Inc. | Systems and methods for enabling a patient to achieve a weight loss objective using an electrical dermal patch |
| US11957895B2 (en) | 2015-02-24 | 2024-04-16 | Elira, Inc. | Glucose-based modulation of electrical stimulation to enable weight loss |
| US10765863B2 (en) | 2015-02-24 | 2020-09-08 | Elira, Inc. | Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy |
| US9956393B2 (en) | 2015-02-24 | 2018-05-01 | Elira, Inc. | Systems for increasing a delay in the gastric emptying time for a patient using a transcutaneous electro-dermal patch |
| US10118035B2 (en) | 2015-02-24 | 2018-11-06 | Elira, Inc. | Systems and methods for enabling appetite modulation and/or improving dietary compliance using an electro-dermal patch |
| US10376145B2 (en) | 2015-02-24 | 2019-08-13 | Elira, Inc. | Systems and methods for enabling a patient to achieve a weight loss objective using an electrical dermal patch |
| US11712562B2 (en) | 2015-02-24 | 2023-08-01 | Elira, Inc. | Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy |
| US10335302B2 (en) | 2015-02-24 | 2019-07-02 | Elira, Inc. | Systems and methods for using transcutaneous electrical stimulation to enable dietary interventions |
| US10143840B2 (en) | 2015-02-24 | 2018-12-04 | Elira, Inc. | Systems and methods for enabling appetite modulation and/or improving dietary compliance using an electro-dermal patch |
| US12357345B2 (en) | 2015-10-21 | 2025-07-15 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
| EP4046571A1 (en) | 2015-10-21 | 2022-08-24 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
| EP4378390A2 (en) | 2015-10-21 | 2024-06-05 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
| US11399721B2 (en) | 2015-12-28 | 2022-08-02 | Dexcom, Inc. | Systems and methods for remote and host monitoring communications |
| US10932672B2 (en) | 2015-12-28 | 2021-03-02 | Dexcom, Inc. | Systems and methods for remote and host monitoring communications |
| US12360074B2 (en) | 2015-12-30 | 2025-07-15 | Dexcom, Inc. | Enzyme immobilized adhesive layer for analyte sensors |
| US12366548B2 (en) | 2015-12-30 | 2025-07-22 | Dexcom, Inc. | Analyte sensor |
| EP4324921A2 (en) | 2015-12-30 | 2024-02-21 | Dexcom, Inc. | Biointerface layer for analyte sensors |
| EP4253536A2 (en) | 2015-12-30 | 2023-10-04 | DexCom, Inc. | Diffusion resistance layer for analyte sensors |
| EP3895614A1 (en) | 2015-12-30 | 2021-10-20 | Dexcom, Inc. | Enzyme immobilized adhesive layer for analyte sensors |
| US11112377B2 (en) | 2015-12-30 | 2021-09-07 | Dexcom, Inc. | Enzyme immobilized adhesive layer for analyte sensors |
| EP4292528A1 (en) | 2015-12-30 | 2023-12-20 | Dexcom, Inc. | Membrane layers for analyte sensors |
| US10561349B2 (en) | 2016-03-31 | 2020-02-18 | Dexcom, Inc. | Systems and methods for display device and sensor electronics unit communication |
| US10568552B2 (en) | 2016-03-31 | 2020-02-25 | Dexcom, Inc. | Systems and methods for display device and sensor electronics unit communication |
| US10980451B2 (en) | 2016-03-31 | 2021-04-20 | Dexcom, Inc. | Systems and methods for display device and sensor electronics unit communication |
| US10980453B2 (en) | 2016-03-31 | 2021-04-20 | Dexcom, Inc. | Systems and methods for display device and sensor electronics unit communication |
| US10980450B2 (en) | 2016-03-31 | 2021-04-20 | Dexcom, Inc. | Systems and methods for display device and sensor electronics unit communication |
| US10799157B2 (en) | 2016-03-31 | 2020-10-13 | Dexcom, Inc. | Systems and methods for display device and sensor electronics unit communication |
| US10881335B2 (en) | 2016-03-31 | 2021-01-05 | Dexcom, Inc. | Systems and methods for display device and sensor electronics unit communication |
| EP4582022A1 (en) | 2017-01-18 | 2025-07-09 | DexCom, Inc. | Sensors for continuous analyte monitoring |
| EP4008240A1 (en) | 2017-06-23 | 2022-06-08 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
| EP3925522A1 (en) | 2017-06-23 | 2021-12-22 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
| US11311241B2 (en) | 2017-06-23 | 2022-04-26 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
| EP3928688A1 (en) | 2017-06-23 | 2021-12-29 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
| US11395631B2 (en) | 2017-06-23 | 2022-07-26 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
| US11504063B2 (en) | 2017-06-23 | 2022-11-22 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
| US11510625B2 (en) | 2017-06-23 | 2022-11-29 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
| EP4111949A1 (en) | 2017-06-23 | 2023-01-04 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and needle hub comprising anti-rotation feature |
| US11943876B2 (en) | 2017-10-24 | 2024-03-26 | Dexcom, Inc. | Pre-connected analyte sensors |
| US11350862B2 (en) | 2017-10-24 | 2022-06-07 | Dexcom, Inc. | Pre-connected analyte sensors |
| US11706876B2 (en) | 2017-10-24 | 2023-07-18 | Dexcom, Inc. | Pre-connected analyte sensors |
| US12150250B2 (en) | 2017-10-24 | 2024-11-19 | Dexcom, Inc. | Pre-connected analyte sensors |
| US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
| US11382540B2 (en) | 2017-10-24 | 2022-07-12 | Dexcom, Inc. | Pre-connected analyte sensors |
| USD1036676S1 (en) | 2018-06-22 | 2024-07-23 | Dexcom, Inc. | Wearable medical monitoring device |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1649260A4 (en) | 2010-07-07 |
| JP2007500336A (en) | 2007-01-11 |
| WO2005012873A2 (en) | 2005-02-10 |
| WO2005012873A3 (en) | 2006-04-13 |
| US7074307B2 (en) | 2006-07-11 |
| USRE43399E1 (en) | 2012-05-22 |
| EP1649260A2 (en) | 2006-04-26 |
| US20050115832A1 (en) | 2005-06-02 |
| US20140001042A1 (en) | 2014-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7074307B2 (en) | Electrode systems for electrochemical sensors | |
| US10610140B2 (en) | Oxygen enhancing membrane systems for implantable devices | |
| US7108778B2 (en) | Electrochemical sensors including electrode systems with increased oxygen generation | |
| US10188333B2 (en) | Calibration techniques for a continuous analyte sensor | |
| US20050056552A1 (en) | Increasing bias for oxygen production in an electrode system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: DEXCOM, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SIMPSON, PETER C.;PETISCE, JAMES R.;CARR-BRENDEL, VICTORIA;AND OTHERS;SIGNING DATES FROM 20050103 TO 20050111;REEL/FRAME:028422/0217 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |